<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5670633 - Sugar modified oligonucleotides that detect and modulate gene expression - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_4ff636b3d23669b7103f3b3a3a18b4cd/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_4ff636b3d23669b7103f3b3a3a18b4cd__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Sugar modified oligonucleotides that detect and modulate gene expression"><meta name="DC.contributor" content="Phillip Dan Cook" scheme="inventor"><meta name="DC.contributor" content="Andrew Mamoro Kawasaki" scheme="inventor"><meta name="DC.contributor" content="Isis Pharmaceuticals, Inc." scheme="assignee"><meta name="DC.date" content="1991-8-12" scheme="dateSubmitted"><meta name="DC.description" content="Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least two of the 2&#39;-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of HIV, herpes virus, papillomavirus and other infections is provided."><meta name="DC.date" content="1997-9-23" scheme="issued"><meta name="DC.relation" content="CA:2017369:A1" scheme="references"><meta name="DC.relation" content="DE:3915462:A1" scheme="references"><meta name="DC.relation" content="DE:4110085:A1" scheme="references"><meta name="DC.relation" content="EP:0260032:A2" scheme="references"><meta name="DC.relation" content="EP:0287313:A2" scheme="references"><meta name="DC.relation" content="EP:0399330:A1" scheme="references"><meta name="DC.relation" content="EP:0417999:A1" scheme="references"><meta name="DC.relation" content="US:4381344" scheme="references"><meta name="DC.relation" content="US:5013830" scheme="references"><meta name="DC.relation" content="US:5134066" scheme="references"><meta name="DC.relation" content="US:5212295" scheme="references"><meta name="DC.relation" content="US:5214135" scheme="references"><meta name="DC.relation" content="US:5466786" scheme="references"><meta name="DC.relation" content="WO:1990015814:A1" scheme="references"><meta name="DC.relation" content="WO:1991006556:A1" scheme="references"><meta name="DC.relation" content="WO:1991015499:A1" scheme="references"><meta name="DC.relation" content="WO:1992007065:A1" scheme="references"><meta name="citation_reference" content="Arnott and Hukins, Biochemical and Biophysical Research Communication, 47:1504 1510 (1970)."><meta name="citation_reference" content="Arnott and Hukins, Biochemical and Biophysical Research Communication, 47:1504-1510 (1970)."><meta name="citation_reference" content="B. S. Sproat et al. Nucleic Acids Research 17: 3373 3386 (1989)."><meta name="citation_reference" content="B. S. Sproat et al. Nucleic Acids Research 17: 3373-3386 (1989)."><meta name="citation_reference" content="B. S. Sproat, et al. Nucleic Acids Research 18:41 49 (1990)."><meta name="citation_reference" content="B. S. Sproat, et al. Nucleic Acids Research 18:41-49 (1990)."><meta name="citation_reference" content="Calvo Mateo, et al., Tetrahedron Letters 29:941 944 (1988)."><meta name="citation_reference" content="Calvo-Mateo, et al., Tetrahedron Letters 29:941-944 (1988)."><meta name="citation_reference" content="Codington et al. Journal of Organic Chemistry, 29:558 564 (1964)."><meta name="citation_reference" content="Codington et al. Journal of Organic Chemistry, 29:558-564 (1964)."><meta name="citation_reference" content="Cohen in Oligonucleotides: Antisense Inhibitors of Gene Expression, CRC Press, Inc., Boca Raton, FL (1989), table of contents only."><meta name="citation_reference" content="Dahma et al., Can J. Chem. 67:831 839 (1989)."><meta name="citation_reference" content="Dahma et al., Can J. Chem. 67:831-839 (1989)."><meta name="citation_reference" content="Divakar, et al., &quot;Approaches to the Synthesis of 2&#39;-Thio Analogues of Pyrimidine Ribosides&quot;, J. Chem. Soc. Perkins Trans., I, (1990), 969-974."><meta name="citation_reference" content="Divakar, et al., &quot;Reaction Between 2,2&#39;-Anhydro-1-Î²-D-arabinofuranosyluracil and Thiolate Ions&quot;, J. Chem. Soc. Perkin Trans. I, (1982), 1625-1628."><meta name="citation_reference" content="Divakar, et al., Approaches to the Synthesis of 2 Thio Analogues of Pyrimidine Ribosides , J. Chem. Soc. Perkins Trans., I, (1990), 969 974."><meta name="citation_reference" content="Divakar, et al., Reaction Between 2,2 Anhydro 1 D arabinofuranosyluracil and Thiolate Ions , J. Chem. Soc. Perkin Trans. I, (1982), 1625 1628."><meta name="citation_reference" content="E. T. Jarvi, et al., Nucleosides &amp; Nucleotides 8:1111 1114 (1989)."><meta name="citation_reference" content="E. T. Jarvi, et al., Nucleosides &amp; Nucleotides 8:1111-1114 (1989)."><meta name="citation_reference" content="F. Hansske, D. Madej, M. J. Robins (1984) Tetrahedron 40:125."><meta name="citation_reference" content="Freskos, J.N., Nucleosides &amp; Nucleotides 8:1075 1076 (1989)."><meta name="citation_reference" content="Freskos, J.N., Nucleosides &amp; Nucleotides 8:1075-1076 (1989)."><meta name="citation_reference" content="G. Butke, et al., Nucleic Acid Chemistry Part 3:149 152."><meta name="citation_reference" content="G. Butke, et al., Nucleic Acid Chemistry Part 3:149-152."><meta name="citation_reference" content="H. Inoue et al. Nucleic Acids Research 15:6131 6148 (1987)."><meta name="citation_reference" content="H. Inoue et al. Nucleic Acids Research 15:6131-6148 (1987)."><meta name="citation_reference" content="Ikehara et al., 1975. Tetrahedron 31:1369 1372."><meta name="citation_reference" content="Ikehara et al., 1975. Tetrahedron 31:1369-1372."><meta name="citation_reference" content="Ikehara et al., 1981. Chem. Pharm. Bull., 29(11):3281 3285."><meta name="citation_reference" content="Ikehara et al., 1981. Chem. Pharm. Bull., 29(11):3281-3285."><meta name="citation_reference" content="Imazawa, et al., &quot;Nucleosides and Nucleotides, XII. Synthesis and Properties of 2&#39;-Dexy-2&#39;-mercaptouridine and Its Derivatives&quot;, Chem. Pharm. Bull., 23, (1975), 604-610."><meta name="citation_reference" content="Imazawa, et al., Nucleosides and Nucleotides, XII. Synthesis and Properties of 2 Dexy 2 mercaptouridine and Its Derivatives , Chem. Pharm. Bull., 23, (1975), 604 610."><meta name="citation_reference" content="Imazawa, M., Ueda, T., and Ukita, T. (1975) Chem. Pharm. Bull. 23:604."><meta name="citation_reference" content="J. Hobbs et al., Biochemistry 11:4336 (1972)."><meta name="citation_reference" content="Journal of American Chemical Society, 112:1253 1255, 1990."><meta name="citation_reference" content="Journal of American Chemical Society, 112:1253-1255, 1990."><meta name="citation_reference" content="K.E.B. Parkes and K. Taylor, Tetrahedron Letters, 29:2995 2996 (1988)."><meta name="citation_reference" content="K.E.B. Parkes and K. Taylor, Tetrahedron Letters, 29:2995-2996 (1988)."><meta name="citation_reference" content="Kazimierczuk et al, Journal of American Chemical Society 106:6379 (1984)."><meta name="citation_reference" content="Koole et al., Journal of Organic Chemistry 54:1657 1664 (1989)."><meta name="citation_reference" content="Koole et al., Journal of Organic Chemistry 54:1657-1664 (1989)."><meta name="citation_reference" content="L. W. Hertel, et al., Journal of Organic Chemistry 53:2406 2409 (1988)."><meta name="citation_reference" content="L. W. Hertel, et al., Journal of Organic Chemistry 53:2406-2409 (1988)."><meta name="citation_reference" content="M. Ikehara Accounts of Chemical Research, 2:47 53 (1969)."><meta name="citation_reference" content="M. Ikehara Accounts of Chemical Research, 2:47-53 (1969)."><meta name="citation_reference" content="M. Ikehara and H. Miki, Chem. Pharm. Bull. 26:2449 2453 (1978)."><meta name="citation_reference" content="M. Ikehara and H. Miki, Chem. Pharm. Bull. 26:2449-2453 (1978)."><meta name="citation_reference" content="M. Ikehara et al., Nucleic Acids Res. 4:4249 (1977)."><meta name="citation_reference" content="M. Ikehara et al., Nucleic Acids Res. 5:3315 (1978)."><meta name="citation_reference" content="M. Ikehara et al., Nucleic Acids Research 5:1877 (1978)."><meta name="citation_reference" content="M. Ikehara et al., Tetrahedron 34:1133 1138 (1978)."><meta name="citation_reference" content="M. Ikehara et al., Tetrahedron 34:1133-1138 (1978)."><meta name="citation_reference" content="M. J. Gait, et., Oligonucleotide Synthesis A Practical Approach, (IRL Press, Washington, DC 1984); Table of contents only."><meta name="citation_reference" content="M. J. Robins, J. S. Wilson, L. Sawyer &amp; M.N.G. Janes (1983) Can. J. Chem. 61:1911."><meta name="citation_reference" content="Marcus Sekura et al. 1987. Nucleic Acid Res. 15(4):5749 5763."><meta name="citation_reference" content="Marcus-Sekura et al. 1987. Nucleic Acid Res. 15(4):5749-5763."><meta name="citation_reference" content="Ohtsuka et al., European Journal of Biochemistry 139:447 450 (1984)."><meta name="citation_reference" content="Ohtsuka et al., European Journal of Biochemistry 139:447-450 (1984)."><meta name="citation_reference" content="P. S. Miller &amp; P.O.P. Ts O Anti Cancer Drug Design, 2:117 128 (1987)."><meta name="citation_reference" content="P. S. Miller &amp; P.O.P. Ts&#39;O Anti-Cancer Drug Design, 2:117-128 (1987)."><meta name="citation_reference" content="Q. Y. Chem &amp; S.W. Wu in the Journal of Chemical Society Perkin Transactions 2385 2387 (1989)."><meta name="citation_reference" content="Q.-Y. Chem &amp; S.W. Wu in the Journal of Chemical Society Perkin Transactions 2385-2387 (1989)."><meta name="citation_reference" content="R. A. Jones, Journal of American Chemical Society 104:1316 1319 (1982)."><meta name="citation_reference" content="R. A. Jones, Journal of American Chemical Society 104:1316-1319 (1982)."><meta name="citation_reference" content="R. Raganthan Tetrahedron Letters 15:1291 1294 (1977)."><meta name="citation_reference" content="R. Raganthan Tetrahedron Letters 15:1291-1294 (1977)."><meta name="citation_reference" content="Rao, T.S. and Reese, C.B. (1989) J. Chem. Soc., Commun. 997."><meta name="citation_reference" content="Ryan, et al., &quot;Synthesis of 2-Thio-D-ribose and 2&#39;-Thioadenosine Derivatives&quot;, J. Org. Chem., 36, No. 18, (1971), 2646-2657."><meta name="citation_reference" content="Ryan, et al., Synthesis of 2 Thio D ribose and 2 Thioadenosine Derivatives , J. Org. Chem., 36, No. 18, (1971), 2646 2657."><meta name="citation_reference" content="S. Beaucage et al., Tetrahedron Letters, 22, 1859 1862, 1981."><meta name="citation_reference" content="S. Beaucage et al., Tetrahedron Letters, 22, 1859-1862, 1981."><meta name="citation_reference" content="S. Chladek et al. Journal of Carbohydrates, Nucleosides &amp; Nucleotides 7:63 75 (1980)."><meta name="citation_reference" content="S. Chladek et al. Journal of Carbohydrates, Nucleosides &amp; Nucleotides 7:63-75 (1980)."><meta name="citation_reference" content="S. Shibahara et al., Nucleic Acids Research 17:239 (1987) 2:117 128 (1987)."><meta name="citation_reference" content="S. Shibahara et al., Nucleic Acids Research 17:239 (1987) 2:117-128 (1987)."><meta name="citation_reference" content="Uesugi et al., Tetrahedron Letters 42:4073 (1979)."><meta name="citation_reference" content="Uesugi et al; Nucleosides &amp; Nucleotides 2:373 385 (1983)."><meta name="citation_reference" content="Uesugi et al; Nucleosides &amp; Nucleotides 2:373-385 (1983)."><meta name="citation_reference" content="Uhlmann, et al., &quot;Antisense Oligonucleotides: A New Therapeutic Principle,&quot; Chemical Reviews, 1990, 558."><meta name="citation_reference" content="Uhlmann, et al., Antisense Oligonucleotides: A New Therapeutic Principle, Chemical Reviews, 1990, 558."><meta name="citation_reference" content="W. Guschlbauer and K. Jankowski, Nucleic Acid Res. 8:1421 (1980)."><meta name="citation_reference" content="W. T. Markiewicz &amp; M. Wiewiorowski in Nucleic Acid Chemistry, Part 3, pp. 229 231, Townsend, L.B., R. S. Tipson, eds. (J. Wiley &amp; Sons, NY 1986)."><meta name="citation_reference" content="W. T. Markiewicz &amp; M. Wiewiorowski in Nucleic Acid Chemistry, Part 3, pp. 229-231, Townsend, L.B., R. S. Tipson, eds. (J. Wiley &amp; Sons, NY 1986)."><meta name="citation_patent_number" content="US:5670633"><meta name="citation_patent_application_number" content="US:07/835,932"><link rel="canonical" href="http://www.google.com/patents/US5670633"/><meta property="og:url" content="http://www.google.com/patents/US5670633"/><meta name="title" content="Patent US5670633 - Sugar modified oligonucleotides that detect and modulate gene expression"/><meta name="description" content="Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least two of the 2&#39;-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of HIV, herpes virus, papillomavirus and other infections is provided."/><meta property="og:title" content="Patent US5670633 - Sugar modified oligonucleotides that detect and modulate gene expression"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("TarpU42uJdWqsQSTvYCIAg"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407464522.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("GBR"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("TarpU42uJdWqsQSTvYCIAg"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407464522.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("GBR"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5670633?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5670633"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=M75DBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5670633&amp;usg=AFQjCNGUIVvPxX5FFtWyfI1kHnI4H5beNA" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5670633.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5670633.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5670633" style="display:none"><span itemprop="description">Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence...</span><span itemprop="url">http://www.google.com/patents/US5670633?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5670633 - Sugar modified oligonucleotides that detect and modulate gene expression</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5670633 - Sugar modified oligonucleotides that detect and modulate gene expression" title="Patent US5670633 - Sugar modified oligonucleotides that detect and modulate gene expression"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5670633 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 07/835,932</td></tr><tr><td class="patent-bibdata-heading">PCT number</td><td class="single-patent-bibdata">PCT/US1991/005720</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Sep 23, 1997</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Aug 12, 1991</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Jan 11, 1990</td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">07835932, </span><span class="patent-bibdata-value">835932, </span><span class="patent-bibdata-value">PCT/1991/5720, </span><span class="patent-bibdata-value">PCT/US/1991/005720, </span><span class="patent-bibdata-value">PCT/US/1991/05720, </span><span class="patent-bibdata-value">PCT/US/91/005720, </span><span class="patent-bibdata-value">PCT/US/91/05720, </span><span class="patent-bibdata-value">PCT/US1991/005720, </span><span class="patent-bibdata-value">PCT/US1991/05720, </span><span class="patent-bibdata-value">PCT/US1991005720, </span><span class="patent-bibdata-value">PCT/US199105720, </span><span class="patent-bibdata-value">PCT/US91/005720, </span><span class="patent-bibdata-value">PCT/US91/05720, </span><span class="patent-bibdata-value">PCT/US91005720, </span><span class="patent-bibdata-value">PCT/US9105720, </span><span class="patent-bibdata-value">US 5670633 A, </span><span class="patent-bibdata-value">US 5670633A, </span><span class="patent-bibdata-value">US-A-5670633, </span><span class="patent-bibdata-value">US5670633 A, </span><span class="patent-bibdata-value">US5670633A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Phillip+Dan+Cook%22">Phillip Dan Cook</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Andrew+Mamoro+Kawasaki%22">Andrew Mamoro Kawasaki</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Isis+Pharmaceuticals,+Inc.%22">Isis Pharmaceuticals, Inc.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5670633.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5670633.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5670633.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (17),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (83),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (265),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (95),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (12)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5670633&usg=AFQjCNH4iiKW-Gxa3kAEjLKrykNrvg8LyQ">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5670633&usg=AFQjCNEJx5bN4la2qHgo4puTzMU73oaoJw">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5670633A%26KC%3DA%26FT%3DD&usg=AFQjCNGRz_UvxFJbifGwJ5X2RbCXYvnlDw">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54206125" lang="EN" load-source="patent-office">Sugar modified oligonucleotides that detect and modulate gene expression</invention-title></span><br><span class="patent-number">US 5670633 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA37679934" lang="EN" load-source="patent-office"> <div class="abstract">Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least two of the 2'-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of HIV, herpes virus, papillomavirus and other infections is provided.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(23)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-13.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-13.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-14.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-14.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-15.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-15.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-16.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-16.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-17.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-17.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-18.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-18.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-19.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-19.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-20.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-20.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-21.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-21.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5670633-22.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5670633-22.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(3)</span></span></div><div class="patent-text"><div mxw-id="PCLM5133952" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. An oligonucleotide that hybridizes with RNA or DNA, having 5 to 50 covalently-bound nucleosides that individually include a ribose or deoxyribose sugar portion and a base portion, wherein:<div class="claim-text">said sugar portions of said nucleosides are joined together by 3'-5' internucleoside linkages such that the base portions of said nucleosides form a mixed base sequence that is complementary to an RNA base sequence or to a DNA base sequence; and</div> <div class="claim-text">at least two of said nucleosides include a modified deoxyfuranosyl moiety bearing a 2'-fluoro substituent; and wherein</div> <div class="claim-text">a duplex formed between said oligonucleotide and its complement exhibits greater thermal stability than does a duplex formed between said complement and an oligonucleotide that does not include 2'-fluoro substituents.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. The oligonucleotide of claim 1 wherein said modified deoxyfuranosyl moiety is a 2'-deoxy-2'-fluororibofuranomyl moiety.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. The oligonucleotide of claim 1 wherein at least two of said nucleosides are covalently bound through phosphorothioate, methyl phosphonate, or phosphate alkylate internucleoside linkages.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES67022368" lang="EN" load-source="patent-office" class="description">
    <heading>CROSS REFERENCE TO RELATED APPLICATIONS</heading> <p>This application is a continuation-in-part of application Ser. No. 566,977, filed Aug. 13, 1990, now abandoned, and application Ser. No. PCT US91/00243, filed Jan. 11, 1991, that in turn is a continuation-in-part of applications Ser. Nos. 463,358, filed Jan. 11, 1990, now abandoned, and the above referenced Ser. No. 566,977, filed Aug. 13, 1990, now abandoned. The entire disclosure of each of these are assigned to the assignee of this application, are incorporated herein by reference.</p>
    <heading>FIELD OF THE INVENTION</heading> <p>This invention relates to the design, synthesis and application of nuclease resistant oligonucleotides which are useful for antisense oligonucleotide therapeutics, diagnostics, and research reagents. Sugar modified oligonucleotide which are resistant to nuclease degradation and are capable of modulating the activity of DNA and RNA are provided. Methods for modulating the production of proteins utilizing the modified oligonucleotide of the invention are also provided.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p>It is well known that most of the bodily states in mammals including infectious disease states, are affected by proteins. Such proteins, either acting directly or through their enzymatic functions, contribute in major proportion to many diseases in animals and man.</p>
    <p>Classical therapeutics has generally focused upon interactions with such proteins in efforts to moderate their disease causing or disease potentiating functions. Recently however, attempts have been made to moderate the actual production of such proteins by interactions with molecules that direct their synthesis, intracellular RNA. By interfering with the production of proteins, it has been hoped to effect therapeutic results with maximum effect and minimal side effects. One approach for inhibiting specific gene expression is the use of oligonucleotide and oligonucleotide analogs as antisense agents.</p>
    <p>Antisense methodology is the complementary hybridization of relatively short oligonucleotides to single-stranded mRNA or single-stranded DNA such that the normal, essential functions of these intracellular nucleic acids are disrupted. Hybridization is the sequence specific hydrogen bonding of oligonucleotides to Watson-Crick base pairs of RNA or single-stranded DNA. Such base pairs are said to be complementary to one another.</p>
    <p>The naturally occurring event that provides the disruption of the nucleic acid function, discussed by Cohen in Oligonucleotides: Antisense Inhibitors of Gene Expression, CRC Press, Inc., Boca Raton, Fla. (1989) is thought to be of two types. The first, hybridization arrest, denotes the terminating event in which the oligonucleotide inhibitor binds to the target nucleic acid and thus prevents, by simple steric hindrance, the binding of essential proteins, most often ribosomes, to the nucleic acid. Methyl phosphonate oligonucleotides; P. S. Miller &amp; P. O. P. Ts'O, Anti-Cancer Drug Design, 2:117-128 (1987), and Î±-anomer oligonucleotides are the two most extensively studied antisense agents which are thought to disrupt nucleic acid function by hybridization arrest.</p>
    <p>The second type of terminating event for antisense oligonucleotides involves the enzymatic cleavage of the targeted RNA by intracellular RNase H. The oligonucleotide or oligonucleotide analog, which must be of the deoxyribo type, hybridizes with the targeted RNA and this duplex activates the RNase H enzyme to cleave the RNA strand, thus destroying the normal function of the RNA. Phosphorothioate oligonucleotides are the most prominent example of an antisense agent which operates by this type of antisense terminating event.</p>
    <p>Considerable research is being directed to the application of oligonucleotide and oligonucleotide analogs as antisense agents for therapeutic purposes. All applications of oligonucleotides as diagnostic, research reagents, and potential therapeutic agents require that the oligonucleotides or oligonucleotide analogs be synthesized in large quantities, be transported across cell membranes or taken up by cells, appropriately hybridize to targeted RNA or DNA, and subsequently terminate or disrupt nucleic acid function. These critical functions depend on the initial stability of oligonucleotides toward nuclease degradation.</p>
    <p>A serious deficiency of oligonucleotides for these purposes, particularly antisense therapeutics, is the enzymatic degradation of the administered oligonucleotide by a variety of ubiquitous nucleolytic enzymes, intracellularly and extracellularly located, hereinafter referred to as "nucleases". It is unlikely that unmodified, "wild type", oligonucleotides will be useful therapeutic agents because they are rapidly degraded by nucleases. Modification of oligonucleotides to render them resistant to nucleases is therefore currently a primary focus of antisense research.</p>
    <p>Modifications of oligonucleotides to enhance nuclease resistance have heretofore exclusively taken place on the sugar-phosphate backbone, particularly on the phosphorus atom. Phosphorothioates, methyl phosphonates, phosphorimidates, and phosphorotriesters (phosphate methylated DNA) have been reported to have various levels of resistance to nucleases. However, while the ability of an antisense oligonucleotide to bind to specific DNA or RNA with fidelity is fundamental to antisense methodology, modified phosphorous oligonucleotides, while providing various degrees of nuclease resistance, suffer from inferior hybridization properties.</p>
    <p>Due to the prochiral nature of the phosphorous atom, modifications on the internal phosphorus atoms of modified phosphorous oligonucleotides result in Rp and Sp stereoisomers. Since a practical synthesis of stereo regular oligonucleotides (all Rp or Sp phosphate linkages) is unknown, oligonucleotides with modified phosphorus atoms have n<sup>2</sup> isomers with n equal to the length or the number of the bases in the oligonucleotide. Furthermore, modifications on the phosphorus atom have unnatural bulk about the phosphorodiester linkage which interferes with the conformation of the sugar-phosphate backbone and consequently, the stability of the duplex. The effects of phosphorus atom modifications cause inferior hybridization to the targeted nucleic acids relative to the unmodified oligonucleotide hybridizing to the same target.</p>
    <p>The relative ability Of an oligonucleotide to bind to complementary nucleic acids is compared by determining the melting temperature of a particular hybridization complex. The melting temperature (T<sub>m</sub>), a characteristic physical property of double helixes, denotes the temperature in degrees centigrade at which 50% helical versus coil (unhybridized) forms are present. T<sub>m</sub> is measured by using the UV spectrum to determine the formation and breakdown (melting) of hybridization. Base stacking, which occurs during hybridization, is accompanied by a reduction in UV absorption (hypochromicity). Consequently a reduction in UV absorption indicates a higher T<sub>m</sub>. The higher the T<sub>m</sub>, the greater the strength of the binding of the strands. Non-Watson-Crick base pairing has a strong destabilizing effect on the T<sub>m</sub>. Consequently, absolute fidelity of base pairing is necessary to have optimal binding of an antisense oligonucleotide to its targeted RNA.</p>
    <p>Considerable reduction in the hybridization properties of methyl phosphonates and phosphorothioates has been reported by Cohen. Methyl phosphonates have a further disadvantage in that the duplex formed with RNA does not activate degradation by RNase H as an terminating event, but instead acts by hybridization arrest which can be reversed due to a helical melting activity located on the ribosome. Phosphorothioates are highly resistant to most nucleases. However, phosphorothioates typically exhibit non-antisense modes of action, particularly the inhibition of various enzyme functions due to nonspecific binding. Enzyme inhibition by sequence-specific oligonucleotides undermines the very basis of antisense chemotherapy.</p>
    <p>Therefore, oligonucleotides modified to exhibit resistance to nucleases, to activate the RNase H terminating event, and to hybridize with appropriate strength and fidelity to its targeted RNA (or DNA) are greatly desired for antisense oligonucleotide therapeutics.</p>
    <p>M. Ikehara et al., European Journal of Biochemistry 139:447-450(1984) report the synthesis of a mixed octamer containing one 2'-deoxy-2'-fluoroguanosine residue or one 2'-deoxy-2'-fluoroadenine residue. W. Guschlbauer and K. Jankowski, Nucleic Acids Res. 8:1421 (1980) have shown that the contribution of the N form (3'-endo, 2'-exo) increases with the electronegativeness of the 2'-substituent. Thus, 2'-deoxy-2'-fluorouridine contains 85% of the C3'-endo conformer. M. Ikehara et al., Tetrahedron Letters 42:4073 (1979) have shown that a linear relationship between the electronegativeness of 2'-substituents and the % N conformation (3'-endo-2'-exo) of a series of 2'-deoxy-adenosines. M. Ikehara et al., Nucleic Acids Research 5:1877 (1978) have chemically transformed 2'-deoxy-2'-fluoro-adenosine to its 5'-diphosphate. This was subsequently enzymatically polymerized to provide poly(2'-deoxy-2'-fluoroadenylic acid).</p>
    <p>Furthermore, evidence was presented which indicates that 2'-substituted 2'-deoxyadenosines polynucleotides resemble double stranded RNA rather, than DNA. M. Ikehara et al., Nucleic Acids Res. 5:3315 (1978) show that a 2'-fluorine substituent in poly A, poly I, and poly C duplexed to their U, C, or I complement are significantly more stable than the ribo or deoxy poly duplexes as determined by standard melting assays. M. Ikehara et al., Nucleic Acids Res. 4:4249 (1978) show that a 2'-chloro or bromo substituents in poly(2'-deoxyadenylic acid) provides nuclease resistance. F. Eckstein et al., Biochemistry 11:4336 (1972) show that poly(2'-chloro-2'-deoxyuridylic acid) and poly(2'-chloro-2'-deoxycytidylic acid) are resistant to various nucleases. H. Inoue et al., Nucleic Acids Research 15:6131 (1987) describe the synthesis of mixed oligonucleotide sequences containing 2'-OMe at every nucleotide unit. The mixed 2'-OMe substituted sequences hybridized to their ribooligonucleotide complement (RNA) as strongly as the ribo-ribo duplex (RNA-RNA) which is significantly stronger than the same sequence ribo-deoxyribo heteroduplex (T<sub>m</sub> s, 49.0 and 50.1 versus 33.0 degrees for nonamers). S. Shibahara et al., Nucleic Acids Research 17:239 (1987) describe the synthesis of mixed oligonucleotides sequences containing 2'-OMe at every nucleotide unit. The mixed 2'-OMe substituted sequences were designed to inhibit HIV replication.</p>
    <p>It is thought that the composite of the hydroxyl group's steric effect, its hydrogen bonding capabilities, and its electronegativeness versus the properties of the hydrogen atom is responsible for the gross structural difference between RNA and DNA. Thermal melting studies indicate that the order of duplex stability (hybridization) of 2'-methoxy oligonucleotides is in the order of RNA-RNA, RNA-DNA, DNA-DNA.</p>
    <p>The 2'-deoxy-2'-halo, azido, amino, methoxy homopolymers of several natural occurring nucleosides have been prepared by polymerase processes. The required 2'-modified nucleosides monomers have not been incorporated into oligonucleotides via nucleic acids synthesizer machines. Thus, mixed sequence (sequence-specific) oligonucleotides containing 2'-modifications at each sugar are not known except for 2'-deoxy-2'-methoxy analogs.</p>
    <heading>OBJECTS OF THE INVENTION</heading> <p>It is a principal object of the invention to provide nuclease resistant, sugar modified oligonucleotides or oligonucleotide analogs for use in antisense oligonucleotide diagnostics, research reagents, and therapeutics.</p>
    <p>It is a further object of the invention to provide such oligonucleotides or oligonucleotides analogs which are effective in modulating the activity of a DNA or an RNA.</p>
    <p>Another object of the invention is to provide such oligonucleotides or oligonucleotide analogs which are less likely to invoke undesired or toxic side reactions.</p>
    <p>Yet another object of the invention is to provide research and diagnostic methods and materials for assaying bodily states in animals, especially diseased states.</p>
    <p>A further object of the invention is to provide therapeutic and research methods and materials for the treatment of diseases through modulation of the activity of DNA and RNA.</p>
    <p>These and other objects will become apparent to persons of ordinary skill in the art from a review of the present specification and attendant claims.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>In accordance with the present invention, compositions which are resistant to nuclease degradation and but which modulate the activity of DNA and RNA are provided. These compositions are comprised of sugar modified oligonucleotides or oligonucleotide analogs, the targeting portions of which are specifically hybridizable with preselected nucleotide sequences of single-stranded or double-stranded DNA or RNA. The sugar modified oligonucleotides recognize and form double strands with single stranded DNA and RNA or triple strands with double stranded DNA and RNA.</p>
    <p>The nuclease resistant oligonucleotides of this invention consist of a single strand of nucleic acid bases linked together through linking groups. The target portion of the nuclease resistant oligonucleotide may range in length from about 5 to about 50 nucleic acid bases. However, in accordance with the preferred embodiment of this invention, a target sequence of about 15 bases in length is optimal.</p>
    <p>The nucleic acid bases may be pyrimidines such as thymine, uracil or cytosine, or purines such as guanine or adenine, or both, arranged in a specific sequence. The sugar moiety of such bases may be of the deoxyribose or ribose type. The groups linking the bases together may be the usual sugar phosphate nucleic acid backbone, but may also be modified as a phosphorothioate, methylphosphonate, or phosphate alkylated moiety to further enhance the sugar modified oligonucleotide properties, along with removal of a 5'-methylene group and/or carbocyclic sugar.</p>
    <p>In accordance with this invention, the targeting portion is an analog of an oligonucleotide wherein at least one of the 2'-deoxy ribofuranosyl moieties of the nucleoside unit is modified. A hydrogen or a hydroxyl, halo, azido, amino, methoxy or alkyl group may be added. For example, H, OH, F, CN, CF<sub>3</sub>, OCF<sub>3</sub>, OCN, O-alkyl, S-alkyl, SO-alkyl, SO<sub>2</sub> -alkyl, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, NH-alkyl, OCH<sub>2</sub> CHâCH<sub>2</sub> (allyloxy), OCHâCH<sub>2</sub>, OCCH where alkyl is a straight or branched chain of C1 to C12 may be used, with unsaturation within the carbon chain, such as allyloxy being particularly preferred.</p>
    <p>The resulting novel oligonucleotides or oligonucleotide analogs are resistant to nuclease degradation and exhibit hybridization properties of higher quality relative to wild type (DNA-DNA and RNA-DNA) duplexes and the phosphorus modified oligonucleotide antisense duplexes containing phosphorothioates, methylphosphonates, phophoramidates and phosphorotriesters.</p>
    <p>The invention is also directed to methods for modulating the production of a protein by an organism comprising contacting the organism with a composition formulated in accordance with the foregoing considerations. It is preferred that the RNA or DNA portion which is to be modulated be preselected to comprise that portion of DNA or RNA which codes for the protein whose formation is to be modulated. The targeting portion of the composition to be employed is, thus, selected to be complementary to the preselected portion of DNA or RNA, that is to be an antisense oligonucleotide for that portion.</p>
    <p>This invention is also directed to methods of treating an organism having a disease characterized by the undesired production of a protein. This method comprises contacting the organism with a composition in accordance with the foregoing considerations. The composition is preferably one which is designed to specifically bind with messenger RNA which codes for the protein whose production is to be inhibited.</p>
    <p>The invention further is directed to diagnostic methods for detecting the presence or absence of abnormal RNA molecules or abnormal or inappropriate expression of normal RNA molecules in organisms or cells.</p>
    <p>The invention is also directed to methods for the selective binding of RNA for research and diagnostic purposes. Such selective, strong binding is accomplished by interacting such RNA or DNA with compositions of the invention which are resistant to degradative nucleases and hybridize stronger and with greater fidelity than any other known oligonucleotide or oligonucleotide analog.</p>
    <p>Additionally this invention is directed to a method of synthesis of 2'-deoxy-2'-substituted nucleosides, particularly guanosine compounds. In accordance with this method, the 2'-hydroxyl moiety of guanosine is first oxidized and then reduced with inversion about the 2' position to yield 9-(Î²-D-arabinofuranosyl)guanine. The 2' arabino hydroxyl group is derivatized with a leaving group. Nucleophilic displacement of the leaving group with a nucleophile is accomplished with a further inversion to give the 2'-deoxy-2'-substituted guanosine compound.</p>
    <heading>DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS</heading> <p>The compositions useful for modulating the activity of an RNA or DNA molecule in accordance with this invention generally comprise a sugar modified oligonucleotide containing a target sequence which is specifically hybridizable with a preselected nucleotide sequence of single stranded or double stranded DNA or RNA molecule and which is nuclease resistant.</p>
    <p>It is generally desirable to select a sequence of DNA of RNA for or which is involved in the production of proteins whose synthesis is ultimately to be modulated or inhibited in entirety. The targeting portion of the composition is generally an oligonucleotide analog. It is synthesized, conveniently through solid state synthesis of known methodology, to be complementary to or at least to be specifically hybridizable with the preselected nucleotide sequence of the RNA or DNA. Nucleic acid synthesizers are commercially available and their use is generally understood by persons of ordinary skill in the art as being effective in generating nearly any oligonucleotide of reasonable length which may be desired.</p>
    <p>In the context of this invention, the term "oligonucleotide" refers to a plurality of joined nucleotide units formed in a specific sequence from naturally occurring bases and pentofuranosyl groups joined through a sugar group by native phosphodiester bonds. These nucleotide units may be nucleic acid bases such as guanine, adenine, cytosine, thymine or uracil. The sugar group may be deoxyribose or ribose. This term refers to both naturally occurring or synthetic species formed from naturally occurring subunits.</p>
    <p>"Oligonucleotide analog" as the term is used in connection with this invention, refers to moieties which function similarly to oligonucleotides but which have non-naturally occurring portions. Oligonucleotide analogs may have altered sugar moieties or inter-sugar linkages, for example, phosphorothioates and other sulfur containing species which are known for use in the art. Oligonucleotide analogs may also comprise altered base units or other modifications consistent with the spirit of this invention, and in particular such modifications as may increase nuclease resistance of the oligonucleotide composition in order to facilitate antisense therapeutic, diagnostic or research reagent use of a particular oligonucleotide.</p>
    <p>It is generally preferred for use in some embodiments of this invention that some positions of the nucleotide base be substituted in order to increase the nuclease resistance of the composition while maintaining the integrity of the oligonucleotide binding capabilities.</p>
    <p>It is preferred in some embodiments of the present invention to employ further modified oligonucleotides. In this context, modified oligonucleotide analogs refers to a structure which is generally similar to native oligonucleotides, but which have been modified in one or more significant ways.</p>
    <p>Such modifications may take place at the sugar backbone of the invention. It is generally preferred to enhance the ability of the target sequence of the sugar modified oligonucleotides to penetrate into the intracellular spaces of cells where the messenger RNA or DNA, which are the targets of the overall composition, reside. Therefore, it is generally preferred to provide modifications of oligonucleotides which are substantially less ionic than native forms in order to facilitate penetration of the oligonucleotide into the intracellular spaces. Any of the existing or yet to be discovered methods for accomplishing this goal may be employed in accordance with the practice of the present invention. At present, it has been found preferable to employ substitutions for the phosphorodiester bond, which substitutions are not only relatively less ionic than the naturally occurring bonds but are also substantially non-chiral.</p>
    <p>As will be appreciated, the phosphorus atom in the phosphorodiester linkage is "pro-chiral". Modifications at the phosphorus, such as is done in methyl phosphonates and phosphorothioates type oligonucleotides, results in essentially chiral structures. Chirality results in the existence of two isomers at each chiral center which may interact differently with cellular molecules. Such an unresolved mixture of isomers may inhibit the transport of the resulting compositions into the intracellular spaces or decrease the affinity and specificity of hybridization to the specific target RNA or DNA. Thus, it is preferred in some embodiments of this invention to employ substantially non-ionic, substantially non-chiral entities in lieu of some or all of the phosphorodiester bonds. For this purpose, short chain alkyl or cycloalkyl structures especially C<sub>2</sub> -C<sub>4</sub> structures are preferred. As is set forth in an application filed on even date herewith and assigned to a common assignee hereof, said application being entitled "Polyamine Oligonucleotides to Enhance Cellular Uptake," application Ser. No. 558,663 filed Jul. 27, 1990 (attorney docket ISIS-24) the modification of the sugar structure including the elimination of one of the oxygen functionality may permit the introduction of such substantially non-chiral, non-ionic substituents in this position. The entirety of the disclosure of application Ser. No. 558,663 is incorporation herein by reference in order to disclose more fully such modifications.</p>
    <p>In keeping with the goals of the invention are the standard backbone modifications such as substituting P for S, Me-P, MeO-P, H<sub>2</sub> N-P, etc. These substitutions are thought in some cases to enhance the sugar modified oligonucleotide properties.</p>
    <p>The targeting portion of the compositions of the present invention, are preferably oligonucleotide analogs having 5 to about 50 base units. It is more preferred that such functionalities have from 8 to about 40 base units and even more preferred that from about 12 to 20 base units be employed. Oligonucleotides or oligonucleotide analogs having about 15 base units are preferable for the practice of certain embodiments of the present invention.</p>
    <p>It is desired that the targeting portion be adapted so as to be specifically hybridizable with the preselected nucleotide sequence of the RNA or DNA selected for modulation. Oligonucleotide analogs particularly suited for the practice of one or more embodiments of the present invention comprise 2'-sugar modified oligonucleotides wherein one or more of the 2'-deoxy ribofuranosyl moieties of the nucleoside unit is modified with a hydrogen or hydroxyl, halo, azido, amino, alkyoxy, thioalkoxy, alkylamino or alkyl group. For example, the substitutions which may occur include H, OH, F, CN, CF<sub>3</sub>, OCF<sub>3</sub>, OCN, O-alkyl, S-alkyl, SOMe, SO<sub>2</sub> Me, ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, NH-alkyl, OCHâCH<sub>2</sub>, OCCH where alkyl is a straight or branched chain of C<sub>1</sub> to C<sub>12</sub> with unsaturation within the carbon chain such as allyloxy.</p>
    <p>These modified bases are linked together and to the rest of the oligonucleotide or oligonucleotide analog through a sugar linking group. The linking group may be any of those structures described herein which are capable of linking sugar moieties of oligonucleotides together to form the targeting portion of the compositions of this invention. It is preferred that these sugar linking groups comprise the phosphodiester structure or a derivative of such. Derivatives of the phosphodiester structure may include substitution of a sulphur, an alkoxy group such as methyl, methyl oxide, or amine group for an oxygen. The sugar phosphate nucleic acid backbone may be modified as a phosphorothioate, alkylphosphonate such as methylphosphonate or phosphate alkylated moiety (a phosphotriester). The phosphodiester linkage may also be replaced by a carbon or ether linkage.</p>
    <p>In further embodiment of this invention, a linking moiety has been devised to allow the direct attachment of a modified unit to the terminal position of the 3'-end of the modified oligonucleotides. Thus, an ester, or more preferably a bromomethylketo group, is attached to the 3'-hydroxyl of a modified 2'-modified nucleoside having its 5'-hydroxyl protected with a dimethoxytriphenylmethyl group and, if the heterocycle is of the cytosine series, having that heterocycle protected with a benzoyl protecting group. If the required targeting sequence has a terminal 3'-thymine or cytosine base, the desired modified thymine or cytosine base containing the bromomethylketo linker is utilized as the first monomer to attach to the control pore glass (CPG) solid support which contains a normal nucleoside attached via its 3'-hydroxyl group. The base sensitive ester linkage attaching the 2'-modified nucleoside to the nucleoside attached to the CPG is cleaved under the usual concentrated ammonium hydroxide conditions that are utilized to remove the oligonucleotide from the CPG support. This will allow the modified oligonucleotide to have a 2'-modified unit at its terminal, 3'-end.</p>
    <p>Cleavage of oligonucleotides by nucleolytic enzymes require the formation of an enzyme-substrate complex, or in particular a nuclease-oligonucleotide complex. The nuclease enzymes will generally require specific binding sites located on the oligonucleotides for appropriate attachment. If the oligonucleotide binding sites are removed or hindered such that the nucleases will not attach to the oligonucleotides, the nuclease resistant oligonucleotides result. In the case of restriction endonucleases that cleave sequence-specific palindromic double-stranded DNA, certain binding sites such as the ring nitrogen in the 3- and 7-positions have been identified as required hiding sites. Removal of one or more of these sites or hindering the nuclease approach to these particular positions within the recognition sequence has provided various levels or resistance to the specific nucleases.</p>
    <p>This invention provides antisense oligonucleotides characterized by superior hybridizing properties. We have discovered from structure activity relationships studies that a significant increase in binding (T<sub>m</sub>)s of certain 2'-sugar modified oligonucleotides to its RNA target (complement) is correlated with an increased "A" type conformation of the heteroduplex. Furthermore, absolute fidelity of the modified oligonucleotides is maintained. The increased binding of our 2'-sugar modified sequence-specific oligonucleotides provides superior potency and specificity compared to phosphorus modified antisense oligonucleotides such as methyl phosphonates, phosphorothioates, phosphate triesters and phosphoramidites as known in the literature.</p>
    <p>The only structural difference between DNA and RNA duplexes is an hydrogen atom in the 2'-position of the DNA ribofuranosyl moieties versus a hydroxyl group in the 2'-position of the RNA ribofuranosyl moieties (assuming that the presence or absence of a methyl group in the uracil ring system has no effect). However, gross conformational differences exist between DNA and RNA duplexes.</p>
    <p>It is known from X-ray diffraction analysis of nucleic acid fibers, Arnott and Hukins, Biochemical and Biophysical Research Communication, 47:1504-1510 (1970), and analysis of crystals of double-stranded nucleic acids that DNA takes a "B" form structure and that RNA only takes the much more rigid "A" form structure. The difference between the sugar puckering (C2' endo for "B" form DNA and C3' endo for A-form RNA) of the nucleoside monomeric units of DNA and RNA is the major conformational difference between double-stranded nucleic acids.</p>
    <p>The primary contributor to the pentofuranosyl moiety conformation is the nature of the substituent in the 2'-position. Thus, the population of the C3'-endo form increases with respect to the C2'-endo as the electronegativity of the 2'-substituent increases. For example, among 2'-deoxy-2'-halo-adenine nucleosides, the 2'-fluoro derivative exhibits the largest population (65%) of C3'-endo, and the 2'-iodo shows the lowest (7%). Those of the adenosine (2'-OH) and deoxyadenosine (2'-H) are 36% and 19%, respectively. Furthermore, the effect of the 2'-fluoro group of adenine dinucleotides (2'-deoxy-2'-fluoroadenosine-2'-deoxy-2'-fluoroadenosine or uridine) is further correlated to the stabilization of the stacked conformations more than ribo or deoxyribo modified dimers. Research indicates that the dinucleosides phosphates have a stacked conformation with a geometry similar to that of A--A but with a greater extent of base-base overlapping than A--A. It was assumed that the highly polar nature of the C2'-F bond and the extreme preference for C3'-endo puckering may stabilize the stacked conformation in an "A" structure.</p>
    <p>Data from UV hypochromicity, circular dichromism, and 'H NMR also indicate that the degree of stacking decreases as the electronegativeness of halogen decreases. Furthermore, a steric bulkiness in the 2'-position is better accommodated in an "A" form duplex than a "B" form duplex.</p>
    <p>Thus, a 2'-substituent on the 3'-nucleotidyl unit of a dinucleoside monophosphate is thought to exert a number of effects on the stacking conformation: steric repulsion, furanose puckering preference, electrostatic repulsion, hydrophobic attraction, and hydrogen bonding capabilities. These substituent effects are thought to be determined by the molecular size, electronegativity, and hydrophobicity of the substituent.</p>
    <p>The 2'-iodo substituted nucleosides possess the lowest C3'-endo population (7%) of the halogen series. Thus, on steric effects alone, one would predict an 2'-iodo or similar groups would contribute stacking destabilizing properties and thus reduced binding (T<sub>m</sub>)s for antisense oligonucleotides. However, the lower electronegativeness and high hydrophobic attractive forces of the iodine atom and similar groups complicates the ability to predict stacking stabilities and binding strengths.</p>
    <p>Studies with the 2'-OMe modification of 2'-deoxy guanosine, cytidine, and uridine dinucleoside phosphates exhibit enhanced stacking effects with respect to the corresponding unmethylated species (2'-OH). In this case, the hydrophobic attractive forces of the methyl group tend to overcome the destablilizing effects of its steric bulkiness (hindrance).</p>
    <p>2'-Fluoro-2'-deoxyadenosine has been determined to have an unusually high population of 3'-endo puckering among nucleosides. Adenosine, 2'-deoxyadenosine, and other derivatives typically have population below 40% in the 3'-endo conformer. It is known that a nucleoside residue in well-stacked oligonucleotides favors 3'-endo ribofuranose puckering.</p>
    <p>Melting temperatures (complementary binding) are increased with the 2'-substituted adenosine diphosphates. It is not clear whether the 3'-endo preference of the conformation or the presence of the substituent is responsible for the increased binding. However, as noted, greater overlap of adjacent bases (stacking) can be achieved with the 3'-endo conformations.</p>
    <p>The present novel approach to obtaining stronger binding is to prepare antisense RNA mimics to bind to the targeted RNA. Therefore, a random structure-activity relationship approach was undertaken to discover nuclease resistant antisense oligonucleotides that maintained appropriate hybridization properties.</p>
    <p>A series of 2'-deoxy-2'-modified nucleosides of adenine, guanine, cytosine, thymidine and certain analogs of these bases have been prepared and have been inserted as the modified nucleosides into sequence-specific oligonucleotides via solid phase nucleic acid synthesis. The novel antisense oligonucleotides were assayed for their ability to resist degradation by nucleases and to possess hybridization properties comparable to the unmodified parent oligonucleotide. Initially, small electronegative atoms or groups were selected because these type are not likely to sterically interfere with required Watson-Crick base pair hydrogen bonding (hybridization). However, electronic changes due to the electronegativeness of the atom or group in the 2'-position may profoundly effect the sugar conformation. During our structure activity relationship studies we discovered that the sugar modified oligonucleotides hybridized to the targeted RNA stronger than the unmodified (2'-deoxyribosyl type).</p>
    <p>2'-Substituted oligonucleotides are synthesized by the standard solid phase, automated nucleic acid synthesizer such as the Applied Biosystems, Incorporated 380B or MilliGen/Biosearch 7500 or 8800. Triester, phosphoramidite, or hydrogen phosphonate coupling chemistries (Oligonucleotides. Antisense Inhibitors of Gene Expression. M. Caruthers, pp 7-24, Edited by J. S. Cohen, CRC Press, Inc. Boca Raton, Fla., 1989) are used in with these synthesizers to provide the desired oligonucleotides. The Beaucage reagent (Journal of American Chemical Society, 112, 1253-1255, 1990) or elemental sulfur (S. Beaucage et al., Tetrahedron Letters, 22,1859-1862, 1981) is used with phosphoramidite or hydrogen phosphonate chemistries to provide 2'-substituted phosphorothioate oligonucleotides.</p>
    <p>The requisite 2'-substituted nucleosides (A, G, C, T(U), and nucleic acid base analogs) are generally prepared by modification of several literature procedures as described below.</p>
    <p>Procedure 1. Nucleophilic Displacement of 2'-Leaving Group in Arabino Purine Nucleosides. Nucleophilic displacement of a leaving group in the 2'-up position (2'-deoxy-2'-(leaving group)arabino sugar) of adenine or guanine or their analog nucleosides. General synthetic procedures of this type have been described by M. Ikehara et al., Tetrahedron 34:1133-1138 (1978); ibid., 31:1369-1372 (1975); Chemistry and Pharmaceutical Bulletin, 26:2449-2453 (1978); ibid., 26:240-244 (1978); M. Ikehara Accounts of Chemical Research, 2:47-53 (1969); and R. Ranganathan Tetrahedron Letters, 15:1291-1294 (1977).</p>
    <p>Procedure 2. Nucleophilic Displacement of 2,2'-Anhydro Pyrimidines. Nucleosides thymine, uracil, cytosine or their analogs are converted to 2'-substituted nucleosides by the intermediacy of 2,2'-cycloanhydro nucleoside as described by J. J. Fox, et al., Journal of Organic Chemistry, 29:558-564 (1964).</p>
    <p>Procedure 3. 2'-Coupling Reactions. Appropriately 3',5'-sugar and base protected purine and pyrimidine nucleosides having a unprotected 2'-hydroxyl group are coupled with electrophilic reagents such as methyl iodide and diazomethane to provide the mixed sequences containing a 2'-OMe group H. Inoue, et al., Nucleic Acids Research 15: 6131-6148.</p>
    <p>Procedure 4. 2-Deoxy-2-substituted Ribosylations. 2-Substituted-2-deoxyribosylation of the appropriately protected nucleic acid bases and nucleic acids base analogs has been reported by E. T. Jarvi, et al., Nucleosides &amp; Nucleotides 8:1111-1114 (1989) and L. W. Hertel, et al., Journal of Organic Chemistry 53:2406-2409 (1988).</p>
    <p>Procedure 5. Enzymatic Synthesis of 2'-Deoxy-2'-Substituted Nucleosides. The 2-Deoxy-2-substituted glycosyl transfer from one nucleoside to another with the aid of pyrimidine and purine ribo or deoxyribo phosphorolyses has been described by J. R. Rideout and T. A. Krenitsky, U.S. Pat. No. 4,381,344 (1983).</p>
    <p>Procedure 6. Conversion of 2'-Substituents Into New Substituents. 2'-Substituted-2'-deoxynucleosides are converted into new substituents via standard chemical manipulations. For example, S. Chladek et al., Journal of Carbohydrates, Nucleosides &amp; Nucleotides 7:63-75 (1980) describes the conversion of 2'-deoxy-2'-azidoadenosine, prepared from arabinofuranosyladenine, into 2'-deoxy-2'-aminoadenosine.</p>
    <p>Procedure 7. Free Radical Reactions. Conversions of halogen substituted nucleosides into 2'-deoxy-2'-substituted nucleosides via free radical reactions has been described by K. E. B. Parkes and K. Taylor, Tetrahedron Letters 29:2995-2996 (1988).</p>
    <p>Procedure 8. Conversion of Ribonucleosides to 2'-Deoxy-2'-Substituted Nucleoside. Appropriately 3',5'-sugar and base protected purine and pyrimidine nucleosides having a unprotected 2'-hydroxyl group are converted to 2'-deoxy-2'-substituted nucleosides by the process of oxidation to the 2'-keto group, reaction with nucleophilic reagents, and finally 2'-deoxygenation. Procedures of this type have been described by F. De las Heras, et al., Tetrahedron Letters 29:941-944 (1988).</p>
    <p>Procedure 9. In a preferred process of the invention, 2'-deoxy-substituted guanosine compounds are prepared via n (arabinofuranosyl)guanine intermediate obtained via an oxidation-reduction reaction. A leaving group at the 2' position of the arabinofuranosyl sugar moiety of the intermediate arabino compound is displaced via an SN<sub>2</sub> reaction with an appropriate nucleophile. This procedure thus incorporate principles of both Procedure 1 and Procedure 8 above. 2'-Deoxy-2'-fluoroguanosine is preferably prepared via this procedure. The intermediate arabino compound was obtained utilizing a variation of the oxidation-reduction procedure of Hansske, F., Madej, D. and Robins, M. J. (1984), Tetrahedron, 40:125. According to this invention, the reduction was effected starting at -78Â° C. and allowing the reduction reaction to exothermically warm to about -2Â° C. This results in a high yield of the intermediate arabino compound.</p>
    <p>In conjunction with use of a low temperature reduction, utilization of a tetraisopropyldisiloxane blocking group (a "TPDS" group) for the 3' and 5' positions of the starting guanosine compound contributes in an improved ratio of intermediate arabino compound verses the ribo compound following oxidization and reduction. Following oxidation/reduction, the N<sup>2</sup> guanine amino nitrogen and the 2'-hydroxyl moieties of the intermediate arabino compound are blocked with isobutyryl protecting groups ("Ibu" groups). The tetraisopropyldisiloxane blocking group is removed and the 3' and 5' hydroxyl's are further protected with a second blocking group, a tetrahydropyranyl blocking group (a "THP" group). The isobutyryl group is selectively removed from 2'-hydroxyl group followed by derivation of the 2' position with a triflate (a trifluoromethylsulfonyl) leaving group. The triflate moiety was then displaced with inversion about the 2' position to yield the desire 2'-deoxy-2'-fluoroguanosine compound.</p>
    <p>In addition to the triflate leaving group, other leaving groups include but are not necessarily limited to alkysulfonyl, substituted alkylsulfonyl, arylsulfonyl, substituted arylsulfonyl, heterocyclosulfonyl or trichloroacetimidate. Representative examples include p-(2,4-dinitroanilino)benzenesulfonyl, benzenesulfonyl, methylsulfonyl, p-methylbenzenesulfonyl, p-bromobenzenesulfonyl, trichloroacetimidate, acyloxy, 2,2,2-trifluoro-ethanesulfonyl, imidazolesulfonyl and 2,4,6-trichlorophenyl.</p>
    <p>The isobutyryl group remaining on the N<sup>2</sup> heterocycllc amino moiety of the guanine ring can be removed to yield a completely deblocked nucleoside; however, preferably for incorporation of the 2'-deoxy-2'-substituted compound in an oligonucleotide, deblocking of the N<sup>2</sup> isobutyryl protecting group is deferred until after oligonucleotide synthesis is complete. Normally for use on automated nucleic acid synthesizers, blocking of the N<sup>2</sup> guanine amino moiety with an isobutyryl group is preferred. Thus advantageously, the N<sup>2</sup> -isobutyryl blocked 2'-deoxy-2'-substituted guanosine compounds resulting from the method of the invention can be directly used for oligonucleotide synthesis on automatic nucleic acid synthesizers.</p>
    <p>The oligonucleotides or oligonucleotide analogs of this invention can be used in diagnostics, therapeutics, and as research reagents and kits. For therapeutic use the oligonucleotide is administered to an animal suffering from a disease affected by some protein. It is preferred to administer to patients suspected of suffering from such a disease with amounts of oligonucleotide which are effective to reduce the symptemology of that disease. It is within the scope of a person's skill in the art to determine optimum dosages and treatment schedules for such treatment regimens.</p>
    <p>It is generally preferred to apply the therapeutic agents in accordance with this invention internally such as orally, intravenously, or intramuscularly. Other forms of administration, such as transdermally, topically, or intralesionally may also be useful. Inclusion in suppositories may also be useful. Use of pharmacologically acceptable carriers is also preferred for some embodiments.</p>
    <p>The following examples illustrate the practice of this invention.</p>
    <heading>EXAMPLE 1</heading> <p>Preparation of 2'-Deoxy-2'-fluoro Modified Oligonucleotides</p>
    <p>A. N<sup>6</sup> -Benzoyl- 2'-deoxy-2'-fluoro-5'-O-(4,4'-dimethoxytrityol)!adenosine-3'-O-(N,N-diisopropyl-Î²-cyanoethyl phosphoramidite.</p>
    <p>N<sup>6</sup> -Benzoyl-9-(2'-fluoro-Î²-D-ribofuranosyl)adenine was prepared from 9-Î²-D-arabinofuranosyladenine in a five-step synthesis using a modification of a procedure reported by M. Ikehara at al., Nucleosides and Nucleotides 2:373-385 (1983). Thus, the N<sup>6</sup> -benzoyl derivative was obtained in good yield utilizing the method of transient protection with chlorotrimethylsilane. R. A. Jones, J. Am. Chem. Soc. 104:1316 (1982). Selective protection of the 3' and 5'-hydroxyl groups of N<sup>6</sup> -Benzoyl-9-Î²-D-arabinofuranosyladenine with tetrahydropyranyl (THP) was accomplished by modification of a literature procedure G. Butke, et al., in Nucleic Acid Chemistry, Part 3:149-152, Townsend, L. B. and Tipson, R. S. eds., (J. Wiley and Sons, New York 1986) to yield N<sup>6</sup> -Benzoyl-9- 3',5'-di-O-(tetrahydropyran-2-yl)-Î²-D-arabino furanosyl!adenine in good yield. Treatment of N<sup>6</sup> -Benzoyl-9- 3',5'-di-O-(tetrahydropyran-2-yl)-Î²-D-arabinofuranosyl! adenine with trifluoromethanesulfonic anhydride in dichloromethane gave the 2'-triflate derivative N<sup>6</sup> -Benzoyl-9- 2'-O-trifluoromethylsulfonyl-3',5'-di-O-tetrahydropyran-2-yl)-Î²-D-arabino furanosyl!adenine which was not isolated due to its lability. Displacement of the 2'-triflate group was effected by reaction with tetrabutylammonium fluoride in tetrahydrofuran to obtain a moderate yield of the 2'-fluoro derivative N<sup>6</sup> -Benzoyl-9- 2'-fluoro-3',5'-di-O-tetrahydro-pyran-2-yl)-Î²-D-arabinofuranosyl!adenine. Deprotection of the THP groups of N<sup>6</sup> -Benzoyl-9- 2'-fluoro-3',5'-di-O-(tetrahydropyran-2-yl)-Î²-D-arabino furanosyl!adenine was accomplished by treatment with Dowex-50W in methanol to yield N<sup>6</sup> -benzoyl-9-(2'-deoxy-2'-fluoro-Î²-D-ribofuranosyl)adenine in moderate yield. The <sup>1</sup> H-NMR spectrum of 6 was in agreement with the literature values. M. Ikehara and H. Miki, Chem. Pharm. Bull. 26: 2449-2453 (1978). Standard methodologies were employed to obtain the 5'-dimethoxytrityl-3'-phosphoramidite intermediates N<sup>6</sup> -Benzoyl-9- 2'-fluoro-5'-O-(4,4'-dimethoxytrityl)-Î²-D-ribofuranosyl!adenine and N<sup>6</sup> -Benzoyl- 2'-deoxy-2'-fluoro-5'-O-(4,4'-dimethoxytrityl)! adenosine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite, K. K. Ogilvie, Can J. Chem. 67: 831-839 (1989).</p>
    <p>B. N<sup>6</sup> -Benzoyl-9-Î²-D-arabinofuranosyladenine.</p>
    <p>9-Î²-D-arabinofuranosyladenine (1.07 g, 4.00 m.mol) was dissolved in anhydrous pyridine (20 mL) and anhydrous dimethylformamide (20 mL) under an argon atmosphere. The solution was cooled to ice temperature and chlorotrimethylsilane (3.88 ml, 30.6 m.mol) was added slowly to the reaction mixture via syringe. After stirring the reaction mixture at ice temperature for 30 minutes, benzoyl chloride (2.32 ml, 20 m.mol) was added slowly. The reaction mixture was allowed to warm to 20Â° C. and stirred for 2 hours. After cooling the reaction mixture to ice temperature, cold water (8 ml) was added and the mixture was stirred for 15 minutes. Concentrated ammonium hydroxide (8 ml) was slowly added to the reaction mixture to give a final concentration of 2M of ammonia. After stirring the cold reaction mixture for 30 minutes, the solvent was evaporated in vacuo (60 torr) at 20Â° C. followed by evaporation in vacuo (1 torr) at 40Â° C. to give an oil. This oil was triturated with diethyl ether (50 ml) to give a solid which was filtered and washed with diethyl ether three times. This crude solid was triturated in methanol (100 ml) at reflux temperature three times and the solvent was evaporated to yield N<sup>6</sup> -benzoyl-9-(Î²-D-arabinofuranosyladenine)adenine as a solid (1.50 g, 100%).</p>
    <p>C. N<sup>6</sup> -Benzoyl-9- 3",5"-di-)-tetrahydropyran-2-yl)-D-arabinofuranosyl! adenine.</p>
    <p>N<sup>6</sup> -benzoyl-9-(Î²-D-arabinofuranosyl)adenine (2.62 g, 7.06 m.mol) was dissolved in anhydrous dimethylformamide (150 ml) under an argon atmosphere and p-toluenesulfonic acid monohydrate (1.32 g, 6.92 m.mol) was added. This solution was cooled to ice temperature and dihydropyran (1.26 ml, 13.8 m.mol) was added via syringe. The reaction mixture was allowed to warm to 20Â° C. Over a period of 5 hours a total of 10 equivalents of dihydropyran were added in 2 equivalent amounts in the fashion described. The reaction mixture was cooled to ice temperature and saturated aqueous sodium bicarbonate was added slowly to a pH of 8, then water was added to a volume of 750 ml. The aqueous mixture was extracted with methylene chloride four times (4Ã200 ml), and the organic phases were combined and dried over magnesium sulfate. The solids were filtered and the solvent was evaporated in vacuo (60 torr) at 30Â° C. to give a small volume of liquid which was evaporated in vacuo (1 torr) at 40Â° C. to give an oil. This oil was coevaporated with p-xylene in vacuo at 40Â° to give an oil which was dissolved in methylene chloride (100 ml). Hexane (200 ml) was added to the solution and the lower-boiling solvent was evaporated in vacuo at 30Â° C. to leave a white solid suspended in hexane. This solid was filtered and washed with hexane three times (3Ã10 ml) then purified by column chromatography using silica and methylene chloride-methanol (93:7, v/v) as eluent. The first fraction yielded the title compound 3 as a white foam (3.19 g, 83%) and a second fraction gave a white foam (0.81 g) which was characterized as the 5'-mono-tetrahydropyranyl derivative of N<sup>6</sup> -benzoyl-9-(Î²-D-arabinofuranosyl)adenine.</p>
    <p>D. N<sup>6</sup> -Benzoyl-9- 2'-O-trifluoromethylsulfonyl-3',5'-di-O-(tetrahydropyran-2-yl)-Î²-D-arabinofuranosyl!adenine.</p>
    <p>N<sup>6</sup> -Benzoyl-9- 3',5'-di-O-(tetrahydropyran-2-yl)-Î²-D-arabinofuranosyl!adenine (2.65 g, 4.91 m.mol) was dissolved in anhydrous pyridine (20 ml) and the solvent was evaporated in vacuo (1 mm Hg) at 40Â° C. The resulting oil was dissolved in anhydrous methylene chloride (130 ml) under an argon atmosphere and anhydrous pyridine (3.34 ml, 41.3 m.mol) and N,N-dimethylaminopyridine (1.95 g, 16.0 mmol) were added. The reaction mixture was cooled to ice temperature and trifluoromethanesulfonic anhydride (1.36 ml, 8.05 mmol) was added slowly via syringe. After stirring the reaction mixture at ice temperature for 1 h, it was poured into cold saturated aqueous sodium bicarbonate (140 ml). The mixture was shaken and the organic phase was separated and kept at ice temperature. The aqueous phase was extracted with methylene chloride two more times (2Ã140 ml). The organic extracts which were diligently kept cold were combined and dried over magnesium sulfate. The solvent was evaporated in vacuo (60 torr) at 20Â° C. then evaporated in vacuo (1 torr) at 30Â° C. to give N<sup>6</sup> -Benzoyl-9- 2'-O-trifluoromethylsulfonyl-3',5'-di-O-(tetrahydropyran-2-yl)-Î²-D-arabinofuranosyl!adenine as a crude oil which was not purified further.</p>
    <p>E. N<sup>6</sup> -Benzoyl-9- 2'-fluoro-3',5'-di-O-(tetrahydropyran-2-yl)-Î²-D-arabinofuranosyl!adenine.</p>
    <p>N<sup>6</sup> -Benzoyl-9- 2'-O-trifluoromethylsulfonyl-3',5'-di-O-(tetrahydropyran-2-yl)-Î²-D-arabinofuranosyl!adenine (&lt;4.9 mmol) as a crude oil was dissolved in anhydrous tetrahydro-furan (120 ml) and this solution was cooled to ice temperature under an argon atmosphere. Tetrabutylammonium fluoride as the hydrate (12.8 g, 49.1 mmol) was dissolved in anhydrous tetrahydrofuran (50 ml) and half of this volume was slowly added via syringe to the cold reaction mixture. After stirring at ice temperature for 1 hour, the remainder of the reagent was added slowly. The reaction mixture was stirred at ice temperature for an additional 1 hour, then the solvent was evaporated in vacuo (60 torr) at 20Â° C. to give an oil. This oil was dissolved in methylene chloride (250 ml) and washed with brine three times. The organic phase was separated and dried over magnesium sulfate. The solids were filtered and the solvent was evaporated to give an oil. The crude product was purified by column chromatography using silica in a sintered-glass funnel (600 ml) and ethyl acetate was used as eluent. N<sup>6</sup> -Benzoyl-9- 2'-deoxy-2'-fluoro-3',5'-di-O-(tetrahydropyran-2-yl)-Î²-D-arabinofuranosyl!adenine was obtained as an oil (2.03 g, 76%).</p>
    <p>F. N<sup>6</sup> -Benzoyl-9-(2'-deoxy-2'-fluoro-Î²-D-ribofuranosyl)adenine.</p>
    <p>N<sup>6</sup> -Benzoyl-9- 2'-fluoro-3',5'-di-O-tetrahydropyran-2-yl)-Î²-D-arabinofuranosyl!adenine (1.31 g, 2.42 mmol) was dissolved in methanol (60 ml), and Dowex 50WÃ2-100 (4 cm3, 2.4 m.eq) was added to the reaction mixture. The reaction mixture was stirred at 20Â° C. for 1 hour then cooled to ice temperature. Triethylamine (5 ml) was then slowly added to the cold reaction mixture to a pH of 12. The resin was filtered and washed with 30% triethylamine in methanol until the wash no longer contained UV absorbing material. Toluene (50 ml) was added to the washes and the solvent was evaporated at 24Â° C. in vacuo (60 torr then 1 torr) to give a residue. This residue was partially dissolved in methylene chloride (30 ml) and the solvent was transferred to a separatory funnel. The remainder of the residue was dissolved in hot (60Â° C.) water and after cooling the solvent it was also added to the separatory funnel. The biphasic system was extracted, and the organic phase was separated and extracted three times with water (3Ã100 ml). The combined aqueous extracts were evaporated in vacuo (60 torr then 1 torr Hg) at 40Â° C. to give an oil which was evaporated with anhydrous pyridine (50 ml). This oil was further dried in vacuo (1 torr Hg) at 20Â° C. in the presence of phosphorous pentoxide overnight to give N<sup>6</sup> -benzoyl-9-(2'-deoxy-2'-fluoro-Î²-D-ribofuranosyl)adenine as a yellow foam (1.08 g, 100%) which contained minor impurities.</p>
    <p>G. N<sup>6</sup> -benzoyl-9- 2'-fluoro-5'-O-(4,4'-dimethoxytrityl)-Î²-D-ribofuranosyl!adenine.</p>
    <p>N<sup>6</sup> -benzoyl-9-(2'-fluoro-b-D-ribofuranosyl)adenine (1.08 g, 2.89 mmol) which contained minor impurities was dissolved in anhydrous pyridine (20 ml) under an argon atmosphere, and dry triethylamine (0.52 ml, 3.76 mmol) was added followed by addition of 4,4'-dimethoxytrityl chloride (1.13 g, 3.32 mmol). After 4 hours of stirring at 20Â° C. the reaction mixture was transferred to a separatory funnel and diethyl ether (40 ml) was added to give a white suspension. This mixture was washed with water three times (3Ã10 ml), the organic phase was separated and dried over magnesium sulfate. Triethylamine (1 ml) was added to the solution and the solvent was evaporated in vacuo (60 torr Hg) at 20Â° C. to give an oil which was evaporated with toluene (20 ml) containing triethylamine (1 ml). This crude product was purified by column chromatography using silica and ethyl-acetate-triethylamine (99:1, v/v) followed by ethyl acetate-methanol-triethylamine (80:19:1) to give the product in two fractions. The fractions were evaporated in vacuo (60 torr then 1 torr Hg) at 20Â° C. to give a foam which was further dried in vacuo (1 torr Hg) at 20Â° C. in the presence of sodium hydroxide to give N<sup>6</sup> -benzoyl-9- 2'-fluoro-5'-O-(4,4'-dimethoxytrityl)-Î²-D-ribofuranosyl!adenine as a foam (1.02 g, 52%).</p>
    <p>H. N<sup>6</sup> -Benzoyl- 2'-fluoro-5'-O-(4,4'-dimethoxytrityl)!adenosine-3'-O-N,N-diisopropyl-Î²-cyanoethyl phosphoramidite.</p>
    <p>N<sup>6</sup> -Benzoyl-9- 2'-fluoro-5'-O-(4,4'-dimethoxytrityl)-Î²-D-ribofuranosyl!adenine (1.26 g, 1.89 mmol) was dissolved in anhydrous dichloromethane (13 ml) under an argon atmosphere, diisopropylethylamine (0.82 ml, 4.66 mmol) was added, and the reaction mixture was cooled to ice temperature. Chloro(diisopropylamino)-Î²-cyanoethoxyphosphine (0.88 ml, 4.03 mmol) was added to the reaction mixture which was allowed to warm to 20Â° C. and stirred for 3 hours. Ethyl acetate (80 ml) and triethylamine (1 ml) were added and this solution was washed with brine solution three times (3Ã25 ml). The organic phase was separated and dried over magnesium sulfate. After filtration of the solids the solvent was evaporated in vacuo at 20Â° C. to give an oil which was purified by column chromatography using silica and hexane-ethyl acetate-triethyl-amine (50:49:1) as eluent. Evaporation of the fractions in vacuo at 20Â° C. gave a foam which was evaporated with anhydrous pyridine (20 ml) in vacuo (1 torr) at 26Â° C. and further dried in vacuo (1 torr Hg) at 20Â° C. in the presence of sodium hydroxide for 24 h to give N<sup>6</sup> -benzoyl- 2'-deoxy-2'-fluoro-5'-O-(4,4'-dimethoxytrityol)!adenosine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite as a foam (1.05 g, 63%).</p>
    <p>I. 2'-Deoxy-2'-fluoro-5'-O-(4,4'-dimethoxytrityl)-uridine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>2,2'-Cyclouridine is treated with a solution of 70% hydrogen fluoride/pyridine in dioxane at 120Â° C. for ten hours to provide after solvent removal a 75% yield of 2'-deoxy-2'-fluorouridine. The 5'-DMT and 3'-cyanoethoxydiisopropylphosphoramidite derivitized nucleoside is obtained by standard literature procedures, M. J. Gait, ed., Oligonucleotide Synthesis. A Practical Approach, (IRL Press, Washington, D.C., 1984) or through the procedure of Example 1A.</p>
    <p>J. 2'-Deoxy-2'-fluoro-5'-O-(4,4'-dimethoxytrityl)-cytidine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>2'-Deoxy-2'-fluorouridine is converted to the corresponding cytidine analog via a triazolo intermediate that in turn was aminated the heterocycle is then protected by selective N<sup>4</sup> -benzoylation. The 5'-O-(4,4'-dimethoxy-trityl)-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite) can be prepared in accordance with Example 1A.</p>
    <p>K. 9-(3',5'- 1,1,3,3'-Tetraisopropyldisilox-1,3-diyl!-Î²-D-arabinofuranosyl)guanine.</p>
    <p>The 3' and 5' positions of guanosine were protected by the addition of a TPDS (1,1,3,3-tetraisopropyldisilox-1,3-diyl) protecting group as per the procedure of Robins, M. J., Wilson, J. S., Sawyer, L. and James, M. N. G. (1983) Can. J. Chem., 61:1911. To a stirred solution of DMSO (160 mls) and acetic anhydride (20.0 ml, 212 mmol) was added the TPDS guanosine (21.0 g, 0.040 mol). The reaction was stirred for 36 hrs at room temperature and then cooled to 0Â° C. Cold EtOH (400 ml, 95%) was added and the reaction mixture further cooled to -78Â° C. in a dry ice/acetone bath. NaBH<sub>4</sub> (2.0 g, 1.32 mol.eq) was added. The reaction was allowed to come to -2Â° C., stirred at -2Â° C. for 30 mins, and again cooled to -78Â° C. This was repeated twice more. After addition of the NaBH<sub>4</sub> was complete, the reaction was stirred at ice temperature for 30 mins and then at RT for 1 hr. The reaction was taken up in EtOAc (11) and washed 2Ã with a saturated NaCl solution. The organic layer was dried over MgSO<sub>4</sub> and evaporated at RT. The residue was co-evaporated 2Ã with toluene and purified by silica gel column chromatography using CH<sub>2</sub> Cl<sub>2</sub> -MeOH (90:10) as the eluent. 6.02 g of pure product precipitate from the appropriate column fractions during evaporation of these fraction and an additional 11.49 g of product was obtained as a residue upon evaporated of the fractions.</p>
    <p>L. N<sup>2</sup> -Isobutyryl-9-(2'-O-isobutyryl-3',5'- 1,1,3,3-tetraisopropyldisilox-1,3-diyl!-Î²-D-arabinofuranosyl)guanine.</p>
    <p>9-(3',5'- 1,1,3,3-Tetraisopropyldisilox-1,3-diyl!-Î²-D-arabinofuranosyl)guanine (6.5 g, 0.01248 mol) was dissolved in anhydrous pyridine (156 ml) under argon. DMAP (9.15 g) was added. Isobutyric anhydride (6.12 ml) was slowly added and the reaction mixture stirred at RT overnight. The reaction mixture was poured into cold sat. NaHCO<sub>3</sub> (156 ml) and stirred for 10 min. The aqueous solution was extracted 3Ã with EtOAc (156 ml). The organic phase was washed 3Ã with sat. NaHCO<sub>3</sub> and evaporated to dryness at RT. The residue was co-evaporated with toluene at RT. The residue was purified by silica gel column chromatography using CH<sub>2</sub> Cl<sub>2</sub> -acetone (85:15) to yield 5.67 g (68%) of product.</p>
    <p>M. N<sup>2</sup> -Isobutyryl-9-(2'-O-isobutyryl-Î²-D-arabinofuranosyl)guanine.</p>
    <p>N<sup>2</sup> -Isobutyryl-9-(2'-isobutyryl-3',5'- 1,1,3,3-tetraisopropyldisilox-1,3-diyl!-Î²-D-arabinofuranosyl)guanine (9.83 g, 0.01476 mol) was dissolved in anhydrous THF (87.4 ml) at RT under argon. 1M N(nBu)<sub>4</sub> F in THF (29.52 ml, 2 eq.) was added and the mixture stirred for 1/2 hr. The reaction mixture was evaporated at RT and the residue purified by silica gel column chromatography using EtOAc-MeOH (85:15) to yield 4.98 g (80%) of product.</p>
    <p>N. N<sup>2</sup> -Isobutyryl-9-(2'-O-isobutyryl-3',5'-di-O- tetrahydropyran-2-yl!-Î²-D-arabinofuranosyl)guanine.</p>
    <p>N<sup>2</sup> -Isobutyryl-9-(2'-O-isobutyryl-Î²-D-arabinofuranosyl)guanine (4.9 g) was dissolved in anhydrous 1,4-dioxane (98 ml) at RT under argon. p-Toluenesulfonic acid monohydrate (0.97 g, 0.44 eq.) was added followed by 3,4-dihydro-2H-pyran, i.e. DHP, (9.34 ml, 8.8 sq.). The mixture was stirred for 2 hrs then cooled to ice temp and sat. NaHCO<sub>3</sub> (125 ml) was added to quench the reaction. The reaction mixture was extracted 3Ã with 125 ml portions of CH<sub>2</sub> Cl<sub>2</sub> and the organic phase dried over MgSO<sub>4</sub>. The organic phase was evaporated and the residue dissolved in a minimum, but sufficient amount to yield a clear liquid not a syrup, volume of CH<sub>2</sub> Cl<sub>2</sub> and dripped into 100 times the CH<sub>2</sub> Cl<sub>2</sub> volume of hexane. The precipitated was filtered to give 5.59 g (81.5%) of product.</p>
    <p>O. N<sup>2</sup> -Isobutyryl-9-(3',5'-di-O- tetrahydropyran-2-yl!-Î²-D-arabinofuranosyl)guanine.</p>
    <p>N<sup>2</sup> -Isobutyryl-9-(2'-O-isobutyryl-3',5'-di-O- tetrahydropyran-2-yl!-Î²-D-arabinofuranosyl)guanine (5.58 g) was dissolved in pyridine:MeOH:H<sub>2</sub> O (65:30:15, 52 ml) at RT. The solution was cooled to ice temp and 52 ml of 2N NaOH in EtOH-MeOH (95:15) was added slowly followed by stirring for 2 hrs at ice temp. Glacial AcOH was added to pH6. Sat. NaHCO<sub>3</sub> was then added to pH 7. The mixture was evaporated at RT and the residue co-evaporated with toluene. The residue was dissolved in EtOAc (150 ml) and wash 3Ã with sat. NaHCO<sub>3</sub>. The organic phase was evaporated and the residue purified by silica gel column chromatography using EtOAc-MeOH (95:5) to yield 3.85 g (78.3%) of product.</p>
    <p>P. N<sup>2</sup> -Isobutyryl-9-(3',5'-di-O- tetrahydropyran-2-yl!-2'-O-trifluormethylsulfonyl-Î²-D-arabinofuranosyl)guanine.</p>
    <p>N<sup>2</sup> -Isobutyryl-9-(3',5'-di-O- tetrahydropyran-2-yl!-Î²-D-arabinofuranosyl)guanine (3.84 g) was dissolved in anhydrous CH<sub>2</sub> Cl<sub>2</sub> (79 ml), anhydrous pyridine (5.0 ml) and 4-dimethylaminopyridine (2.93 g) at RT under argon. The solution was cooled to ice temp. and trifluoromethanesulfonic anhydride (1.99 ml) was slowly added with stirring. The mixture was stirred for 1 hr then poured into 100 ml of sat. NaHCO<sub>3</sub>. The aqueous phase was extracted 3Ã with cold CH<sub>2</sub> Cl<sub>2</sub>. The organic phase was dried over MgSO<sub>4</sub>, evaporated and co-evaporated with anhydrous CH<sub>3</sub> CN at RT to yield the crude product.</p>
    <p>Q. N<sup>2</sup> -Isobutyryl-9-(2'-deoxy-2'-fluoro-3',5'-di-O- tetrahydropyran-2-yl!-Î²-D-ribofuranosyl)guanine.</p>
    <p>The crude product from Example 1-P, i.e. N<sup>2</sup> -isobutyryl-9-(3',5'-di-O- tetrahydropyran-2-yl!-2'-O-trifluormethylsulfonyl-Î²-D-arabinofuranosyl)guanine, was dissolved in anhydrous THF (113 ml) under argon at ice temp. 1M anhydrous N(nBu)<sub>4</sub> F (dried by co-evaporation with pyridine) in THF (36.95 ml) was added with stirring. After 1 hr a further aliquot of 1M N(nBu)<sub>4</sub> F in THF (36.95 ml) (10 mol. eq. total) was added. The mixture was stirred for 5 hrs at ice temp. and stored in a -30Â° C. freezer overnight. The reaction mixture was evaporated at RT and the residue dissolved in CH<sub>2</sub> Cl<sub>2</sub> (160 ml) and extracted 5Ã with deionized H<sub>2</sub> O. The organic phase was dried over MgSO<sub>4</sub> and evaporated. The residue was purified by silica gel column chromatography using EtOAc-MeOH (95:5) to yield 5.25 g of product.</p>
    <p>R. N<sup>2</sup> -Isobutyryl-9-(2'-deoxy-2'-fluoro-Î²-D-ribofuranosyl)guanine</p>
    <p>N<sup>2</sup> -Isobutyryl-9-(2'-deoxy-2'-fluoro-3',5'-di-O- tetrahydropyran-2-yl!-Î²-D-ribofuranosyl)guanine (3.85 g) was dissolved in MeOH (80 ml) at RT. 12.32 cm<sup>3</sup> of pre-washed Dowex 50W resin was added and the mixture stirred at RT for 1 hr. The resin was filtered and the filtrate evaporated to dryness. The resin was washed with pyridinetriethylamino-H<sub>2</sub> O (1:3:3) until clear. This filtrate was evaporated to an oil. The residues from the two filtrates were combined in H<sub>2</sub> O (200 ml) and washed 3Ã with CH<sub>2</sub> Cl<sub>2</sub> (100 ml). The aqueous phase was evaporated to dryness and the residue recrystallized from hot MeOH to yield a 0.299 g first crop of product as a white powder. The remaining MeOH solution was purified by silica gel column chromatography yielding a further crop of 0.783 g by elution with EtOH-MeOH (80:20).</p>
    <p>S. N<sup>2</sup> -Isobutyryl-9-(2'-deoxy-2'-fluoro-5'-O- 4,4'-dimethoxytrityl!-Î²-D-ribofuranosyl)guanine.</p>
    <p>N<sup>2</sup> -Isobutyryl-9-(2'-deoxy-2'-fluoro-Î²-D-ribofuranosyl)guanine (1.09 g) was dissolved in pyridine (20 ml) and triethylamine (0.56 ml) at RT under argon. 4,4'-Dimethoxytrityl chloride (1.20 g, 1.15 molar eq.) was added and the mixture stirred at RT for 5 hrs. The mixture was transferred to a separatory funnel and extracted with Et<sub>2</sub> O (100 ml). The organic phase was washed 3Ã with sat. NaHCO<sub>3</sub> (70 ml portions) and the aqueous phase back extracted 3Ã with Et<sub>2</sub> O. The combined organic phases were dried over MgSO<sub>4</sub> and triethylamine (4 ml) added to maintain the solution basic. The solvent was evaporated and the residue purified by silica gel column chromatography. The column was eluted with EtOAc-Et<sub>3</sub> N (100:1) and then EtOAc-MeOH-Et<sub>3</sub> N (95:5:1) to yield 1.03 g of product. <sup>1</sup> H-NMR (DMSO-d<sub>6</sub>) Î´ 6.09 (dd, 1, H1', J<sub>1-2</sub> =2.61, J<sub>1'</sub>,F =16.2 Hz); Î´ 5.28 (ddd, 1, H2', J<sub>2'-F</sub> =52.8 Hz); Î´ 4.38 (m, 1, H3', J<sub>3'</sub>,F =19.8 Hz).</p>
    <p>T. N<sup>2</sup> -Isobutyzyl-9-(2'-deoxy-2'-fluoro-5'-O- 4,4'-dimethoxytrityl!)guanosine-3'-O-N,N-diisopropyl-Î²-cyanoethyl phosphoramidite.</p>
    <p>N<sup>2</sup> -Isobutyryl-9-(2'-deoxy-2'-fluoro-5'-O- 4,4'-dimethoxytrityl!-Î²-D-ribofuranosyl)guanine (0.587 g) was dissolved in anhydrous CH<sub>2</sub> Cl<sub>2</sub> (31 ml) and diisopropylethylamine (0.4 ml) at RT under argon. The solution was cooled to ice temp and chloro(diisopropylamino)-Î²-cyanoethoxyphosphine (0.42 ml) was slowly added. The reaction was allowed to warm to RT and stirred for 3.5 hrs. CH<sub>2</sub> Cl<sub>2</sub> -Et<sub>3</sub> N (100:1, 35 ml) was added and the mixture washed 1Ã with sat. NaHCO<sub>3</sub> (6 ml). The organic phase was dried over MgSO<sub>4</sub> and evaporated at RT. The residue was purified by silica gel column chromatography using Hex-EtOAc-Et<sub>3</sub> N (75:25:1) for 2 column volumes, then Hex-EtOAc-Et<sub>3</sub> N (25:75:1) and finally EtOAc-Et<sub>3</sub> N. The product containing fractions were pooled and evaporated at RT. The resulting oil was co-evaporated 2Ã with CH<sub>3</sub> CN and placed on a vacuum pump overnight to dry. The resulting white solid was dissolved in CH<sub>2</sub> Cl<sub>2</sub> (3 ml) and dripped into stirring hexane (300 ml). The resulting precipitate was filtered and dried on a vacuum pump to yield 0.673 g (88%) of product. <sup>31</sup> P-NMR (CDCl<sub>3</sub>) Î´ 150.5, 151.5.</p>
    <heading>EXAMPLE 2</heading> <p>Preparation of 2'-Deoxy-2'-cyano Modified Oligonucleotides</p>
    <p>A. N<sup>6</sup> -Benzoyl- 2'-deoxy-2'-cyano-5'-O-(4,4'-dimethoxytrityl)! adenosine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>2'-Deoxy-2'-cyanoadenosine is prepared by the free radical replacement of the 2'-iodo group of 2'-deoxy-2'-iodo-3',5'-O-(disiloxytetraisopropyl)-N6-benzoyladenosine according to a similar procedure described by K. E. B. Parkes and K. Taylor, Tetrahedron Letters 29:2995-2996 (1988). 2'-Deoxy-2'-iodoadenosine was prepared by R. Ranganathan as described in Tetrahedron Letters 15:1291-1294 (1977), and disilyated as described by W. T. Markiewicz and M. Wiewiorowski in Nucleic Acid Chemistry, Part 3, pp. 222-231, Townsend, L. B.; Tipson, R. S. eds. (J. Wiley and Sons, New York, 1986). This material is treated with hexamethylditin, AIBN, and t-butylisocyanate in toluene to provide protected 2'-deoxy-2'-cyanoadenosine. This material, after selective deprotection, is converted to its 5'-DMT-3'-phosphoramidite as described in Example 1A.</p>
    <p>B. 2'-Deoxy-2'-cyano-5'-O-(4,4'-dimethoxytrityl)uridine-3'-O-(N,N-diisopropyl-Î²-cyanoethyl phosphoramidite).</p>
    <p>2'-Deoxyuridine (or 5-methyluridine), 3',5'-disilylated as described above, is converted to the 2'-iodo derivative by triphenylphosphonium methyl iodide treatment as described by K. E. B. Parkes and K. Taylor, Tetrahedron Letters 29:2995-2996 (1988). Application of free radical reaction conditions as described by K. E. B. Parkes and K, Taylor, Tetrahedron Letters 29:2995-2996 (1988), provides the 2'-cyano group of the protected nucleoside. Deprotection of this material and subsequent conversion to the protected monomer as described above provides the requisite nucleic acid synthesizer material.</p>
    <p>C. 2'-Deoxy-2'-cyano-5'-O-(4,4'-dimethoxytrityl)cytidine-3'-O-(N,N-diisopropyl-Î²-cyanoethyl phosphoramidite),</p>
    <p>2'-Deoxy-2'-iodocytidine is obtained from the corresponding above described uridine compound via a conventional keto to amino conversion.</p>
    <p>D. 2'-Deoxy-2'-cyano-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-O-(N,N-diisopropyl-Î²-cyanoethyl phos-phoramidite).</p>
    <p>2'-Deoxy-2'-cyanoguanosine is obtained by the displacement of the triflate group in the 2'-up position (arabino sugar) of 3',5'-disilylated N2-isobutrylguanosine. Standard deprotection and subsequent reprotection provides the title monomer.</p>
    <heading>EXAMPLE 3</heading> <p>Preparation of 2'-Deoxy-2'-(trifluoromethyl) Modified Oligonucleotides</p>
    <p>The requisite 2'-deoxy-2'-trifluromethyribosides of nucleic acid bases A, G, U(T), and C are prepared by modifications of a literature procedure described by Q.-Y. Chen and S. W. Wu in the Journal of Chemical Society Perkin Transactions 2385-2387 (1989). Standard procedures, as described in Example 1A, are employed to prepare the 5'-DMT and 3'-phosphoramidites as listed below.</p>
    <p>A. N<sup>6</sup> -Benzoyl- 2'-deoxy-2'-trifluoromethyl-5'-O-(4,4'-dimethoxytrityl)!adenosine-3'-O-(N,N-diisopropyl-Î²-cyanoethyl phosphoramidite).</p>
    <p>B. 2'-Deoxy-2'-trifluoromethyl-5'-O-(4,4'-dimethoxytrityl)uridine-3'-O-(N,N-diisopropyl-Î²-cyanoethyl-phosphoramidite).</p>
    <p>C. 2'-Deoxy-2'-trifluoromethyl-5'-O-(4,4'-dimethoxytrityl)cytidine-3'-O-(N,N-diisopropyl-Î²-cyanoethyl-phosphoramidite).</p>
    <p>D. 2'-Deoxy-2'-trifluoromethyl-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-O-(N,N-diisopropyl-Î²-cyano-ethylphosphoramidite).</p>
    <heading>EXAMPLE 4</heading> <p>Preparation of 2'-Deoxy-2'-(trifluoromethoxy) Modified Oligonucleotides</p>
    <p>The requisite 2'-deoxy-2'-O-trifluoromethylribosides of nucleic acid bases A, G, U(T), and C are prepared by modifications of literature procedures described by B. S. Sproat, et al., Nucleic Acids Research 18:41-49 (1990) and H. Inoue, et al., Nucleic Acids Research 15:6131-6148 (1987). Standard procedures, as described in Example 1A, are employed to prepare the 5'-DMT and 3'-phosphoramidites as listed below.</p>
    <p>A. N6-Benzoyl- 2'-deoxy-2'-(trifluoromethoxy)-5'-O-(4,4'-dimethoxytrityl)!adenosine-3'-O-(N,N-diisoporopyl-Î²-cyanoethylphosphoramidite).</p>
    <p>B. 2'-Deoxy-2'-(trifluoromethoxy)-5'-O-(4,4'-dimethoxytrityl)uridine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>C. 2'-Deoxy-2'-(trifluoromethoxy)-5'-O-(4,4'-dimethoxytrityl)cytidine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>D. 2'-Deoxy-2'-(trifluoromethoxy)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <heading>EXAMPLE 5</heading> <p>Preparation of 2'-Deoxy-2'-(1-proproxy) Modified Oligonucleotides</p>
    <p>The requisite 2'-deoxy-2'-O-propyl ribosides of nucleic acid bases A, G, U(T), and C are prepared by modifications of literature procedures described by B. S. Sproat, et al., Nucleic Acids Research 18:41-49 (1990) and H. Inoue, et al., Nucleic Acids Research 15:6131-6148 (1987). Standard procedures, as described in Example 1A, are employed to prepare the 5'-DMT and 3'-phosphoramidites as listed below.</p>
    <p>A. N<sup>6</sup> -Benzoyl- 2'-deoxy-2'-(1-proproxy)-5'-O-(4,4'-dimethoxytrityl)!adenosine-3'-O-(N,N-diisopropyl-Î²-cyanoethyl phosphoramidite).</p>
    <p>B. 2'-Deoxy-2'-(1-proproxy)-5'-O-(4,4'-dimethoxytrityl)uridine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>C. 2'-Deoxy-2'-(1-proproxy)-5'-O-(4,4'-dimethoxytrityl)cytidine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>D. 2'-Deoxy-2'-(1-proproxy)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <heading>EXAMPLE 6</heading> <p>Preparation of 2'-Deoxy-2'-(vinyloxy) Modified Oligonucleotides</p>
    <p>The requisite 2'-deoxy-2'-O-vinyl ribosides of nucleic acid bases A, G, U(T), and C are prepared by modifications of literature procedures described by B. S. Sproat, et al., Nucleic Acids Research 18:41-49 (1990) and H. Inoue, et al., Nucleic Acids Research 15:6131-6148 (1987). In this case 1,2-dibromoethane is coupled to the 2'-hydroxyl and subsequent dehydrobromination affords the desired blocked 2'-vinyl nucleoside. Standard procedures, as described in Example 1A, are employed to prepare the 5'-DMT and 3'-phosphoramidites as listed below.</p>
    <p>A. N<sup>6</sup> -Benzoyl- 2'-deoxy-2'-(vinyloxy)-5'-O-(4,4'-dimethoxytrityl)!adenosine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>B. 2'-Deoxy-2'-(vinyloxy)-5'-O-(4,4'-dimethoxytrityl)uridine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>C. 2'-Deoxy-2'-(vinyloxy)-5'-O-(4,4'-dimethoxyltrityl)cytidine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>D. 2'-Deoxy-2'-(vinyloxy)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <heading>EXAMPLE 7</heading> <p>Preparation of 2'-Deoxy-2'-(allyloxy) Modified Oligonucleotides</p>
    <p>The requisite 2'-deoxy-2'-O-allyl ribosides of nucleic acid bases A, G, U(T), and C are prepared by modifications of literature procedures described by B. S. Sproat, et al., Nucleic Acids Research 18:41-49 (1990) and H. Inoue, et al., Nucleic Acids Research 15:6131-6148 (1987). Standard procedures, as described in Example 1A, are employed to prepare the 5'-DMT and 3'-phosphoramidites as listed below.</p>
    <p>A. N<sup>6</sup> -Benzoyl- 2'-deoxy-2'-(allyloxy)-5'-(4,4'-dimethoxytrityl)!adenosine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphorsmidite).</p>
    <p>B. 2'-Deoxy-2'-(allyloxy)-5'-O-(4,4'-dimethoxytrityl)-uridine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>C. 2'-Deoxy-2'-(allyloxy)-5'-O-(4,4'-dimethoxytrityl)-cytidine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <p>D. 2'-Deoxy-2'-(allyloxy)-5'-O-(4,4'-dimethoxytrityl)-guanosine-3'-O-(N,N-diisopropyl-Î²-cyanoethylphosphoramidite).</p>
    <heading>EXAMPLE 8</heading> <p>Preparation of 2'-Deoxy-2'-(methylthio), (methylsulfinyl) and (methylsulfonyl) Modified Oligonucleotides</p>
    <p>A. 2'-Deoxy-2'-Methylthiouridine</p>
    <p>2,2'-Anhydrouridine (15.5 g, 68.2 mmol)  Rao, T. S. and Reese, C. B. (1989) J. Chem. Soc., Chem. Commun., 997!, methanethiol (15.7 g, 327 mmol), 1,1,3,3-tetramethylguanidine (39.2 g, 341 mmol) and dimethylforamide (150 ml), were heated together at 60Â° C. After 12 hr, the reaction mixture was cooled and concentrated under reduced pressure. The residual oil was purified by flash column chromatography on silica gel (300 g). Concentration of the appropriate, fractions, which were eluted with CH<sub>2</sub> Cl<sub>2</sub> -MeOH (9:1, v/v), and drying of the residue under high vacuum gave 2'-deoxy-2'-methylthiouridine as a pale yellow solid (14.11 g, 75.4%). Attempts to crystallize the solids from ethanol-hexanes (as reported by Imazawa, M., Ueda, T., and Ukita, T. (1975) Chem. Pharm. Bull., 23:604) failed and the material turned into a hygroscopic foam.</p>
    <p> <sup>1</sup> H NMR (Me<sub>2</sub> SO-d<sub>6</sub>) Î´ 2.0 (3H, s, SCH<sub>3</sub>), 3.34 (1H, dd, J<sub>3'</sub>,2' =54 Hz, 2'H), 3.59 (2H, br m, 5'CH<sub>2</sub>), 3.84 (1H, m, 4'H), 4.2 (1H, dd, J<sub>3'</sub>,4' =2.2 Hz, 3'H), 5.15 (1H, t, 5'OH), 5.62 (1H, t, 3'OH), 5.64 (1H, d, J<sub>C6</sub>,C5 =8.2 Hz), 6.02 (1H, d, J<sub>1'</sub>,2' =6 Hz, 1'H), 7.82 (1H, d, J<sub>C5</sub>,C6 =8.2 Hz, C<sub>6</sub> H), 11.38 (1H, br s, NH).</p>
    <p>B. 2,2'-Anhydro-5-Methyluridine</p>
    <p>A mixture of 5-methyluridine (16.77 g, 69.2 mmol), diphenyl carbonate (17.8 g, 83.1 mmol) and sodium bicarbonate (100 mg) in hexamethylphosphoramide (175 ml) was heated to 150Â° C. with stirring until evolution of CO<sub>2</sub> ceased (approximately 1 hr). The reaction mixture was cooled and then poured into diethylether (11) while stirring to furnish a brown gum. Repeated washings with diethylether (4Ã250 ml) furnished a straw colored hygroscopic powder. The solid was purified by short column chromatography on silica gel (400 g). Pooling and concentration of appropriate fractions, which were eluted with CH<sub>2</sub> Cl<sub>2</sub> -MeOH (85:15, v/v) furnished the title compound as a straw colored solid (12 g, 77.3%) which crystallized from EtOH as long needles, m.p. 226Â°-227Â° C.</p>
    <p>C. 2'-Deoxy-2'-Methylthio-5-Methyluridine</p>
    <p>2.2'-Anhydro-5-methyluridine (17.02 g, 70.6 mmol), methanethiol (16.3 g, 339 mmol), 1,1,3,3-tetramethylguanidine (40.6 g, 353 mmol), and dimethylformamide (150 ml) were heated together at 60Â° C. After 12 hr, the products were cooled and concentrated under reduced pressure. The residual oil was purified by short silica gel (300 g) column chromatography. Concentration of appropriate fractions, which were eluted with CH<sub>2</sub> Cl<sub>2</sub> -MeOH (93:7, v/v), furnished the title compound as a white foam (15.08 g, 74.1%). Crystallization from EtOH-CH<sub>2</sub> Cl<sub>2</sub> furnished white needles.</p>
    <p>D. 2'-Deoxy-2'-Methylsulfinyluridine</p>
    <p>To a stirred solution of 2'-deoxy-2'methylthiouridine (1 g, 3.65 mmol) in EtOH (50 ml) was added a solution of m-chloroperbenzoic acid (50%, 1.26 g, 3.65 mmol in 50 ml EtOH) over a period of 45 min at 0Â° C. The solvent was removed under vacuum and the residue purified by short silica gel (30 g) column chromatography. Concentration of appropriate fractions, which were eluted with CH<sub>2</sub> Cl<sub>2</sub> -MeOH (75:25, v/v), afforded the title compound as a white solid (0.65 g, 61.4%). Crystallization from EtOH furnished white granules, m.p. 219Â°-221Â° C.</p>
    <p> <sup>1</sup> H NMR (Me<sub>2</sub> SO-d<sub>6</sub>) Î´ 2.5(3H, s, SOCH<sub>3</sub>), 3.56 (2H, br s, 5'CH<sub>2</sub>), 3.8 (1H, m, 4'H), 3.91 (1H, m, 2'H), 4.57 (1H, m, 3'H), 5.2 (1H, br s, 5'OH), 5.75 (1H, d, C<sub>5</sub> H), 6.19 (1H, d, 3'OH), 6.35 (1H, d, 1'H), 7.88 (1H, d, C<sub>6</sub> H), 11.43 (1H, br s, NH).</p>
    <p>E. 2'-Deoxy-2'-Methylsulfonyluridine</p>
    <p>To a stirred solution of 2'-deoxy-2'-methyluridine (1 g, 3.65 mmol) in EtOH (50 ml) was added m-chloroperbenzoic acid (50%, 3.27 g, 14.6 mmol) in one portion at room temperature. After 2 hr., the solution was filtered to collect a white precipitate, which on washing (2Ã20 ml, EtOH and 2Ã20 ml Et<sub>2</sub> O) and drying furnished the title compound as a fine powder (0.76 g, 68%), m.p. 227Â°-228Â° C.</p>
    <p> <sup>1</sup> H NMR (Me<sub>2</sub> SO-d<sub>6</sub>) Î´ 3.1 (3H, s, SO<sub>2</sub> CH<sub>3</sub>), 3.58 (2H, m, 5'CH<sub>2</sub>), 3.95 (1H, m, 2'H), 3.98 (1H, m, 4'H), 4.5 (1H, br s, 3'H), 5.2 (1H, br s, 5'OH), 5.75 (1H, d, C<sub>5</sub> H), 6.25 (1H, d, 3'OH), 6.5 (1H, d, 1'H), 7.8 (1H, d, C<sub>6</sub> H), 11.45 (1H, br s, NH).</p>
    <p>F. 2'-Deoxy-5-O-(4,4'-Dimethoxytrityl)-2'-Methylthiouridine</p>
    <p>To a stirred solution of 2'-deoxy-2'-methylthiouridine (1.09 g, 4 mmol)) in dry pyridine (10 ml) was added 4,4'-dimethoxytritylchloride (1.69 g, 5 mmol) and 4-dimethylaminopyridine (50mg) at room temperature. The solution was stirred for 12 hr and the reaction quenched by adding MeOH (1 ml). The reaction mixture was concentrated under vacuum and the residue dissolved in CH<sub>2</sub> Cl<sub>2</sub> (100 ml), washed with sat. aq. NaHCO<sub>3</sub> (2Ã50 ml), sat. aq. NaCl (2Ã50 ml), and dried (MgSO<sub>4</sub>). The solution was concentrated under vacuum and the residue purified by silica gel (30 g) column Chromatography. Elution with CH<sub>2</sub> Cl<sub>2</sub> -MeOH:triethylamine (89:1:1, v/v) furnished the title compound as homogeneous material. Pooling and concentration of appropriate fractions furnished the 5'-O-DMT nucleoside as a foam (1.5 g, 66.5%).</p>
    <p> <sup>1</sup> H NMR (MeSO-d<sub>6</sub>) Î´ 2.02 (3H, s, SCH<sub>3</sub>), 3.15-3.55 (1H, m, 2'CH), 3.75 (6H, s, 2 OCH<sub>3</sub>), 3.97 (1H, m, 4'H), 4.24 (1H, m, 3'H), 5.48 (1H, d, C<sub>5</sub> H), 5.73 (1H, d, 3'-OH), 6.03 (1H, d, C1'H), 6.82-7.4 (13H, m, ArH), 6.65 (1H, d, C<sub>6</sub> H), 11.4 (1H, br s, NH).</p>
    <p>G. 2'-Deoxy-3'-O- (N,N-diisopropyl)-O-Î²-cyanoethylphosphoramide!-5'-O-(4,4'-dimethoxytrityl)-2'-Methylthiouridine</p>
    <p>To a stirred solution of 2'-deoxy-5'-O-(4,4'-dimethoxytrityl)-2'-methylthiouridine (1.5 g, 2.67 mmol) in dry THF (25 ml) was added diisopropylethylamine (1.4 ml, 8 mmol) and the solution cooled to 0Â° C. N,N-diisopropyl-Î²-cyanoethylphosphoramidic chloride (1.26 ml, 5.34 mmol) was added dropwise over a period of 15 min. The reaction mixture was then stirred at room temperature for 2 hr. EtOAc (100 ml, containing 1% triethylamine) was added and the solution washed with sat NaCl (2Ã50 ml) and the organic layer dried over MgSO<sub>4</sub>. The solvent was removed under pressure and the residue purified by short silica gel (30 g) column chromatography. Elution with CH<sub>2</sub> Cl<sub>2</sub> :MeOH:triethylamine (98:1:1, v/v) furnished the product as a mixture of diastereoisomers. Evaporation of the appropriate fractions provided the title compound as a foam (1.32 g, 64.7%).</p>
    <p> <sup>1</sup> H NMR (CDCl<sub>3</sub>) Î´ 2.0 and 2.02 (3H, 2s, SCH<sub>3</sub>), 5.3 and 5.35 (1H, 2d, C<sub>5</sub> H), 6.23 (1H, d, 1'M), 7.8 and 7.78 (1H, 2d, C<sub>6</sub> H) and other protons. <sup>31</sup> P NMR (CDCl<sub>3</sub>) Î´ 151.68 and 152.2 ppm.</p>
    <p>H. 2'-Deoxy-3',5'-di-O-Acetyl-2'-Methylthiouridine</p>
    <p>2'-Deoxy-2'-methylthiouridine (5.0 g, 18.24 mmol) and acetic anhydride (5.6 ml, 54.74 mmol) were stirred together in dry pyridine (30 ml) at room temperature for 12 hr. The products were then concentrated under reduced pressure and the residue obtained was purified by short silica gel column chromatography. The appropriate fractions, which were eluted with CH<sub>2</sub> Cl<sub>2</sub> :MeOH (9:1, v/v), were combined, evaporated under reduced pressure and the residue was crystallized from EtOH to give the title compound (6.0 g, 91.8%) as white needles, m.p. 132Â° C.</p>
    <p> <sup>1</sup> H NMR (CDCl<sub>3</sub>) Î´ 2.17 (3H, s, SCH<sub>3</sub>), 2.20 (6H, s, 2 COCH<sub>3</sub>), 3.40 (1H, t, 2'H), 4.31-4.40 (3H, m, 4',5'H), 5.31 (1H, m, 3'H), 5.80 (1H, d, C<sub>5</sub> H), 6.11 (1H, d, 1'H), 7.45 (1H, d, C<sub>6</sub> H), 8.7 (1H, br s, NH).</p>
    <p>I. 2'-Deoxy-3',5'-di-O-Acetyl-4-(1,2,4-triazol-1-yl)-2'-Methylthiouridine</p>
    <p>Triethylamine (8.4 ml, 60.3 mmol) and phosphoryl chloride (1.2 ml, 12.9 mmol) were added to a stirred solution of 2'-deoxy-3',5'-di-O-acetyl-2'-methylthiouridine (4.6 g, 13 mmol) in CH<sub>3</sub> CN (50 ml). 1,2,4-Triazole (4.14 g, 59.9 mmol) was then added and the reactants were stirred together at room temperature. After 16 hr, triethylamine-water (6:1, v/v; 20 ml) followed by sat. aq. NaHCO<sub>3</sub> (100 ml) were added to the products and the resulting mixture was extracted with CH<sub>2</sub> Cl<sub>2</sub> (2Ã100 ml). The organic layer was dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The residue was purified by short silica gel column chromatography. The appropriate fractions, which were eluted with CH<sub>2</sub> Cl<sub>2</sub> :MeOH (9:1, v/v), were evaporated under vacuum and the residue was crystallized from EtOH to give the title compound (3.01 g, 56.4%) as pale needles, m.p. 127Â°-130Â° C.</p>
    <p> <sup>1</sup> H NMR (CDCl<sub>3</sub>) Î´ 2.18 (6H, s, 2 COCH<sub>3</sub>), 2.30 (3H, s, SCH<sub>3</sub>), 3.67 (1H, m, 2'H), 4.38-4.50 (3H, m, 4',5'H), 5.17 (1H, t, 3'H), 6.21 (1H, d, 1'H), 7.08 (1H, d, C<sub>5</sub> H), 8.16 (1H,s, CH), 8.33 (1H, d, C<sub>6</sub> H), 9.25 (1H, s, CH).</p>
    <p>J. 2'-Deoxy-2'-Methylthiocytidine</p>
    <p>2'-Deoxy-3',5'-di-O-acetyl-4-(1,2,4-triazol-1-yl)-2-methylthiouridine (3.0 g, 7.5 mmol) was dissolved in a saturated solution of ammonia in MeOH (70 ml) and the solution was stirred at room temperature in a pressure bottle for 3 days. The products were then concentrated under reduced pressure and the residue was crystallized from EtOH:CH<sub>2</sub> Cl<sub>2</sub> to give the title compound (1.06 g, 51.7%) as crystals, m.p. 201Â° C.</p>
    <p> <sup>1</sup> H NMR (Me<sub>2</sub> SO-d<sub>6</sub>) Î´ 1.95 (3H, s, SCH<sub>3</sub>), 3.36 (1H, m, 2'H), 3.55 (2H, m, 5'CH<sub>2</sub>), 3.82 (1H, m, 4'H), 4.18 (1H, dd, 3'H), 5.75 (1H, d, C<sub>5</sub> H), 6.1 (1H, d, 1'H), 7.77 (1H, d, C<sub>6</sub> H).</p>
    <p>Anal. calcd. for C<sub>10</sub> H<sub>15</sub> N<sub>3</sub> O<sub>4</sub> S: C, 43.94; H, 5.53; N, 15.37; S, 11.73. Found, C, 44.07; H, 5.45; N, 15.47; S, 11.80.</p>
    <p>K. 2'-Deoxy-N<sup>4</sup> -Benzoyl-2'-Methylthiocytidine</p>
    <p>To a stirred solution of 2'-deoxy-2'-methylthiocytidine (0.86 g, 3.15 mmol) in dry pyridine (20 ml) was added trimethylchlorosilane (2.0 ml, 15.75 mmol), and stirring continued for 15 min. Benzoyl chloride (2.18 ml, 18.9 mmol) was added to the solution followed by stirring for 2 hr. The mixture was then cooled in an ice-bath and MeOH (10 ml) was added. After 5 mins., NH<sub>4</sub> OH (20 ml, 30% aq.) was added and the mixture stirred for 30 min. The reaction mixture was then concentrated under vacuum and the residue purified by short silica gel (70 g) column chromatography. Elution with CH<sub>2</sub> Cl<sub>2</sub> :MeOH (9:1, v/v), pooling of appropriate fractions and evaporation furnished the title compound (0.55 g, 46.6%) which crystallized from EtOH as needles, m.p. 193Â°-194Â° C.</p>
    <p>L. N<sup>4</sup> -Benzoylamino-1- 2-Deoxy-5-(4,4'-Dimethoxytrityl)-2-Methylthio-Î²-D-Ribofuranosyl!pyrimidin-3(2H)-one (or 2'-Deoxy-N<sup>4</sup> -Benzoyl-5'-(4,4'-Dimethoxytrityl)-2'-Methylthiocytidine)</p>
    <p>To a stirred solution of 2'-deoxy-N<sup>4</sup> -benzoyl-2'-methylthiocytidine (0.80 g, 2.12 mmol) in dry pyridine (10 ml) was added 4,4'-dimethoxytrityl chloride (1.16 g, 3.41 mmol) and 4-dimethylaminopyridine (10 mg) at room temperature. The solution was stirred for 2 hr and the products concentrated under vacuum. The residue was dissolved in CH<sub>2</sub> Cl<sub>2</sub> (70 ml), washed with sat. NaHCO<sub>3</sub> (50 ml), sat. NaCl (2Ã50 ml), dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The residue was purified by short silica gel (50 g) column chromatography. Elution with CH<sub>2</sub> Cl<sub>2</sub> :triethylamine (99:1, v/v), pooling and concentration of appropriate fractions furnished the title compound (1.29 g, 90%) as a White foam.</p>
    <p> <sup>1</sup> H NMR (DMSO-d<sub>6</sub>) Î´ 2.1 (3H, s, SCH<sub>3</sub>), 3.5 (1H, m, 2'H), 3.75 (6H, s, OCH<sub>3</sub>), 4.15 (1H, m, 4'H) 4.4 (1H, t, 3'H), 5.74 (1H, br d, 3'OH), 6.15 (1H, d, C1'H) 6.8-8.0 (25H, m, ArH, and C<sub>5</sub> H), 8.24 (1H, d, C<sub>6</sub> H), 11.3 (1H, br s, NH).</p>
    <p>M. 2'-Deoxy-N<sup>4</sup> -Benzoyl-3-O- (N,N-Diisopropyl)-Î²-Cyanoethylphosphoramide!-5'-O'(4,4'-Dimethoxytrityl)-2'-Methylthiocytidine</p>
    <p>2'-Deoxy-N<sup>4</sup> -benzoyl-5'-(4,4'-dimethoxytrityl)-2'-methylthiocytidine (1.41 g, 2.07 mmol) was treated with diisopropylethylamine (1.4 ml, 8 mmol) and N,N-diisopropyl-Î²-cyanoethylphophoramide chloride (1.26 ml, 5.34 mmol) in dry THF (25 ml) as described in Example 8-G above. The crude product was purified by short silica gel (50 g) chromatography to furnish the title compound on elution with CH<sub>2</sub> Cl<sub>2</sub> :hexanes:triethylamine (89:10:1, v/v). The appropriate fractions were mixed and evaporated under pressure to give the title compound (1.30 g, 71%) as a white foam (mixture of diastereoisomers).</p>
    <p> <sup>1</sup> H NMR (CDCl<sub>3</sub>) Î´ 2.31 (3H, s, SCH<sub>3</sub>), 3.45-3.7 (3H, m, 2'H and 5'CH<sub>2</sub>), 3.83 (6H, s, OCH<sub>3</sub>), 4.27-4.35 (1H, m, 4'H), 4.6-4.8 (1H, m, 3'H), 6.35 (1H, 2d, 1'H), 6.82-7.8 (25H, m, ArH and C<sub>5</sub> H), 8.38 and 8.45 (1H, 2d, C<sub>6</sub> H) and other protons. <sup>31</sup> P NMR Î´ 151.03 and 151.08 ppm.</p>
    <p>N. 2'-Deoxy-2'-Methylsulfinylcytidine</p>
    <p>2'-Deoxy-2'-methylthiocytidine of Example 8-J was treated as per the procedure of Example 8-D to yield the title compound as a mixture of diastereoisomers having a complex <sup>1</sup> H NMR spectrum.</p>
    <p>O. 2'-Deoxy-2'-Methylsulfonylcytidine</p>
    <p>2'-Deoxy-2'-methylthiocytidine of Example 8-J was treated as per the procedure of Example 8-E to yield the title compound.</p>
    <p>P. N<sup>6</sup> -Benzoyl-3',5'-di-O- Tetrahydropyran-2-yl!-2'-Deoxy-2'-Methylthioadenosine</p>
    <p>N<sup>6</sup> -Benzoyl-9- 2'-O-trifluoromethylsulfonyl-3',5'-di-O-(tetrahydropyran-2-yl)-Î²-D-arabinofuranosyl!adenine from Example 1-D is prepared by treatment with methanethiol in the presence of tetramethylguanidine to yield the title compound.</p>
    <p>Q. N<sup>6</sup> -Benzoyl-2'-Deoxy-2'-Methylthioadenosine</p>
    <p>N<sup>6</sup> -Benzoyl-3',5'-di-O-(tetrahydropyran-2-yl)-2'-deoxy-2'-methylthioadenosine from Example 8-P is treated as per Example 1-F to yield the title compound.</p>
    <p>R. N<sup>6</sup> -Benzoyl-2'-Deoxy-2'-Methylsulfinyladenosine</p>
    <p>N<sup>6</sup> -Benzoyl-2'-deoxy-2'-methylthioadenosine from Example 8-Q was treated as per the procedure of Example 8-D to yield the title compound.</p>
    <p>S. N<sup>6</sup> -Benzoyl-2'-Deoxy-2'-Methylsulfonyladenosine</p>
    <p>N<sup>6</sup> -Benzoyl-2'-deoxy-2'-methylthioadenosine from Example 8-Q was treated as per the procedure of Example 8-E to yield the title compound.</p>
    <p>T. N<sup>2</sup> -Isobutyryl-3',5'-di-O-(tetrahydropyran-2-yl)-2'-Deoxy-2'-Methylthioguanosine</p>
    <p>N<sup>2</sup> -Isobutyryl-9-(3',5'-di-O- tetrahydropyran-2-yl!-2'-O-trifluoromethylsulfonyl-Î²-D-arabinofuranosyl)guanine from Example 1-P is treated with methanethiol in the presence of 1,1,3,3-tetramethylguanidine to yield the title compound.</p>
    <p>U. N<sup>2</sup> -Isobutyryl-2'-Deoxy-2'-Methylthioguanosine</p>
    <p>N<sup>2</sup> -Isobutyryl-3',5'-di-O-(tetrahydropyran-2-yl)-2'-deoxy-2'-methylthioguanosine is treated as per Example 1-R to yield the title compound.</p>
    <p>V. N<sup>2</sup> -Isobutyryl-2'-Deoxy-2'-Methylsulfinylguanosine</p>
    <p>N<sup>2</sup> -Isobutyryl-2'-Deoxy-2'-methylthioguanosine from Example 8-U was treated as per the procedure of Example 8-D to yield the title compound.</p>
    <p>W. N<sup>2</sup> -Isobutyryl-2'-Deoxy-2'-Methylsulfonylguanosine</p>
    <p>N<sup>2</sup> -Isobutyryl-2'-Deoxy-2'-methylthioguanosine from Example 8-U was treated as per the procedure of Example 8-E to yield the title compound.</p>
    <p>X. 2'-Deoxy-5-O-(4,4'-Dimethoxytrityl)-2-Methylsulfinyluridine</p>
    <p>2'-Deoxy-2'-methylsulfinyluridine from Example 8-D above is treated as per Example 8-F to yield the title compound.</p>
    <p>Y. 2'-Deoxy-3'-O- (N,N-Diisopropyl)-O-Î²-cyanoethylphosphoramide!-5'-O-(4,4'-Dimethoxytrityl)-2'-Methylsulfinyluridine</p>
    <p>2'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-2-methylsulfinyluridine is treated as per Example 8-G to yield the title compound.</p>
    <p>Z. N<sup>6</sup> -Benzoyl-2'-Deoxy-5-O-(4,4'-Dimethoxytrityl)-2'-Methylthioadenosine</p>
    <p>N<sup>6</sup> -benzoyl-2'-Deoxy-2'-methylthioadenosine from Example 8-Q above is treated as per Example 8-F to yield the title compound.</p>
    <p>AA. N<sup>6</sup> -Benzoyl-2'-Deoxy-3'-O- (N,N-Diisopropyl)-O-Î²-Cyanoethylphosphoramide!-5'-O-(4,4'-Dimethoxytrityl)-2'-Methylthioadenosine</p>
    <p>N<sup>6</sup> -benzoyl-2'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-2'-methylthioadenosine is treated as per Example 8-G to yield the title compound.</p>
    <p>BB. 2'-Deoxy-N<sup>2</sup> -Isobutyryl-5-O-(4,4'-Dimethoxytrityl)-2'-Methylthioguanosine</p>
    <p>2'-Deoxy-N<sup>2</sup> -isobutyryl-2'-methylthioguanosine from Example 8-U above is treated as per Example 8-F to yield the title compound.</p>
    <p>CC. 2'-Deoxy-N<sup>2</sup> -Isobutyryl-3'-O- (N,N-Diisopropyl)-O-Î²-Cyanoethylphosphoramide!-5'-O-(4,4'-Dimethoxytrityl)-2'-Methylthioguanosine</p>
    <p>2'-Deoxy-N<sup>2</sup> -isobutyryl-5'-O-(4,4'-dimethoxytrityl)-2'-methylthioguanosine is treated as per Example 8-G to yield the title compound.</p>
    <p>DD. 2'-Deoxy-5-O-(4,4'-Dimethoxytrityl)-2'-Methylsulfonyluridine</p>
    <p>2'-Deoxy-2'-methylsulfonyluridine from Example 8-E above is treated as per Example 8-F to yield the title compound.</p>
    <p>EE. 2'-Deoxy-3'-O- (N,N-Diisopropyl)-O-Î²-Cyanoethylphosphoramide!-5'-O-(4,4'-Dimethoxytrityl)-2'-Methylsulfinyluridine</p>
    <p>2'-Deoxy-5'-O-(4,4'-dimethoxytrityl)-2'-methylsulfinyluridine is treated as per Example 8-G to yield the title compound.</p>
    <heading>EXAMPLE 9</heading> <p>Chemical conversion of an thymine or cytosine (pyrimidine type base) to its Î²-D-2'-deoxy-2'-substituted erythro-pentofuranosyl nucleoside; 2'-substituted ribosylation).</p>
    <p>The thymine or cytosine type analogs are trimethylsilylated under standard conditions such as hexamethyldisilazane (HMDS) and an acid catalyst (ie. ammonium chloride) and then treated with 3,5-O-ditoluoyl-2-deoxy-2-substituted-Î±-D-erythro-pentofuranosyl chloride in the presence of Lewis acid catalysts (ie. stannic chloride, iodine, boron tetrafluoroborate, etc.). A specific procedure has recently been described by J. N. Freskos, Nucleosides &amp; Nucleotides 8:1075-1076 (1989) in which copper (I) iodide is the catalyst employed.</p>
    <heading>EXAMPLE 10</heading> <p>Chemical conversion of an adenine or guanine (purine type base) to its Î²-D-2'-deoxy-2'-substituted erythro-pentofuranosyl nucleoside; 2'-substituted ribosylation).</p>
    <p>The protected purine type analogs are converted to their sodium salts via sodium hydride in acetonitrile and are then treated with 3,5-O-ditoluoyl-2-deoxy-2-substituted-Î±-D-erythro-pentofuranosyl chloride at ambient temperature. A specific procedure has recently been described by R. K. Robins et al., Journal of American Chemical Society 106:6379 (1984).</p>
    <heading>EXAMPLE 11</heading> <p>Conversion of 2'-deoxy-2-substituted thymidines to the corresponding 2'-deoxy-2'-substituted cytidines (chemical conversion of an pyrimidine type 4-keto group to an 4-amino group).</p>
    <p>The 3',5'-sugar hydroxyls of the 2'-modified nucleoside types are protected by acyl groups such as toluoyl, benzoyl, p-nitrobenzoyl, acetyl, isobutryl, trifluoroacetyl, etc. using standards conditions of the acid chlorides or anhydrides and pyridine/dimethylaminopyridine solvent and catalyst. The protected nucleoside is now chlorionated with thionyl chloride or phosphoryl chloride in pyridine or other appropriate basic solvents. The pyrimidine type 4-chloro groups or now displaced with ammonium in methanol. Deprotection of the sugar hydroxyls also takes place. The amino group is benzoylated by the standard two-step process of complete benzylation (sugar hydroxyls and amino group) and the acyls are selectively removed by aqueous sodium hydroxide solution. Alternatively, the in situ process of first treating the nucleoside with chlorotrimethylsilane and base to protect the sugar hydroxyls from subsequent acylation may be employed. K. K. Ogilvie, Can J. Chem. 67:831-839 (1989). Another conversion approach is to replace the pyrimidine type 4-chloro group with an 1,2,4-triazolo group which remains intact throughout the oligonucleotide synthesis on the DNA synthesizer and is displaced by ammonium during the ammonium hydroxide step which removes the oligonucleotide from the CPG support and deprotection of the heterocycles. Furthermore, in many cases the pyrimidine type 4-chloro group can utilized as just described and replaced at the end of the oligonucleotide synthesis.</p>
    <heading>EXAMPLE 12</heading> <p>Procedure for the attachment of 2'-deoxy-2'-substituted 5'-dimethoxytriphenylmethyl ribonucleosides to the 5'-hydroxyl of nucleosides bound to CPG support.</p>
    <p>The 2'-deoxy-2'-substituted nucleosides that will reside in the terminal 3'-position of certain antisense oligonucleotides is protected as their 5'-DMT (the cytosine and adenine exocyclic amino groups are benzoylated and the guanine amino is isobutyrylated) and treated with trifluoro-acetic acid/bromoacetic acid mixed anhydride in pyridine and dimethylaminopyridine at 50Â° C. for five hours. The solution is evaporated under reduced pressure to a thin syrup which is dissolved in ethyl acetate and passed through a column of silica gel. The homogenous fractions were collected and evaporated to dryness. A solution of 10 ml of acetonitrile, 10 micromoles of the 3'-O-bromomethylester modified pyrimidine nucleoside, and one ml of pyridine/dimethylaminopyridine (1:1) is syringed slowly (60 to 90 sec) through a one micromole column of CPG thymidine (Applied Biosystems, INC.) that had previously been treated with acid according to standard conditions to afford the free 5'-hydroxyl group. Other nucleoside bound CPG columns could be employed. The eluent is collected and syringed again through the column. This process is repeated three times. The CPG column is washed slowly with 10 ml of acetonitrile and then attached to an ABI 380B nucleic acid synthesizer. Oligonucleotide synthesis is now initiated. The standard conditions of concentrated ammonium hydroxide deprotection that cleaves the thymidine ester linkage from the CPG support also cleaves the 3',5' ester linkage connecting the pyrimidine modified nucleoside to the thymidine that was initially bound to the CPG nucleoside. In this manner, any 2'-substituted nucleoside or generally any nucleoside with modifications in the heterocycle and/or sugar can be attached at the very 3'-end of an oligonucleotide sequence.</p>
    <heading>EXAMPLE 13</heading> <p>Procedure for the conversion of 2'-deoxy-2'-substituted ribonucleoside-5'-DMT-3'-phosphoramidites into oligonucleotides.</p>
    <p>The polyribonucleotide solid phase synthesis procedure of B. S. Sproat, et al., Nucleic Acids Research 17:3373-3386 (1989) is utilized to prepare the 2'-modified oligonucleotides.</p>
    <p>Oligonucleotides of the sequence CGA CTA TGC AAG TAC having 2'-deoxy-2'-fluoro substituent nucleotides were incorporated at various positions within this sequence. In a first oligonucleotide each of the adenosine nucleotides at positions 3, 6, 10, 11 and 14 (counted in a 5' to 3' directed) were modified to include a 2'-deoxy-2'-fluoro moiety. In a further oligonucleotide, the adenosine and the uridine nucleotides at positions 3, 5, 6, 7, 10, 11, 13 and 14 were so modified. In even a further oligonucleotide, the adenosine, uridine and cytidine nucleotides at positions 1, 3, 4, 5, 6, 7, 9, 10, 11, 13 and 14 were so modified and in even a further oligonucleotide, the nucleotides (adenosine, uridine, cytidine and guanosine) at every position was so modified. Additionally an oligonucleotide having the sequence CTC GTA CCT TCC GGT CC was prepared having adenosine, uridine and cytidine nucleotides at positions 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 15 and 16 also modified to contain 2'-deoxy-2'-fluoro substituent moieties.</p>
    <p>Various oligonucleotides were prepared that incorporated nucleotides having 2'-deoxy-2'-methylthio substituents. For ascertaining the coupling efficiencies of 2'-deoxy-2'-methylthio bearing nucleotides into oligonucleotides, the trimer TCC and the tetramer TUU U were synthesized. In the trimer, TCC, the central cytidine nucleotide (the second nucleotide) included a 2'-deoxy-2'-methylthio substituent. In the tetramer, each of the Uridine nucleotides included a 2'-deoxy-2'-methylthio substituent. In further oligonucleotides, 2'-deoxy-2'-methylthio substituent bearing nucleotides were incorporated within the oligonucleotide sequence in selected sequence positions. Each of the nucleotides at the remaining sequence positions incorporated a 2'-O-methyl substituent on its nucleotide. Thus all of the nucleotides within the oligonucleotide included a substituent group thereon, either a 2'-deoxy-2'-methylthio substituent or a 2'-O-methyl substituent. These oligonucleotides are: GAG CUC CCA GGC having 2'-deoxy-2'-methylthio substituents at positions 4, 5, 6, 7 and 8; CGA CUA UGC AAG UAC having 2'-deoxy-2'-methylthio substituents at positions 1, 4, 5, 7, 9 and 13; UCC AGG UGU CCG AUC having 2'-deoxy-2'-methylthio substituents are positions 1, 2, 3, 7, 9, 10, 11 and 14; TCC AGG CCGUUU C having 2'-deoxy-2'-methylthio substituents at positions 10, 11 and 12; and TCC AGG TGT CCC C having 2'-deoxy-2'-methylthio substituents at positions 10, 11 and 12.</p>
    <heading>EXAMPLE 14</heading> <p>Preparation of 2'-Deoxy-2'-fluoro Modified Phosphorothioates Oligonucleotides.</p>
    <p>2'-Deoxy-2'-substituted 5'-DMT nucleoside 3'-phosphoramidites prepared as described in Examples 1-7 were inserted into sequence-specific oligonucleotide phosphorothioates as described by S. Beaucage et al., Journal of American Chemical Society 112:1253-1255 (1990) and B. S. Sproat, et al., Nucleic Acids Research 17:3373-3386 (1989).</p>
    <p>Oligonucleotides of the sequence CGA CTA TGC AAG TAC having phosphorothioate backbone linkages and 2'-deoxy-2'-fluoro substituent nucleotides were incorporated at various positions within this sequence. In a first oligonucleotide each of the backbone linkages was a phosphorothioate linkage and each of the adenosine, uridine and cytidine nucleotides at positions 1, 3, 4, 5, 6, 7, 9, 10, 11, 13 and 14 (counted in a 5' to 3' directed) were modified to include a 2'-deoxy-2'-fluoro moiety. In a further oligonucleotide each of the backbone linkages was a phosphorothioate linkages and the nucleotides (adenosine, uridine, cytidine and guanosine) at every position were modified to include a 2'-deoxy-2'-fluoro moiety.</p>
    <heading>EXAMPLE 15</heading> <p>Preparation of 2'-Deoxy-2'-fluoro Modified Phosphate Methylated Oligonucleotides.</p>
    <p>The protection, tosyl chloride mediated methanolysis, and mild deprotection described by L. H. Koole et al., in the Journal of Organic Chemistry 54:1657-1664 (1989), is applied to 2'-substituted oligonucleotides to afford phosphate-methylated 2'-substituted oligonucleotides.</p>
    <heading>EXAMPLE 16</heading> <p>Hybridization Analysis.</p>
    <p>A. Evaluation of the thermodynamics of hybridization of 2'-modified oligonucleotides.</p>
    <p>The ability of the 2'-modified oligonucleotides to hybridize to their complementary RNA or DNA sequences was determined by thermal melting analysis. The RNA complement was synthesized from T7 RNA polymerase and a template-promoter of DNA synthesized with an Applied Biosystems, Inc. 380B RNA species was purified by ion exchange using FPLC (LKB Pharmacia,Inc.). Natural antisense oligonucleotides or those containing 2'-modifications at specific locations were added to either the RNA or DNA complement at stoichiometric concentrations and the absorbance (260 nm) hyperchromicity upon duplex to random coil transition was monitored using a Gilford Response II spectrophotometer. These measurements were performed in a buffer of 10 mM Na-phosphate, pH 7.4, 0.1 mM EDTA, and NaCl to yield an ionic strength of 10 either 0.1M or 1.0M. Data was analyzed by a graphic representation of 1/T<sub>m</sub> vs ln Ct!, where  Ct! was the total oligonucleotide concentration. From this analysis the thermodynamic para-meters were determined. Based upon the information gained concerning the stability of the duplex of heteroduplex formed, the placement of nucleotides containing 2'-deoxy-2'-substituents into oligonucleotides were assessed for their effects on helix stability. Modifications that drastically alter the stability of the hybrid exhibit reductions in the free energy (delta G) and decisions concerning their usefulness as antisense oligonucleotides were made.</p>
    <p>As is shown in the following Table 1, the incorporation of 2'-deoxy-2'-fluoro nucleotides into oligonucleotides resulted in significant increases in the duplex stability of the modified oligonucleotide strand (the antisense strand) and its complementary RNA strand (the sense strand). In both phosphodiester backbone and phosphorothioate backbone oligonucleotides, the stability of the duplex increased as the number of 2'-deoxy-2'-fluoro containing nucleotides in the antisense strand increased. As is evident from Table 1, without exception, the addition of a 2'-deoxy-2'-fluoro bearing nucleotide, irrespective of the individual substituent bearing nucleotide or irrespective of the position of that nucleotide in the oligonucleotide sequence, resulted in a increase in the duplex stability.</p>
    <p>In Table 1, the underline nucleotides represent nucleotides that include a 2'-deoxy-2'-fluoro substituent. The non-underlined nucleotides are normal nucleotides. The oligonucleotides prefaced with the designation "ps" have a phosphorothioate backbone. Unlabeled oligonucleotides are normal phosphodiester backboned oligonucleotides.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 1__________________________________________________________________________EFFECTS OF 2'-DEOXY-2'-FLUORO MODIFICATIONS ON DNA(ANTISENSE)RNA(SENSE) DUPLEX STABILITY         GÂ°37                GÂ°37    Tm(Â°(C.)/Antisence Sequence         (kcal/mol)                (kcal/mol)                       Tm(Â°C.)                           Tm(Â°C.)                               subst__________________________________________________________________________CGA CTA TGC AAG TAC         -10.11 Â± 0.04                       45.1CG A CT A TGC -13.61 Â± 0.08                -3.50 Â± 0.09                       53.0                           +7.9                               +1.6CG A C UA  UG C  AAG  UAC         -16.18 Â± 0.08                -6.07 Â± 0.09                       58.9                           +13.8                               +1.7 CG A  CUA  UG C  AAG  UAC         -19.85 Â± 0.05                -9.74 Â± 0.06                       65.2                           +20.1                               +1.8ps(CGA CTA TGC AAG TAC)          -7.58 Â± 0.06                       33.9                           -11.2ps( CG A  CUA -15.90 Â± 0.34                -8.32 Â± 0.34                       60.9                           27.0                               +2.5CTC GTA CCT TCC GGT CC         -14.57 Â± 0.13                       61.6 CUC G UA  CCU  UCC GG U  CC         -27.81 Â± 0.05                -13.24 Â± 0.14                       81.6                           +20.0                               +1.4__________________________________________________________________________</pre>
    
    <p>As is evident from Table 1, the duplexes formed between RNA and an oligonucleotides containing 2'-deoxy-2'-fluoro substituted nucleotides exhibited increased binding stability as measured by the hybridization thermodynamic stability. Delta Tm's of greater than 20Â° C. were measured. By modifying the backbone to a phosphorothioate backbone even greater delta Tm's were observed. In this instance delta Tm's greater than 31Â° C. were measured. These fluoro substituted oligonucleotides exhibited a consistent and additive increase in the thermodynamic stability of the duplexes formed with RNA. While we do not wish to be bound by theory, it is presently believed that the presence of the 2'-fluoro substituent results in the sugar moiety of 2'-fluoro substituted nucleotide assuming substantially a 3'-endo conformation and this results in the oligonucleotide-RNA duplex assuming an A-type helical conformation.</p>
    <p>B. Fidelity of hybridization of 2'-modified oligonucleotides</p>
    <p>The ability of the 2'-modified antisense oligonucleotides to hybridize with absolute specificity to the targeted mRNA was shown by Northern blot analysis of purified target mRNA in the presence of total cellular RNA. Target mRNA was synthesized from a vector containing the cDNA for the target mRNA located downstream from a T7 RNA polymerase promoter. Synthesized mRNA was electrophoresed in an agarose gel and transferred to a suitable support membrane (ie. nitrocellulose). The support membrane was blocked and probed using  <sup>32</sup> P!-labeled antisense oligonucleotides. The stringency was determined by replicate blots and washing in either elevated temperatures or decreased ionic strength of the wash buffer. Autoradiography was performed to assess the presence of heteroduplex formation and the autoradiogram quantitated by laser densitometry (LKB Pharmacia, Inc.). The specificity of hybrid formation was determined by isolation of total cellular RNA by standard techniques and its analysis by agarose electrophoresis, membrane transfer and probing with the labeled 2'-modified oligonucleotides. Stringency was predetermined for the unmodified antisense oligonucleotides and the conditions used such that only the specifically targeted mRNA was capable of forming a heteroduplex with the 2'-modified oligonucleotide.</p>
    <p>C. Base-Pair Specificity of Oligonucleotides and RNA</p>
    <p>Base-pair specificity of 2-deoxy-2'-fluoro modified oligonucleotides with the RNA complement (a "Y strand") was determined by effecting single base-pair mismatches and a bulge. The results of these determinations are shown in Table 2. An 18 mer "X strand" oligonucleotide containing 14 adenosine, uridine and cytidine nucleotides having a 2'-deoxy-2'-fluoro substituent was hybridized with the RNA complement "Y strand" in which the 10 position was varied. In Table 2, the underline nucleotides represent nucleotides that include a 2'-deoxy-2'-fluoro substituent.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 2__________________________________________________________________________EFFECTS OF SINGLE BASE MISMATCHES ON 2'-DEOXY-2'-FLUOROMODIFIED DNA Â· RNA DUPLEX STABILITY    base-pair       GÂ°37                GÂ°37Y   type    (kcalol) (kcal/mol)                         Tm(Â°C.)                              Tm(Â°C.)__________________________________________________________________________X strand: deoxy(CTC GTA CCT TTC CGG TCC)Y strand: ribo(<sup>3'</sup> GAG CAU GGY AAG GCC AGG<sup>5'</sup>)A   Watson-Crick       -14.57 Â± 0.13  61.6C   T--C mismatch       -12.78 Â± 0.11                1.79 Â± 0.17                         54.4 -7.2G   T--G mismatch       -16.39 Â± 0.25                -1.82 Â± 0.28                         61.7 0.1U   T--U mismatch       -13.48 Â± 0.17                1.09 Â± 0.22                         55.9 -5.7none    bulged T       -14.86 Â± 0.35                -0.284 Â± 0.37                         59.4 -2.2X strand: deoxy( CUC G UA  CCU  UUC  CGG  UCC)Y strand: ribo(<sup>3'</sup> GAG CAU GGY AAG CCC AGG<sup>5'</sup>)A   Watson-Crick       -27.80 Â± 0.05  81.6C   U--C mismatch       -21.98 Â± 0.26                5.82 Â± 0.28                         73.8 -7.8G   U--G mismatch       -21.69 Â± 0.16                6.12 Â± 0.17                         77.8 -3.8U   U--U mismatch       -18.68 Â± 0.15                9.13 Â± 0.16                         73.6 -8.0none    bulged U       -22.87 Â± 0.27                4.94 Â± 0.27                         75.5 -6.2__________________________________________________________________________</pre>
    
    <p>As is evident from Table 2, the 2'-deoxy-2'-fluoro modified oligonucleotide formed a duplex with the RNA complement with greater specificity than a like sequenced unmodified oligonucleotide.</p>
    <heading>EXAMPLE 17</heading> <p>Nuclease Resistance</p>
    <p>A. Evaluation of the resistance of 2'-modified oligonucleotides to serum and cytoplasmic nucleases.</p>
    <p>Natural phosphorothioate, and 2-modified oligonucleotides were assessed for their resistance to serum nucleases by incubation of the oligonucleotides in media containing various concentrations of fetal calf serum or adult human serum. Labeled oligonucleotides were incubated for various times, treated with protease K and then analyzed by gel electrophoresis on 20% polyacrylamine-urea denaturing gels and subsequent autoradiography. Autoradiograms were quantitated by laser densitometry. Based upon the location of the modifications and the known length of the oligonucleotide it was possible to determine the effect on nuclease degradation by the particular 2'-modification. For the cytoplasmic nucleases, a HL60 cell line was used. A post-mitochondrial supernatant was prepared by differential centrifugation and the labeled oligonucleotides were incubated in this supernatant for various times. Following the incubation, oligo-nucleotides were assessed for degradation as outlined above for serum nucleolytic degradation. Autoradiography results were quantitated for comparison of the unmodified, the phosphorothioates, and the 2'-modified oligonucleotides. Utilizing these test systems, the stability of a 15-mer oligonucleotide having 2-deoxy-2'-fluoro substituted nucleotides at positions 12 and 14 and a phosphorothioate backbone was investigated. As a control, an unsubstituted phosphodiester oligonucleotide was 50% degraded within 1 hr and 100% degraded within 20 hours. In comparison for the 2'-deoxy-2'-fluoro substituted oligonucleotide having the phosphorothioate backbone, degradation was limited to less than 10% after 20 hours.</p>
    <p>B. Evaluation of the resistance of 2'-modified oligonucleotides to specific endo- and exo-nucleases.</p>
    <p>Evaluation of the resistance of natural and 2'-modified oligonucleotides to specific nucleases (ie, endonucleases, 3',5'-exo-, and 5',3'-exonucleases) was done to determine the exact effect of the modifications on degradation. Modified oligonucleotides were incubated in defined reaction buffers specific for various selected nucleases. Following treatment of the products with proteinase K, urea was added and analysis on 20% poly-acrylamide gels containing urea was done. Gel products were visualized by staining using Stains All (Sigma Chemical Co.). Laser densitometry was used to quantitate the extend of degradation. The effects of the 2'-modifications were determined for specific nucleases and compared with the results obtained from the serum and cytoplasmic systems.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 7(2) INFORMATION FOR SEQ ID NO: 1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 15(B) TYPE: nucleic(C) STRANDEDNESS: single(D) TOPOLOGY: linear(iv) ANTI-SENSE: yes(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:CGACTATGCAAGTAC15(2) INFORMATION FOR SEQ ID NO: 2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 15(B) TYPE: nucleic(C) STRANDEDNESS: single(D) TOPOLOGY: linear(iv) ANTI-SENSE: yes(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:CGACUAUGCAAGUAC15(2) INFORMATION FOR SEQ ID NO: 3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17(B) TYPE: nucleic(C) STRANDEDNESS: single(D) TOPOLOGY: linear(iv) ANTI-SENSE: yes(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:CTCGTACCTTCCGGTCC17(2) INFORMATION FOR SEQ ID NO: 4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17(B) TYPE: nucleic(C) STRANDEDNESS: single(D) TOPOLOGY: linear(iv) ANTI-SENSE: yes(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:CUCGUACCUUCCGGUCC17(2) INFORMATION FOR SEQ ID NO: 5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 18(B) TYPE: nucleic(C) STRANDEDNESS: single(D) TOPOLOGY: linear(iv) ANTI-SENSE: yes(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:CTCGTACCTTTCCGGTCC18(2) INFORMATION FOR SEQ ID NO: 6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 18(B) TYPE: nucleic(C) STRANDEDNESS: single(D) TOPOLOGY: linear(iv) ANTI-SENSE: yes(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:GAGCAUGGYAAGGCCAGG18(2) INFORMATION FOR SEQ ID NO: 7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 18(B) TYPE: nucleic(C) STRANDEDNESS: single(D) TOPOLOGY: linear(iv) ANTI-SENSE: yes(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:CUCGUACCUUUCCGGUCC18__________________________________________________________________________</pre>
    
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4381344">US4381344</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 25, 1980</td><td class="patent-data-table-td patent-date-value">Apr 26, 1983</td><td class="patent-data-table-td ">Burroughs Wellcome Co.</td><td class="patent-data-table-td ">Process for producing deoxyribosides using bacterial phosphorylase</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5013830">US5013830</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 12, 1990</td><td class="patent-data-table-td patent-date-value">May 7, 1991</td><td class="patent-data-table-td ">Ajinomoto Co., Inc.</td><td class="patent-data-table-td ">Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5134066">US5134066</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 29, 1989</td><td class="patent-data-table-td patent-date-value">Jul 28, 1992</td><td class="patent-data-table-td ">Monsanto Company</td><td class="patent-data-table-td ">Improved probes using nucleosides containing 3-dezauracil analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5212295">US5212295</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 15, 1991</td><td class="patent-data-table-td patent-date-value">May 18, 1993</td><td class="patent-data-table-td ">Isis Pharmaceuticals</td><td class="patent-data-table-td ">Monomers for preparation of oligonucleotides having chiral phosphorus linkages</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5214135">US5214135</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 30, 1991</td><td class="patent-data-table-td patent-date-value">May 25, 1993</td><td class="patent-data-table-td ">Chemgenes Corporation</td><td class="patent-data-table-td ">N-protected-2&#39;-O-methyl-ribonucleosides and N-protected 2&#39;-O-methyl-3&#39;-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5466786">US5466786</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 10, 1994</td><td class="patent-data-table-td patent-date-value">Nov 14, 1995</td><td class="patent-data-table-td ">Gilead Sciences</td><td class="patent-data-table-td ">2&#39;modified nucleoside and nucleotide compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/CA2017369A1?cl=en">CA2017369A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 23, 1990</td><td class="patent-data-table-td patent-date-value">Nov 24, 1990</td><td class="patent-data-table-td ">Seliger Heinz Hartmut</td><td class="patent-data-table-td ">Modified phosphoramidite process for the production or modified nucleic acids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE3915462A1?cl=en">DE3915462A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 11, 1989</td><td class="patent-data-table-td patent-date-value">Sep 6, 1990</td><td class="patent-data-table-td ">Europ Lab Molekularbiolog</td><td class="patent-data-table-td ">Verwendung von 2-tert.-alkylimino-2-di-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)-(pfeil abwaerts)(pfeil abwaerts)4(pfeil abwaerts)-alkylamino- 1,3-di-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)-(pfeil abwaerts)(pfeil abwaerts)3(pfeil abwaerts)-alkyl-perhydro-1,3,2-diazaphosphorin fuer 0-substituierungsreaktionen von ribonukleosiden</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/DE4110085A1?cl=en">DE4110085A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 27, 1991</td><td class="patent-data-table-td patent-date-value">Oct 1, 1992</td><td class="patent-data-table-td ">Boehringer Ingelheim Int</td><td class="patent-data-table-td ">New 2&#39;O-alkyl-oligo-ribonucleotide(s) with 8-35 nucleotide units - useful as anti-sense oligo-nucleotide(s), primers and probes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0260032A2?cl=en">EP0260032A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 27, 1987</td><td class="patent-data-table-td patent-date-value">Mar 16, 1988</td><td class="patent-data-table-td ">Ajinomoto Co., Inc.</td><td class="patent-data-table-td ">Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0287313A2?cl=en">EP0287313A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 12, 1988</td><td class="patent-data-table-td patent-date-value">Oct 19, 1988</td><td class="patent-data-table-td ">THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce</td><td class="patent-data-table-td ">Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0399330A1?cl=en">EP0399330A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 15, 1990</td><td class="patent-data-table-td patent-date-value">Nov 28, 1990</td><td class="patent-data-table-td ">Boehringer Mannheim Gmbh</td><td class="patent-data-table-td ">Modified phosphoramidite process for preparing modified nucleic acids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0417999A1?cl=en">EP0417999A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 7, 1990</td><td class="patent-data-table-td patent-date-value">Mar 20, 1991</td><td class="patent-data-table-td ">The Wellcome Foundation Limited</td><td class="patent-data-table-td ">Antiviral compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1990015814A1?cl=en">WO1990015814A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 20, 1990</td><td class="patent-data-table-td patent-date-value">Dec 27, 1990</td><td class="patent-data-table-td ">Meiogenics Inc</td><td class="patent-data-table-td ">Nuclease resistant, single-stranded, non-naturally occurring nucleic acid molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1991006556A1?cl=en">WO1991006556A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 24, 1990</td><td class="patent-data-table-td patent-date-value">May 16, 1991</td><td class="patent-data-table-td ">Gilead Sciences Inc</td><td class="patent-data-table-td ">2&#39; modified oligonucleotides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1991015499A1?cl=en">WO1991015499A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 8, 1991</td><td class="patent-data-table-td patent-date-value">Oct 10, 1991</td><td class="patent-data-table-td ">Europ Lab Molekularbiolog</td><td class="patent-data-table-td ">2&#39;-o-alkyl nucleotides and polymers containing them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1992007065A1?cl=en">WO1992007065A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 23, 1991</td><td class="patent-data-table-td patent-date-value">Apr 30, 1992</td><td class="patent-data-table-td ">Max Planck Gesellschaft</td><td class="patent-data-table-td ">Modified ribozymes</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Arnott and Hukins, Biochemical and Biophysical Research Communication, 47:1504 1510 (1970).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Arnott and Hukins, Biochemical and Biophysical Research Communication, 47:1504-1510 (1970).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">B. S. Sproat et al. Nucleic Acids Research 17: 3373 3386 (1989).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">B. S. Sproat et al. Nucleic Acids Research 17: 3373-3386 (1989).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">B. S. Sproat, et al. Nucleic Acids Research 18:41 49 (1990).</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">B. S. Sproat, et al. Nucleic Acids Research 18:41-49 (1990).</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Calvo Mateo, et al., Tetrahedron Letters 29:941 944 (1988).</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Calvo-Mateo, et al., Tetrahedron Letters 29:941-944 (1988).</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Codington et al. Journal of Organic Chemistry, 29:558 564 (1964).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Codington et al. Journal of Organic Chemistry, 29:558-564 (1964).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Cohen in Oligonucleotides: Antisense Inhibitors of Gene Expression, CRC Press, Inc., Boca Raton, FL (1989), table of contents only.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Dahma et al., Can J. Chem. 67:831 839 (1989).</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Dahma et al., Can J. Chem. 67:831-839 (1989).</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Divakar, et al., "<a href='http://scholar.google.com/scholar?q="Approaches+to+the+Synthesis+of+2%27-Thio+Analogues+of+Pyrimidine+Ribosides"'>Approaches to the Synthesis of 2'-Thio Analogues of Pyrimidine Ribosides</a>", J. Chem. Soc. Perkins Trans., I, (1990), 969-974.</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Divakar, et al., "<a href='http://scholar.google.com/scholar?q="Reaction+Between+2%2C2%27-Anhydro-1-%CE%B2-D-arabinofuranosyluracil+and+Thiolate+Ions"'>Reaction Between 2,2'-Anhydro-1-Î²-D-arabinofuranosyluracil and Thiolate Ions</a>", J. Chem. Soc. Perkin Trans. I, (1982), 1625-1628.</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Divakar, et al., Approaches to the Synthesis of 2 Thio Analogues of Pyrimidine Ribosides , J. Chem. Soc. Perkins Trans., I, (1990), 969 974.</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Divakar, et al., Reaction Between 2,2 Anhydro 1 D arabinofuranosyluracil and Thiolate Ions , J. Chem. Soc. Perkin Trans. I, (1982), 1625 1628.</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">E. T. Jarvi, et al., Nucleosides &amp; Nucleotides 8:1111 1114 (1989).</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">E. T. Jarvi, et al., Nucleosides &amp; Nucleotides 8:1111-1114 (1989).</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">F. Hansske, D. Madej, M. J. Robins (1984) Tetrahedron 40:125.</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Freskos, J.N., Nucleosides &amp; Nucleotides 8:1075 1076 (1989).</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Freskos, J.N., Nucleosides &amp; Nucleotides 8:1075-1076 (1989).</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">G. Butke, et al., Nucleic Acid Chemistry Part 3:149 152.</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">G. Butke, et al., Nucleic Acid Chemistry Part 3:149-152.</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">H. Inoue et al. Nucleic Acids Research 15:6131 6148 (1987).</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">H. Inoue et al. Nucleic Acids Research 15:6131-6148 (1987).</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ikehara et al., 1975. Tetrahedron 31:1369 1372.</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ikehara et al., 1975. Tetrahedron 31:1369-1372.</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ikehara et al., 1981. Chem. Pharm. Bull., 29(11):3281 3285.</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ikehara et al., 1981. Chem. Pharm. Bull., 29(11):3281-3285.</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Imazawa, et al., "<a href='http://scholar.google.com/scholar?q="Nucleosides+and+Nucleotides%2C+XII.+Synthesis+and+Properties+of+2%27-Dexy-2%27-mercaptouridine+and+Its+Derivatives"'>Nucleosides and Nucleotides, XII. Synthesis and Properties of 2'-Dexy-2'-mercaptouridine and Its Derivatives</a>", Chem. Pharm. Bull., 23, (1975), 604-610.</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Imazawa, et al., Nucleosides and Nucleotides, XII. Synthesis and Properties of 2 Dexy 2 mercaptouridine and Its Derivatives , Chem. Pharm. Bull., 23, (1975), 604 610.</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Imazawa, M., Ueda, T., and Ukita, T. (1975) Chem. Pharm. Bull. 23:604.</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">J. Hobbs et al., Biochemistry 11:4336 (1972).</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Journal of American Chemical Society, 112:1253 1255, 1990.</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Journal of American Chemical Society, 112:1253-1255, 1990.</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">K.E.B. Parkes and K. Taylor, Tetrahedron Letters, 29:2995 2996 (1988).</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">K.E.B. Parkes and K. Taylor, Tetrahedron Letters, 29:2995-2996 (1988).</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Kazimierczuk et al, Journal of American Chemical Society 106:6379 (1984).</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Koole et al., Journal of Organic Chemistry 54:1657 1664 (1989).</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Koole et al., Journal of Organic Chemistry 54:1657-1664 (1989).</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">L. W. Hertel, et al., Journal of Organic Chemistry 53:2406 2409 (1988).</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">L. W. Hertel, et al., Journal of Organic Chemistry 53:2406-2409 (1988).</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">M. Ikehara Accounts of Chemical Research, 2:47 53 (1969).</td></tr><tr><td class="patent-data-table-td ">45</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">M. Ikehara Accounts of Chemical Research, 2:47-53 (1969).</td></tr><tr><td class="patent-data-table-td ">46</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">M. Ikehara and H. Miki, Chem. Pharm. Bull. 26:2449 2453 (1978).</td></tr><tr><td class="patent-data-table-td ">47</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">M. Ikehara and H. Miki, Chem. Pharm. Bull. 26:2449-2453 (1978).</td></tr><tr><td class="patent-data-table-td ">48</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">M. Ikehara et al., Nucleic Acids Res. 4:4249 (1977).</td></tr><tr><td class="patent-data-table-td ">49</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">M. Ikehara et al., Nucleic Acids Res. 5:3315 (1978).</td></tr><tr><td class="patent-data-table-td ">50</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">M. Ikehara et al., Nucleic Acids Research 5:1877 (1978).</td></tr><tr><td class="patent-data-table-td ">51</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">M. Ikehara et al., Tetrahedron 34:1133 1138 (1978).</td></tr><tr><td class="patent-data-table-td ">52</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">M. Ikehara et al., Tetrahedron 34:1133-1138 (1978).</td></tr><tr><td class="patent-data-table-td ">53</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">M. J. Gait, et., Oligonucleotide Synthesis A Practical Approach, (IRL Press, Washington, DC 1984); Table of contents only.</td></tr><tr><td class="patent-data-table-td ">54</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">M. J. Robins, J. S. Wilson, L. Sawyer &amp; M.N.G. Janes (1983) Can. J. Chem. 61:1911.</td></tr><tr><td class="patent-data-table-td ">55</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Marcus Sekura et al. 1987. Nucleic Acid Res. 15(4):5749 5763.</td></tr><tr><td class="patent-data-table-td ">56</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Marcus-Sekura et al. 1987. Nucleic Acid Res. 15(4):5749-5763.</td></tr><tr><td class="patent-data-table-td ">57</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ohtsuka et al., European Journal of Biochemistry 139:447 450 (1984).</td></tr><tr><td class="patent-data-table-td ">58</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ohtsuka et al., European Journal of Biochemistry 139:447-450 (1984).</td></tr><tr><td class="patent-data-table-td ">59</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">P. S. Miller &amp; P.O.P. Ts O Anti Cancer Drug Design, 2:117 128 (1987).</td></tr><tr><td class="patent-data-table-td ">60</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">P. S. Miller &amp; P.O.P. Ts'O Anti-Cancer Drug Design, 2:117-128 (1987).</td></tr><tr><td class="patent-data-table-td ">61</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Q. Y. Chem &amp; S.W. Wu in the Journal of Chemical Society Perkin Transactions 2385 2387 (1989).</td></tr><tr><td class="patent-data-table-td ">62</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Q.-Y. Chem &amp; S.W. Wu in the Journal of Chemical Society Perkin Transactions 2385-2387 (1989).</td></tr><tr><td class="patent-data-table-td ">63</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">R. A. Jones, Journal of American Chemical Society 104:1316 1319 (1982).</td></tr><tr><td class="patent-data-table-td ">64</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">R. A. Jones, Journal of American Chemical Society 104:1316-1319 (1982).</td></tr><tr><td class="patent-data-table-td ">65</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">R. Raganthan Tetrahedron Letters 15:1291 1294 (1977).</td></tr><tr><td class="patent-data-table-td ">66</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">R. Raganthan Tetrahedron Letters 15:1291-1294 (1977).</td></tr><tr><td class="patent-data-table-td ">67</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Rao, T.S. and Reese, C.B. (1989) J. Chem. Soc., Commun. 997.</td></tr><tr><td class="patent-data-table-td ">68</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ryan, et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+of+2-Thio-D-ribose+and+2%27-Thioadenosine+Derivatives"'>Synthesis of 2-Thio-D-ribose and 2'-Thioadenosine Derivatives</a>", J. Org. Chem., 36, No. 18, (1971), 2646-2657.</td></tr><tr><td class="patent-data-table-td ">69</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ryan, et al., Synthesis of 2 Thio D ribose and 2 Thioadenosine Derivatives , J. Org. Chem., 36, No. 18, (1971), 2646 2657.</td></tr><tr><td class="patent-data-table-td ">70</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">S. Beaucage et al., Tetrahedron Letters, 22, 1859 1862, 1981.</td></tr><tr><td class="patent-data-table-td ">71</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">S. Beaucage et al., Tetrahedron Letters, 22, 1859-1862, 1981.</td></tr><tr><td class="patent-data-table-td ">72</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">S. Chladek et al. Journal of Carbohydrates, Nucleosides &amp; Nucleotides 7:63 75 (1980).</td></tr><tr><td class="patent-data-table-td ">73</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">S. Chladek et al. Journal of Carbohydrates, Nucleosides &amp; Nucleotides 7:63-75 (1980).</td></tr><tr><td class="patent-data-table-td ">74</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">S. Shibahara et al., Nucleic Acids Research 17:239 (1987) 2:117 128 (1987).</td></tr><tr><td class="patent-data-table-td ">75</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">S. Shibahara et al., Nucleic Acids Research 17:239 (1987) 2:117-128 (1987).</td></tr><tr><td class="patent-data-table-td ">76</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Uesugi et al., Tetrahedron Letters 42:4073 (1979).</td></tr><tr><td class="patent-data-table-td ">77</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Uesugi et al; Nucleosides &amp; Nucleotides 2:373 385 (1983).</td></tr><tr><td class="patent-data-table-td ">78</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Uesugi et al; Nucleosides &amp; Nucleotides 2:373-385 (1983).</td></tr><tr><td class="patent-data-table-td ">79</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Uhlmann, et al., "<a href='http://scholar.google.com/scholar?q="Antisense+Oligonucleotides%3A+A+New+Therapeutic+Principle%2C"'>Antisense Oligonucleotides: A New Therapeutic Principle,</a>" Chemical Reviews, 1990, 558.</td></tr><tr><td class="patent-data-table-td ">80</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Uhlmann, et al., Antisense Oligonucleotides: A New Therapeutic Principle, Chemical Reviews, 1990, 558.</td></tr><tr><td class="patent-data-table-td ">81</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">W. Guschlbauer and K. Jankowski, Nucleic Acid Res. 8:1421 (1980).</td></tr><tr><td class="patent-data-table-td ">82</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">W. T. Markiewicz &amp; M. Wiewiorowski in Nucleic Acid Chemistry, Part 3, pp. 229 231, Townsend, L.B., R. S. Tipson, eds. (J. Wiley &amp; Sons, NY 1986).</td></tr><tr><td class="patent-data-table-td ">83</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">W. T. Markiewicz &amp; M. Wiewiorowski in Nucleic Acid Chemistry, Part 3, pp. 229-231, Townsend, L.B., R. S. Tipson, eds. (J. Wiley &amp; Sons, NY 1986).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6121437">US6121437</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 16, 1999</td><td class="patent-data-table-td patent-date-value">Sep 19, 2000</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Phosphate and thiophosphate protecting groups</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6124099">US6124099</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 22, 1998</td><td class="patent-data-table-td patent-date-value">Sep 26, 2000</td><td class="patent-data-table-td ">The University Of Vermont And State Agricultural College</td><td class="patent-data-table-td ">Method for placing a photo-cross-linking agent at specific internal sites within the sequence of synthetic strands of ribonucleic acids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6147200">US6147200</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 19, 1999</td><td class="patent-data-table-td patent-date-value">Nov 14, 2000</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">2&#39;-O-acetamido modified monomers and oligomers</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6168778">US6168778</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 6, 1997</td><td class="patent-data-table-td patent-date-value">Jan 2, 2001</td><td class="patent-data-table-td ">Nexstar Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6169177">US6169177</a></td><td class="patent-data-table-td patent-date-value">Nov 6, 1998</td><td class="patent-data-table-td patent-date-value">Jan 2, 2001</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Processes for the synthesis of oligomeric compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6207819">US6207819</a></td><td class="patent-data-table-td patent-date-value">Feb 12, 1999</td><td class="patent-data-table-td patent-date-value">Mar 27, 2001</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6251588">US6251588</a></td><td class="patent-data-table-td patent-date-value">Feb 10, 1998</td><td class="patent-data-table-td patent-date-value">Jun 26, 2001</td><td class="patent-data-table-td ">Agilent Technologies, Inc.</td><td class="patent-data-table-td ">Monitoring preferential nucleotide hybridization to target nucleotide sequence; generate nucleotide sequence of preferential size, incubate with target nucleotide sequences and monitor hybridization</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6307040">US6307040</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 23, 1997</td><td class="patent-data-table-td patent-date-value">Oct 23, 2001</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Sugar modified oligonucleotides that detect and modulate gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6326358">US6326358</a></td><td class="patent-data-table-td patent-date-value">Jul 7, 1999</td><td class="patent-data-table-td patent-date-value">Dec 4, 2001</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Carbohydrate or 2â²-modified oligonucleotides having alternating internucleoside linkages</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6335439">US6335439</a></td><td class="patent-data-table-td patent-date-value">Jun 11, 1998</td><td class="patent-data-table-td patent-date-value">Jan 1, 2002</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Method of preparing phosphoramidites</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6399756">US6399756</a></td><td class="patent-data-table-td patent-date-value">Jul 8, 1999</td><td class="patent-data-table-td patent-date-value">Jun 4, 2002</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Process for the synthesis of oligomeric compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6414135">US6414135</a></td><td class="patent-data-table-td patent-date-value">Jul 7, 1999</td><td class="patent-data-table-td patent-date-value">Jul 2, 2002</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Phosphonylation of alkylnucleoside with bis(trimethylsilyl)phosphonite in base presence; concentration; adding methanol solvent; nuclease resistance; hybridization</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6426335">US6426335</a></td><td class="patent-data-table-td patent-date-value">Oct 17, 1997</td><td class="patent-data-table-td patent-date-value">Jul 30, 2002</td><td class="patent-data-table-td ">Gilead Sciences, Inc.</td><td class="patent-data-table-td ">Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6440943">US6440943</a></td><td class="patent-data-table-td patent-date-value">Jul 14, 1999</td><td class="patent-data-table-td patent-date-value">Aug 27, 2002</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Mimic and/or modulate the activity of wild-type nucleic acids; the 5&#39; and the 3&#39;-terminal internucleoside linkages are chirally sp and internal internucleoside linkages are chirally rp; resistant to nuclease degradation; psoriasis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6462184">US6462184</a></td><td class="patent-data-table-td patent-date-value">Nov 29, 2000</td><td class="patent-data-table-td patent-date-value">Oct 8, 2002</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6486313">US6486313</a></td><td class="patent-data-table-td patent-date-value">Feb 18, 1999</td><td class="patent-data-table-td patent-date-value">Nov 26, 2002</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligonucleotides having alkylphosphonate linkages and methods for their preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6492111">US6492111</a></td><td class="patent-data-table-td patent-date-value">Nov 25, 1998</td><td class="patent-data-table-td patent-date-value">Dec 10, 2002</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligonucleotides identiphores are caused to bind specifically to target nucleic acid which is predictive of a disease state such as cancer within cells, and are detected by spectrum analysis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6521775">US6521775</a></td><td class="patent-data-table-td patent-date-value">Dec 11, 2001</td><td class="patent-data-table-td patent-date-value">Feb 18, 2003</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Genetically engineered oligonucleotides for use as diagnostic and therapeutic tools in gene therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6531584">US6531584</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 2, 1999</td><td class="patent-data-table-td patent-date-value">Mar 11, 2003</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Nuclease resistant oligonucleotide analogs; DNA or RNA modulation; diagnosis, thearpy of viral diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6534639">US6534639</a></td><td class="patent-data-table-td patent-date-value">Jul 7, 2000</td><td class="patent-data-table-td patent-date-value">Mar 18, 2003</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Guanidinium functionalized oligonucleotides and method/synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6576752">US6576752</a></td><td class="patent-data-table-td patent-date-value">Jun 25, 1999</td><td class="patent-data-table-td patent-date-value">Jun 10, 2003</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Aminooxy functionalized oligomers</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6593466">US6593466</a></td><td class="patent-data-table-td patent-date-value">Jul 7, 1999</td><td class="patent-data-table-td patent-date-value">Jul 15, 2003</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Guanidinium functionalized nucleotides and precursors thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6610842">US6610842</a></td><td class="patent-data-table-td patent-date-value">May 6, 1999</td><td class="patent-data-table-td patent-date-value">Aug 26, 2003</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Removing hydroxyl protecting group from compound of given formula and treating with another compound; wide range of diagnostic and therapeutic uses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6617442">US6617442</a></td><td class="patent-data-table-td patent-date-value">Sep 30, 1999</td><td class="patent-data-table-td patent-date-value">Sep 9, 2003</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Human Rnase H1 and oligonucleotide compositions thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6639061">US6639061</a></td><td class="patent-data-table-td patent-date-value">Jul 7, 1999</td><td class="patent-data-table-td patent-date-value">Oct 28, 2003</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">C3â²-methylene hydrogen phosphonate oligomers and related compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6639062">US6639062</a></td><td class="patent-data-table-td patent-date-value">Aug 9, 1999</td><td class="patent-data-table-td patent-date-value">Oct 28, 2003</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligonucleotides which elicit ribonuclease for cleavage in complementary nucleic acid strand, having increased binding affinity/nuclease resistance; for medical diagnosis, gene therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6677471">US6677471</a></td><td class="patent-data-table-td patent-date-value">Nov 8, 2002</td><td class="patent-data-table-td patent-date-value">Jan 13, 2004</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Intermediates for the synthesis of oligonucleotide analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6716625">US6716625</a></td><td class="patent-data-table-td patent-date-value">Aug 9, 2000</td><td class="patent-data-table-td patent-date-value">Apr 6, 2004</td><td class="patent-data-table-td ">Claude Selitrennikoff</td><td class="patent-data-table-td ">Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6753423">US6753423</a></td><td class="patent-data-table-td patent-date-value">Apr 10, 2000</td><td class="patent-data-table-td patent-date-value">Jun 22, 2004</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">For preferentially modulated gene expression in liver and associated tissues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6825331">US6825331</a></td><td class="patent-data-table-td patent-date-value">Sep 3, 2002</td><td class="patent-data-table-td patent-date-value">Nov 30, 2004</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Aminooxy functionalized oligomers, oligomer arrays and methods of using them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6914148">US6914148</a></td><td class="patent-data-table-td patent-date-value">Sep 20, 2002</td><td class="patent-data-table-td patent-date-value">Jul 5, 2005</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Monomer for use in huaman therapeutics and diagnostics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6958214">US6958214</a></td><td class="patent-data-table-td patent-date-value">Apr 12, 2001</td><td class="patent-data-table-td patent-date-value">Oct 25, 2005</td><td class="patent-data-table-td ">Sequenom, Inc.</td><td class="patent-data-table-td ">Polymorphic kinase anchor proteins and nucleic acids encoding the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6962784">US6962784</a></td><td class="patent-data-table-td patent-date-value">Jul 25, 2002</td><td class="patent-data-table-td patent-date-value">Nov 8, 2005</td><td class="patent-data-table-td ">Gilead Sciences, Inc.</td><td class="patent-data-table-td ">Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6974865">US6974865</a></td><td class="patent-data-table-td patent-date-value">Dec 18, 2002</td><td class="patent-data-table-td patent-date-value">Dec 13, 2005</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">C3â² -methylene hydrogen phosphonate oligomers and related compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7002006">US7002006</a></td><td class="patent-data-table-td patent-date-value">Feb 12, 2003</td><td class="patent-data-table-td patent-date-value">Feb 21, 2006</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">reacting a nucleoside with a protecting reagent and activator to produce a regioselectively protected oligonucleoside; lutidine activator improves selectivity; for automatic synthesis of primers, probes and antiseisure agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7022828">US7022828</a></td><td class="patent-data-table-td patent-date-value">May 28, 2002</td><td class="patent-data-table-td patent-date-value">Apr 4, 2006</td><td class="patent-data-table-td ">Sirna Theraputics, Inc.</td><td class="patent-data-table-td ">Anticancer agents, antiinflammatory agents, autoimmune disease; modulation of gene expression; nuclear factor kappa B</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7056896">US7056896</a></td><td class="patent-data-table-td patent-date-value">Sep 27, 2001</td><td class="patent-data-table-td patent-date-value">Jun 6, 2006</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Carbohydrate or 2â²-modified oligonucleotides having alternating internucleoside linkages</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7074769">US7074769</a></td><td class="patent-data-table-td patent-date-value">Jan 2, 2001</td><td class="patent-data-table-td patent-date-value">Jul 11, 2006</td><td class="patent-data-table-td ">The Trustees Of Columbia University In The City Of New York</td><td class="patent-data-table-td ">Antisense oligonucleotide or analog thereof comprising 10 or more contiguous bases or base analogs; for treating cancer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7119184">US7119184</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 4, 2001</td><td class="patent-data-table-td patent-date-value">Oct 10, 2006</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligonucleotides having A-DNA form and B-DNA form conformational geometry</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7125945">US7125945</a></td><td class="patent-data-table-td patent-date-value">Sep 19, 2003</td><td class="patent-data-table-td patent-date-value">Oct 24, 2006</td><td class="patent-data-table-td ">Varian, Inc.</td><td class="patent-data-table-td ">Chromatographic separation of a mixture of analytes by using an absorber, a halogenated polymers of vinyl aromatic monomers comprising styrene and divinylbenzene; separating polar analytes from nonpolar analytes; separating labeled nucleic acids from unlabeled nucleic acids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7138517">US7138517</a></td><td class="patent-data-table-td patent-date-value">Nov 28, 2001</td><td class="patent-data-table-td patent-date-value">Nov 21, 2006</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Sugar modified oligonucleotides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7169916">US7169916</a></td><td class="patent-data-table-td patent-date-value">Mar 31, 2003</td><td class="patent-data-table-td patent-date-value">Jan 30, 2007</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Chloral-free DCA in oligonucleotide synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7176181">US7176181</a></td><td class="patent-data-table-td patent-date-value">May 21, 2002</td><td class="patent-data-table-td patent-date-value">Feb 13, 2007</td><td class="patent-data-table-td ">Yeda Research And Development Co. Ltd.</td><td class="patent-data-table-td ">Enhancement or inhibition of the interactions of galectin-8 and galectin-8-like proteins with other extracellular matrix proteins or cell surface receptors; the use of modulators of cell adhesion; antitumor, -carcinogenic, -metastasis agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7176304">US7176304</a></td><td class="patent-data-table-td patent-date-value">May 11, 2004</td><td class="patent-data-table-td patent-date-value">Feb 13, 2007</td><td class="patent-data-table-td ">Mcswiggen James</td><td class="patent-data-table-td ">RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7300922">US7300922</a></td><td class="patent-data-table-td patent-date-value">May 28, 2002</td><td class="patent-data-table-td patent-date-value">Nov 27, 2007</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">Enhancing or inhibiting the biological activity of nucleic acid ligands by administrating a modulator, to change the binding of the nucleic acid ligand for its target or degrading or cleaving</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7304041">US7304041</a></td><td class="patent-data-table-td patent-date-value">Apr 22, 2005</td><td class="patent-data-table-td patent-date-value">Dec 4, 2007</td><td class="patent-data-table-td ">Regado Biosciences, Inc.</td><td class="patent-data-table-td ">A nucleic acid ligand whose sequence optionally includes a 2&#39;-O-methyl modification and/or a 2&#39;-O-fluoro modification, useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7312325">US7312325</a></td><td class="patent-data-table-td patent-date-value">Sep 26, 2001</td><td class="patent-data-table-td patent-date-value">Dec 25, 2007</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">RNA aptamers and methods for identifying the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7320965">US7320965</a></td><td class="patent-data-table-td patent-date-value">Oct 27, 2006</td><td class="patent-data-table-td patent-date-value">Jan 22, 2008</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of Huntingtin gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7416725">US7416725</a></td><td class="patent-data-table-td patent-date-value">Dec 19, 2006</td><td class="patent-data-table-td patent-date-value">Aug 26, 2008</td><td class="patent-data-table-td ">Yeda Research And Development Co. Ltd.</td><td class="patent-data-table-td ">Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7452987">US7452987</a></td><td class="patent-data-table-td patent-date-value">Aug 5, 2003</td><td class="patent-data-table-td patent-date-value">Nov 18, 2008</td><td class="patent-data-table-td ">Silence Therapeutics Aktiengesellschaft (Ag)</td><td class="patent-data-table-td ">having a double-stranded structure; for gene expression inhibition in treating cancer, diabetes, obesity; genetic engineering</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7491805">US7491805</a></td><td class="patent-data-table-td patent-date-value">Feb 13, 2004</td><td class="patent-data-table-td patent-date-value">Feb 17, 2009</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">Biological conjugates used for drug delivery; side effect reduction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7517864">US7517864</a></td><td class="patent-data-table-td patent-date-value">Dec 9, 2005</td><td class="patent-data-table-td patent-date-value">Apr 14, 2009</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">Study and interfererance, diagnosis and treatment of polyglutamine using short interfering nucleic acid for treatment of dementia or siezures or muscular dystrophy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7531524">US7531524</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 2006</td><td class="patent-data-table-td patent-date-value">May 12, 2009</td><td class="patent-data-table-td ">Regado Biosciences, Inc.</td><td class="patent-data-table-td ">For host undergoing surgery or coronary artery bypass</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7582745">US7582745</a></td><td class="patent-data-table-td patent-date-value">Nov 3, 2006</td><td class="patent-data-table-td patent-date-value">Sep 1, 2009</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of Nav1.8 gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7595387">US7595387</a></td><td class="patent-data-table-td patent-date-value">Dec 22, 2004</td><td class="patent-data-table-td patent-date-value">Sep 29, 2009</td><td class="patent-data-table-td ">Dharmacon, Inc.</td><td class="patent-data-table-td ">Modified polynucleotides for reducing off-target effects in RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7723315">US7723315</a></td><td class="patent-data-table-td patent-date-value">Jun 22, 2007</td><td class="patent-data-table-td patent-date-value">May 25, 2010</td><td class="patent-data-table-td ">Regado Biosciences, Inc.</td><td class="patent-data-table-td ">A nucleic acid ligand whose sequence optionally includes a 2&#39;-O-methyl modification and/or a 2&#39;-O-fluoro modification, useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7741307">US7741307</a></td><td class="patent-data-table-td patent-date-value">Oct 26, 2007</td><td class="patent-data-table-td patent-date-value">Jun 22, 2010</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">Oligonucleotide sequences which bind biomolecules such as peptides, hydrophobic molecules and extracellular proteins for diagnosing and treating cardiovascular disorders in mammals; selectively bind coagulation factors, E2F family members, Ang1 or Ang2</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7749978">US7749978</a></td><td class="patent-data-table-td patent-date-value">Nov 26, 2007</td><td class="patent-data-table-td patent-date-value">Jul 6, 2010</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Double-stranded ribonucleic acid (dsRNA), mediating RNA interference, Huntington&#39;s disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7759480">US7759480</a></td><td class="patent-data-table-td patent-date-value">Jan 29, 2007</td><td class="patent-data-table-td patent-date-value">Jul 20, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Chloral-free DCA in oligonucleotide synthesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7776836">US7776836</a></td><td class="patent-data-table-td patent-date-value">Oct 26, 2007</td><td class="patent-data-table-td patent-date-value">Aug 17, 2010</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">RNA aptamers and methods for identifying the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7776837">US7776837</a></td><td class="patent-data-table-td patent-date-value">Nov 6, 2007</td><td class="patent-data-table-td patent-date-value">Aug 17, 2010</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">RNA aptamers and methods for identifying the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7790691">US7790691</a></td><td class="patent-data-table-td patent-date-value">Jun 3, 2004</td><td class="patent-data-table-td patent-date-value">Sep 7, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">A first oligonucletide and a second are complimentary and hybridize with each other to a target nucleic acid for their use in modulating gene expression; hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7794931">US7794931</a></td><td class="patent-data-table-td patent-date-value">Sep 22, 2003</td><td class="patent-data-table-td patent-date-value">Sep 14, 2010</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">mRNAs serve as metabolite-sensitive genetic switches for regulating gene expression; nonimmunogenic aptamer domains are swapped to create new recognition domain which causes genetic modulation with effector compounds; drug screening; gene therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7807372">US7807372</a></td><td class="patent-data-table-td patent-date-value">Jun 4, 2008</td><td class="patent-data-table-td patent-date-value">Oct 5, 2010</td><td class="patent-data-table-td ">Northwestern University</td><td class="patent-data-table-td ">efficient method of screening libraries of molecules for DNA selectivity using a gold nanoparticle based colorimetric assay</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7812001">US7812001</a></td><td class="patent-data-table-td patent-date-value">Oct 26, 2007</td><td class="patent-data-table-td patent-date-value">Oct 12, 2010</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">RNA aptamers and methods for identifying the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7833992">US7833992</a></td><td class="patent-data-table-td patent-date-value">Apr 30, 2003</td><td class="patent-data-table-td patent-date-value">Nov 16, 2010</td><td class="patent-data-table-td ">Merck Sharpe &amp; Dohme</td><td class="patent-data-table-td ">biological conjugates used for drug delivery; side effect reduction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7834171">US7834171</a></td><td class="patent-data-table-td patent-date-value">Sep 19, 2007</td><td class="patent-data-table-td patent-date-value">Nov 16, 2010</td><td class="patent-data-table-td ">Dharmacon, Inc.</td><td class="patent-data-table-td ">Modified polynucleotides for reducing off-target effects in RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7858591">US7858591</a></td><td class="patent-data-table-td patent-date-value">Oct 26, 2007</td><td class="patent-data-table-td patent-date-value">Dec 28, 2010</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">Oligonucleotide sequences which bind biomolecules such as peptides; selectively bind coagulation factors, E2F family members, Ang1 or Ang2; hydrophobic molecules and extracellular proteins for diagnosing and treating cardiovascular disorders in mammals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7893245">US7893245</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 2008</td><td class="patent-data-table-td patent-date-value">Feb 22, 2011</td><td class="patent-data-table-td ">Silence Therapeutics Aktiengesellschaft (Ag)</td><td class="patent-data-table-td ">Interfering RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7919612">US7919612</a></td><td class="patent-data-table-td patent-date-value">Nov 4, 2003</td><td class="patent-data-table-td patent-date-value">Apr 5, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Comprises modified nucleotide sequences for use in gene expression inhibition, viral defense, transposon silencing and treatment of metabolic disorders; antisense agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7923206">US7923206</a></td><td class="patent-data-table-td patent-date-value">Nov 18, 2005</td><td class="patent-data-table-td patent-date-value">Apr 12, 2011</td><td class="patent-data-table-td ">Dharmacon, Inc.</td><td class="patent-data-table-td ">Method of determining a cellular response to a biological agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7923207">US7923207</a></td><td class="patent-data-table-td patent-date-value">Nov 18, 2005</td><td class="patent-data-table-td patent-date-value">Apr 12, 2011</td><td class="patent-data-table-td ">Dharmacon, Inc.</td><td class="patent-data-table-td ">Apparatus and system having dry gene silencing pools</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7923547">US7923547</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 4, 2006</td><td class="patent-data-table-td patent-date-value">Apr 12, 2011</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">for antisense therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7935811">US7935811</a></td><td class="patent-data-table-td patent-date-value">Nov 18, 2005</td><td class="patent-data-table-td patent-date-value">May 3, 2011</td><td class="patent-data-table-td ">Dharmacon, Inc.</td><td class="patent-data-table-td ">Apparatus and system having dry gene silencing compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7956176">US7956176</a></td><td class="patent-data-table-td patent-date-value">Aug 4, 2006</td><td class="patent-data-table-td patent-date-value">Jun 7, 2011</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7964578">US7964578</a></td><td class="patent-data-table-td patent-date-value">Oct 16, 2008</td><td class="patent-data-table-td patent-date-value">Jun 21, 2011</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">Conjugates and compositions for cellular delivery</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7989612">US7989612</a></td><td class="patent-data-table-td patent-date-value">Aug 4, 2006</td><td class="patent-data-table-td patent-date-value">Aug 2, 2011</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">Antisense against viral sequence such as hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human papilloma virus (HPV), herpes simplex virus (HSV), or influenza virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8084437">US8084437</a></td><td class="patent-data-table-td patent-date-value">Nov 27, 2007</td><td class="patent-data-table-td patent-date-value">Dec 27, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for treating hypercholesterolemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8084600">US8084600</a></td><td class="patent-data-table-td patent-date-value">May 2, 2007</td><td class="patent-data-table-td patent-date-value">Dec 27, 2011</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Short interfering ribonucleic acid (siRNA) with improved pharmacological properties</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8093222">US8093222</a></td><td class="patent-data-table-td patent-date-value">Jun 4, 2009</td><td class="patent-data-table-td patent-date-value">Jan 10, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for treating hypercholesterolemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8097716">US8097716</a></td><td class="patent-data-table-td patent-date-value">Dec 18, 2008</td><td class="patent-data-table-td patent-date-value">Jan 17, 2012</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Interfering RNA duplex having blunt-ends and 3â²-modifications</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8101585">US8101585</a></td><td class="patent-data-table-td patent-date-value">Aug 6, 2007</td><td class="patent-data-table-td patent-date-value">Jan 24, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and methods for the modulation of JNK proteins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8143230">US8143230</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Mar 27, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of PCSK9</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8143233">US8143233</a></td><td class="patent-data-table-td patent-date-value">Dec 17, 2010</td><td class="patent-data-table-td patent-date-value">Mar 27, 2012</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">RNA aptamers and methods for identifying the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8188060">US8188060</a></td><td class="patent-data-table-td patent-date-value">Feb 10, 2009</td><td class="patent-data-table-td patent-date-value">May 29, 2012</td><td class="patent-data-table-td ">Dharmacon, Inc.</td><td class="patent-data-table-td ">Duplex oligonucleotides with enhanced functionality in gene regulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8202979">US8202979</a></td><td class="patent-data-table-td patent-date-value">May 23, 2003</td><td class="patent-data-table-td patent-date-value">Jun 19, 2012</td><td class="patent-data-table-td ">Sirna Therapeutics, Inc.</td><td class="patent-data-table-td ">siNA molecule comprising a double-stranded structure that down-regulates expression of a target nucleic acid, wherein said siNA molecule does not require a 2&#39;-hydroxyl group containing ribonucleotide; treating viral diseases such as SARS (severe acute respiratory syndrome virus), herpes, hepatitis, HIV</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8252755">US8252755</a></td><td class="patent-data-table-td patent-date-value">Sep 20, 2007</td><td class="patent-data-table-td patent-date-value">Aug 28, 2012</td><td class="patent-data-table-td ">Dharmacon, Inc.</td><td class="patent-data-table-td ">Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8273866">US8273866</a></td><td class="patent-data-table-td patent-date-value">Nov 24, 2003</td><td class="patent-data-table-td patent-date-value">Sep 25, 2012</td><td class="patent-data-table-td ">Merck Sharp &amp; Dohme Corp.</td><td class="patent-data-table-td ">Chemically synthesized doubled stranded micro-RNA (miRNA) molecule; nucleic acids with a pyrimidine modification</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8283330">US8283330</a></td><td class="patent-data-table-td patent-date-value">Dec 14, 2009</td><td class="patent-data-table-td patent-date-value">Oct 9, 2012</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">Modulators of pharmacological agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8313901">US8313901</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2006</td><td class="patent-data-table-td patent-date-value">Nov 20, 2012</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Methods and compositions related to the modulation of riboswitches</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8314075">US8314075</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2011</td><td class="patent-data-table-td patent-date-value">Nov 20, 2012</td><td class="patent-data-table-td ">Alynylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of huntingtin gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8324370">US8324370</a></td><td class="patent-data-table-td patent-date-value">Jan 7, 2011</td><td class="patent-data-table-td patent-date-value">Dec 4, 2012</td><td class="patent-data-table-td ">Silence Therapeutics Aktiengesellschaft (Ag)</td><td class="patent-data-table-td ">Interfering RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8329463">US8329463</a></td><td class="patent-data-table-td patent-date-value">Jul 19, 2010</td><td class="patent-data-table-td patent-date-value">Dec 11, 2012</td><td class="patent-data-table-td ">MAX-PLANCK-Gesellschaft zur FÃ¶rderung der Wissenschaften e.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8344128">US8344128</a></td><td class="patent-data-table-td patent-date-value">Aug 26, 2011</td><td class="patent-data-table-td patent-date-value">Jan 1, 2013</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Short interfering ribonucleic acid (siRNA) for oral administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8362231">US8362231</a></td><td class="patent-data-table-td patent-date-value">Jan 6, 2010</td><td class="patent-data-table-td patent-date-value">Jan 29, 2013</td><td class="patent-data-table-td ">Max-Planck-Gesellschaft zur FÃ¶derung der Wissenschaften E.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8372968">US8372968</a></td><td class="patent-data-table-td patent-date-value">Aug 7, 2009</td><td class="patent-data-table-td patent-date-value">Feb 12, 2013</td><td class="patent-data-table-td ">MAX-PLANCK-Gesellschaft zur FÃ¶rderung der Wissenschaften e.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8389489">US8389489</a></td><td class="patent-data-table-td patent-date-value">Apr 12, 2010</td><td class="patent-data-table-td patent-date-value">Mar 5, 2013</td><td class="patent-data-table-td ">Regado Biosciences, Inc.</td><td class="patent-data-table-td ">Modulators of coagulation factors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8394628">US8394628</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2010</td><td class="patent-data-table-td patent-date-value">Mar 12, 2013</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">RNA sequence-specific mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8404831">US8404831</a></td><td class="patent-data-table-td patent-date-value">Aug 26, 2011</td><td class="patent-data-table-td patent-date-value">Mar 26, 2013</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Short interfering ribonucleic acid (siRNA) for oral administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8404832">US8404832</a></td><td class="patent-data-table-td patent-date-value">Aug 26, 2011</td><td class="patent-data-table-td patent-date-value">Mar 26, 2013</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Short interfering ribonucleic acid (siRNA) for oral administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8420391">US8420391</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2010</td><td class="patent-data-table-td patent-date-value">Apr 16, 2013</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">RNA sequence-specific mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8440810">US8440810</a></td><td class="patent-data-table-td patent-date-value">Feb 23, 2011</td><td class="patent-data-table-td patent-date-value">May 14, 2013</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Riboswitches, methods for their use, and compositions for use with riboswitches</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8445237">US8445237</a></td><td class="patent-data-table-td patent-date-value">Jul 12, 2010</td><td class="patent-data-table-td patent-date-value">May 21, 2013</td><td class="patent-data-table-td ">MAX-PLANCK-Gesellschaft zur FÃ¶rderung der Wissenschaften e.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8524680">US8524680</a></td><td class="patent-data-table-td patent-date-value">Aug 31, 2009</td><td class="patent-data-table-td patent-date-value">Sep 3, 2013</td><td class="patent-data-table-td ">Applied Biosystems, Llc</td><td class="patent-data-table-td ">High potency siRNAS for reducing the expression of target genes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8552171">US8552171</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2010</td><td class="patent-data-table-td patent-date-value">Oct 8, 2013</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">RNA sequence-specific mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8586524">US8586524</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 2007</td><td class="patent-data-table-td patent-date-value">Nov 19, 2013</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">Modulators of pharmacological agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8586554">US8586554</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Nov 19, 2013</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of PTP1B</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8586727">US8586727</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2012</td><td class="patent-data-table-td patent-date-value">Nov 19, 2013</td><td class="patent-data-table-td ">Mirna Therapeutics, Inc.</td><td class="patent-data-table-td ">Synthetic mimics of miR-34</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8632997">US8632997</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2010</td><td class="patent-data-table-td patent-date-value">Jan 21, 2014</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">RNA sequence-specific mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8664189">US8664189</a></td><td class="patent-data-table-td patent-date-value">Sep 22, 2009</td><td class="patent-data-table-td patent-date-value">Mar 4, 2014</td><td class="patent-data-table-td ">Rxi Pharmaceuticals Corporation</td><td class="patent-data-table-td ">RNA interference in skin indications</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8664190">US8664190</a></td><td class="patent-data-table-td patent-date-value">Nov 22, 2011</td><td class="patent-data-table-td patent-date-value">Mar 4, 2014</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for treating hypercholesterolemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8742092">US8742092</a></td><td class="patent-data-table-td patent-date-value">Oct 4, 2010</td><td class="patent-data-table-td patent-date-value">Jun 3, 2014</td><td class="patent-data-table-td ">University Of Massachusetts</td><td class="patent-data-table-td ">RNA sequence-specific mediators of RNA interference</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8765930">US8765930</a></td><td class="patent-data-table-td patent-date-value">Jun 4, 2010</td><td class="patent-data-table-td patent-date-value">Jul 1, 2014</td><td class="patent-data-table-td ">MAX-PLANCK-Gesellschaft zur FÃ¶rderung der Wissenschaften e.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8778902">US8778902</a></td><td class="patent-data-table-td patent-date-value">Jul 13, 2010</td><td class="patent-data-table-td patent-date-value">Jul 15, 2014</td><td class="patent-data-table-td ">MAX-PLANCK-Gesellschaft zur FÃ¶rderung der Wissenschaften e.V.</td><td class="patent-data-table-td ">RNA interference mediating small RNA molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/USRE39464">USRE39464</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 24, 2004</td><td class="patent-data-table-td patent-date-value">Jan 9, 2007</td><td class="patent-data-table-td ">Isis Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Oligonucleolotides having site specific chiral phosphorothioate internucleoside linkages</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2003207A2?cl=en">EP2003207A2</a></td><td class="patent-data-table-td patent-date-value">Jan 4, 2001</td><td class="patent-data-table-td patent-date-value">Dec 17, 2008</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense inhibition of PTP1B expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2070939A1?cl=en">EP2070939A1</a></td><td class="patent-data-table-td patent-date-value">May 28, 2002</td><td class="patent-data-table-td patent-date-value">Jun 17, 2009</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">Modulators of pharmacological agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2161038A1?cl=en">EP2161038A1</a></td><td class="patent-data-table-td patent-date-value">Jan 26, 2007</td><td class="patent-data-table-td patent-date-value">Mar 10, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and their uses directed to Huntingtin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2213291A1?cl=en">EP2213291A1</a></td><td class="patent-data-table-td patent-date-value">Jan 4, 2001</td><td class="patent-data-table-td patent-date-value">Aug 4, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense inhibition of PTP1B expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2218727A1?cl=en">EP2218727A1</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 2004</td><td class="patent-data-table-td patent-date-value">Aug 18, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of C-reactive protein expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2221376A2?cl=en">EP2221376A2</a></td><td class="patent-data-table-td patent-date-value">Jun 19, 2002</td><td class="patent-data-table-td patent-date-value">Aug 25, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of superoxide dismutase 1, soluble expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2233494A1?cl=en">EP2233494A1</a></td><td class="patent-data-table-td patent-date-value">Sep 22, 2003</td><td class="patent-data-table-td patent-date-value">Sep 29, 2010</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Riboswitches, methods for their use, and compositions for use with riboswitches</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2239327A2?cl=en">EP2239327A2</a></td><td class="patent-data-table-td patent-date-value">Aug 11, 2006</td><td class="patent-data-table-td patent-date-value">Oct 13, 2010</td><td class="patent-data-table-td ">Synthetic Genomics, Inc.</td><td class="patent-data-table-td ">Method for in vitro recombination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2241572A2?cl=en">EP2241572A2</a></td><td class="patent-data-table-td patent-date-value">Jun 3, 2004</td><td class="patent-data-table-td patent-date-value">Oct 20, 2010</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Modulation of survivin expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2246443A1?cl=en">EP2246443A1</a></td><td class="patent-data-table-td patent-date-value">May 13, 2002</td><td class="patent-data-table-td patent-date-value">Nov 3, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of PTP1B expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2253706A2?cl=en">EP2253706A2</a></td><td class="patent-data-table-td patent-date-value">Nov 17, 2004</td><td class="patent-data-table-td patent-date-value">Nov 24, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of kinesin-like 1 expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2256200A2?cl=en">EP2256200A2</a></td><td class="patent-data-table-td patent-date-value">Sep 17, 2004</td><td class="patent-data-table-td patent-date-value">Dec 1, 2010</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of eIF4E expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2256201A2?cl=en">EP2256201A2</a></td><td class="patent-data-table-td patent-date-value">Sep 17, 2004</td><td class="patent-data-table-td patent-date-value">Dec 1, 2010</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of eIF4E expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2261371A2?cl=en">EP2261371A2</a></td><td class="patent-data-table-td patent-date-value">Dec 19, 2003</td><td class="patent-data-table-td patent-date-value">Dec 15, 2010</td><td class="patent-data-table-td ">QIAGEN GmbH</td><td class="patent-data-table-td ">Nucleic acid amplification</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2266997A1?cl=en">EP2266997A1</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 2004</td><td class="patent-data-table-td patent-date-value">Dec 29, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of C-reactive protein expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2270024A1?cl=en">EP2270024A1</a></td><td class="patent-data-table-td patent-date-value">Jun 19, 2002</td><td class="patent-data-table-td patent-date-value">Jan 5, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of superoxide dismutase 1, soluble expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2270230A2?cl=en">EP2270230A2</a></td><td class="patent-data-table-td patent-date-value">Oct 7, 2002</td><td class="patent-data-table-td patent-date-value">Jan 5, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of insulin-like growth factor binding protein 5 expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2270231A2?cl=en">EP2270231A2</a></td><td class="patent-data-table-td patent-date-value">Oct 7, 2002</td><td class="patent-data-table-td patent-date-value">Jan 5, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of insulin-like growth factor binding protein 5 expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2272857A1?cl=en">EP2272857A1</a></td><td class="patent-data-table-td patent-date-value">Apr 28, 2004</td><td class="patent-data-table-td patent-date-value">Jan 12, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of glucagon receptor expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2272958A1?cl=en">EP2272958A1</a></td><td class="patent-data-table-td patent-date-value">Sep 25, 2003</td><td class="patent-data-table-td patent-date-value">Jan 12, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of forkhead box O1A expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2272985A1?cl=en">EP2272985A1</a></td><td class="patent-data-table-td patent-date-value">Aug 5, 2002</td><td class="patent-data-table-td patent-date-value">Jan 12, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of apolipoprotein (A) expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2280019A1?cl=en">EP2280019A1</a></td><td class="patent-data-table-td patent-date-value">Jul 15, 2002</td><td class="patent-data-table-td patent-date-value">Feb 2, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of C-reactive protein expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2281869A2?cl=en">EP2281869A2</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 2004</td><td class="patent-data-table-td patent-date-value">Feb 9, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of diacylglycerol acyltransferase 1 expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2284267A2?cl=en">EP2284267A2</a></td><td class="patent-data-table-td patent-date-value">Aug 18, 2004</td><td class="patent-data-table-td patent-date-value">Feb 16, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of diacylglycerol acyltransferase 2 expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2292259A2?cl=en">EP2292259A2</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2003</td><td class="patent-data-table-td patent-date-value">Mar 9, 2011</td><td class="patent-data-table-td ">MUSC Foundation For Research Development</td><td class="patent-data-table-td ">Complement receptor 2 targeted complement modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2298829A1?cl=en">EP2298829A1</a></td><td class="patent-data-table-td patent-date-value">May 31, 2006</td><td class="patent-data-table-td patent-date-value">Mar 23, 2011</td><td class="patent-data-table-td ">Ãcole Polytechnique FÃ©dÃ©rale De Lausanne</td><td class="patent-data-table-td ">Triblock copolymers for cytoplasmic delivery of gene-based drugs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2314594A1?cl=en">EP2314594A1</a></td><td class="patent-data-table-td patent-date-value">Jan 27, 2007</td><td class="patent-data-table-td patent-date-value">Apr 27, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">6-modified bicyclic nucleic acid analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2316968A1?cl=en">EP2316968A1</a></td><td class="patent-data-table-td patent-date-value">Aug 5, 2002</td><td class="patent-data-table-td patent-date-value">May 4, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of apolipoprotein (A) expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2322535A2?cl=en">EP2322535A2</a></td><td class="patent-data-table-td patent-date-value">Sep 22, 2003</td><td class="patent-data-table-td patent-date-value">May 18, 2011</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Riboswitches, methods for their use, and compositions for use with riboswitches</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2325315A1?cl=en">EP2325315A1</a></td><td class="patent-data-table-td patent-date-value">Oct 27, 2006</td><td class="patent-data-table-td patent-date-value">May 25, 2011</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of huntingtin gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2327709A2?cl=en">EP2327709A2</a></td><td class="patent-data-table-td patent-date-value">Apr 28, 2004</td><td class="patent-data-table-td patent-date-value">Jun 1, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of glucagon receptor expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2329830A2?cl=en">EP2329830A2</a></td><td class="patent-data-table-td patent-date-value">Jan 4, 2001</td><td class="patent-data-table-td patent-date-value">Jun 8, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense inhibition of PTP1B expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2332951A2?cl=en">EP2332951A2</a></td><td class="patent-data-table-td patent-date-value">Jan 27, 2007</td><td class="patent-data-table-td patent-date-value">Jun 15, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">6-modified bicyclic nucleic acid analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2332955A2?cl=en">EP2332955A2</a></td><td class="patent-data-table-td patent-date-value">Jul 15, 2002</td><td class="patent-data-table-td patent-date-value">Jun 15, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2336145A1?cl=en">EP2336145A1</a></td><td class="patent-data-table-td patent-date-value">Jul 30, 2002</td><td class="patent-data-table-td patent-date-value">Jun 22, 2011</td><td class="patent-data-table-td ">Genzyme Corporation</td><td class="patent-data-table-td ">Antisense modulation of apolipoprotein B expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2336317A1?cl=en">EP2336317A1</a></td><td class="patent-data-table-td patent-date-value">Jun 14, 2004</td><td class="patent-data-table-td patent-date-value">Jun 22, 2011</td><td class="patent-data-table-td ">Alnylam Europe AG</td><td class="patent-data-table-td ">Double-stranded ribonucleic acid with increased effectiveness in an organism</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2336318A1?cl=en">EP2336318A1</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2003</td><td class="patent-data-table-td patent-date-value">Jun 22, 2011</td><td class="patent-data-table-td ">Genzyme Corporation</td><td class="patent-data-table-td ">Antisense modulation of apolipoprotein B expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2336319A1?cl=en">EP2336319A1</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2003</td><td class="patent-data-table-td patent-date-value">Jun 22, 2011</td><td class="patent-data-table-td ">Genzyme Corporation</td><td class="patent-data-table-td ">Antisense modulation of apolipoprotein B expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2338991A2?cl=en">EP2338991A2</a></td><td class="patent-data-table-td patent-date-value">Aug 29, 2006</td><td class="patent-data-table-td patent-date-value">Jun 29, 2011</td><td class="patent-data-table-td ">Regulus Therapeutics, Inc</td><td class="patent-data-table-td ">Methods for use in modulating MIR-122a</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2338992A2?cl=en">EP2338992A2</a></td><td class="patent-data-table-td patent-date-value">Aug 29, 2006</td><td class="patent-data-table-td patent-date-value">Jun 29, 2011</td><td class="patent-data-table-td ">Regulus Therapeutics, Inc</td><td class="patent-data-table-td ">Antisense compounds having enhanced anti-microRNA activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2363134A1?cl=en">EP2363134A1</a></td><td class="patent-data-table-td patent-date-value">Nov 7, 2006</td><td class="patent-data-table-td patent-date-value">Sep 7, 2011</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of factor V Leiden mutant gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2363480A2?cl=en">EP2363480A2</a></td><td class="patent-data-table-td patent-date-value">Jan 20, 2005</td><td class="patent-data-table-td patent-date-value">Sep 7, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of glucocorticoid receptor expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2363481A1?cl=en">EP2363481A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Sep 7, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2363482A1?cl=en">EP2363482A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Sep 7, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating gene expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2363503A1?cl=en">EP2363503A1</a></td><td class="patent-data-table-td patent-date-value">Nov 21, 2003</td><td class="patent-data-table-td patent-date-value">Sep 7, 2011</td><td class="patent-data-table-td ">ISIS Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of HIF1A and HIF2A expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2364990A1?cl=en">EP2364990A1</a></td><td class="patent-data-table-td patent-date-value">May 28, 2002</td><td class="patent-data-table-td patent-date-value">Sep 14, 2011</td><td class="patent-data-table-td ">Duke University</td><td class="patent-data-table-td ">Modulators of pharmacological agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2365094A1?cl=en">EP2365094A1</a></td><td class="patent-data-table-td patent-date-value">May 13, 2002</td><td class="patent-data-table-td patent-date-value">Sep 14, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of PTP1B expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2382997A1?cl=en">EP2382997A1</a></td><td class="patent-data-table-td patent-date-value">Sep 15, 2005</td><td class="patent-data-table-td patent-date-value">Nov 2, 2011</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of anti-apoptotic genes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2388318A1?cl=en">EP2388318A1</a></td><td class="patent-data-table-td patent-date-value">Dec 9, 2002</td><td class="patent-data-table-td patent-date-value">Nov 23, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense modulation of connective tissue growth factor expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2388327A1?cl=en">EP2388327A1</a></td><td class="patent-data-table-td patent-date-value">Jan 27, 2007</td><td class="patent-data-table-td patent-date-value">Nov 23, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligomeric compounds and compositions for the use in modulation of micrornas</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2388328A1?cl=en">EP2388328A1</a></td><td class="patent-data-table-td patent-date-value">Jan 27, 2007</td><td class="patent-data-table-td patent-date-value">Nov 23, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligomeric compounds and compositions for the use in modulation of micrornas</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2392583A1?cl=en">EP2392583A1</a></td><td class="patent-data-table-td patent-date-value">May 18, 2007</td><td class="patent-data-table-td patent-date-value">Dec 7, 2011</td><td class="patent-data-table-td ">Alnylam Europe AG.</td><td class="patent-data-table-td ">RNAi modulation of Aha and therapeutic uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2392645A1?cl=en">EP2392645A1</a></td><td class="patent-data-table-td patent-date-value">Oct 16, 2006</td><td class="patent-data-table-td patent-date-value">Dec 7, 2011</td><td class="patent-data-table-td ">MUSC Foundation For Research Development</td><td class="patent-data-table-td ">Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2392646A1?cl=en">EP2392646A1</a></td><td class="patent-data-table-td patent-date-value">Oct 16, 2006</td><td class="patent-data-table-td patent-date-value">Dec 7, 2011</td><td class="patent-data-table-td ">MUSC Foundation For Research Development</td><td class="patent-data-table-td ">Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2392647A1?cl=en">EP2392647A1</a></td><td class="patent-data-table-td patent-date-value">Oct 16, 2006</td><td class="patent-data-table-td patent-date-value">Dec 7, 2011</td><td class="patent-data-table-td ">MUSC Foundation For Research Development</td><td class="patent-data-table-td ">Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2395076A1?cl=en">EP2395076A1</a></td><td class="patent-data-table-td patent-date-value">Oct 16, 2006</td><td class="patent-data-table-td patent-date-value">Dec 14, 2011</td><td class="patent-data-table-td ">MUSC Foundation For Research Development</td><td class="patent-data-table-td ">Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2397551A1?cl=en">EP2397551A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Dec 21, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of PCSK9</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2402435A2?cl=en">EP2402435A2</a></td><td class="patent-data-table-td patent-date-value">Oct 16, 2006</td><td class="patent-data-table-td patent-date-value">Jan 4, 2012</td><td class="patent-data-table-td ">MUSC Foundation For Research Development</td><td class="patent-data-table-td ">Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2410053A1?cl=en">EP2410053A1</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2007</td><td class="patent-data-table-td patent-date-value">Jan 25, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2410054A1?cl=en">EP2410054A1</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2007</td><td class="patent-data-table-td patent-date-value">Jan 25, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2410332A1?cl=en">EP2410332A1</a></td><td class="patent-data-table-td patent-date-value">Nov 21, 2003</td><td class="patent-data-table-td patent-date-value">Jan 25, 2012</td><td class="patent-data-table-td ">The University Of Utah</td><td class="patent-data-table-td ">Method for identifying purinergic modulators of the olfactory system</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2422819A2?cl=en">EP2422819A2</a></td><td class="patent-data-table-td patent-date-value">Jan 26, 2007</td><td class="patent-data-table-td patent-date-value">Feb 29, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and their uses directed to Huntingtin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2426218A1?cl=en">EP2426218A1</a></td><td class="patent-data-table-td patent-date-value">May 29, 2008</td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Riboswitches and methods and compositions for use of and with riboswitches</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2426219A1?cl=en">EP2426219A1</a></td><td class="patent-data-table-td patent-date-value">May 29, 2008</td><td class="patent-data-table-td patent-date-value">Mar 7, 2012</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Riboswitches and methods and compositions for use of and with riboswitches</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2428227A1?cl=en">EP2428227A1</a></td><td class="patent-data-table-td patent-date-value">Jan 26, 2007</td><td class="patent-data-table-td patent-date-value">Mar 14, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and their uses directed to Huntingtin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2441449A1?cl=en">EP2441449A1</a></td><td class="patent-data-table-td patent-date-value">Apr 15, 2004</td><td class="patent-data-table-td patent-date-value">Apr 18, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of apolipoprotein C-III expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2444482A1?cl=en">EP2444482A1</a></td><td class="patent-data-table-td patent-date-value">Nov 3, 2004</td><td class="patent-data-table-td patent-date-value">Apr 25, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of SGLT2 expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2447274A2?cl=en">EP2447274A2</a></td><td class="patent-data-table-td patent-date-value">Oct 23, 2009</td><td class="patent-data-table-td patent-date-value">May 2, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligomeric compounds and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2458006A1?cl=en">EP2458006A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">May 30, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression APOB</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2460811A1?cl=en">EP2460811A1</a></td><td class="patent-data-table-td patent-date-value">Apr 22, 2005</td><td class="patent-data-table-td patent-date-value">Jun 6, 2012</td><td class="patent-data-table-td ">Regado Biosciences, Inc.</td><td class="patent-data-table-td ">Improved modulators of coagulation factors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2468865A1?cl=en">EP2468865A1</a></td><td class="patent-data-table-td patent-date-value">Sep 30, 2004</td><td class="patent-data-table-td patent-date-value">Jun 27, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense oligonucleotide modulation of stat3 expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2471925A1?cl=en">EP2471925A1</a></td><td class="patent-data-table-td patent-date-value">Mar 22, 2008</td><td class="patent-data-table-td patent-date-value">Jul 4, 2012</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Methods and compositions related to riboswitches that control alternative splicing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2492282A1?cl=en">EP2492282A1</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2004</td><td class="patent-data-table-td patent-date-value">Aug 29, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of growth hormone receptor expression and insulin-like growth factor expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2505646A1?cl=en">EP2505646A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of CRP</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2505647A1?cl=en">EP2505647A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of DGAT2</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2505648A1?cl=en">EP2505648A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of PTP1B</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2505649A1?cl=en">EP2505649A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of GCGR</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2505650A1?cl=en">EP2505650A1</a></td><td class="patent-data-table-td patent-date-value">May 7, 2007</td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compounds and methods for modulating expression of PCSK9</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2527444A2?cl=en">EP2527444A2</a></td><td class="patent-data-table-td patent-date-value">Sep 30, 2004</td><td class="patent-data-table-td patent-date-value">Nov 28, 2012</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Antisense oligonucleotide modulation of stat3 expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2530157A2?cl=en">EP2530157A2</a></td><td class="patent-data-table-td patent-date-value">Jul 30, 2004</td><td class="patent-data-table-td patent-date-value">Dec 5, 2012</td><td class="patent-data-table-td ">Regulus Therapeutics, Inc</td><td class="patent-data-table-td ">Oligomeric compounds and compositions for use in modulation of small non-coding rnas</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2540734A2?cl=en">EP2540734A2</a></td><td class="patent-data-table-td patent-date-value">Apr 5, 2005</td><td class="patent-data-table-td patent-date-value">Jan 2, 2013</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Process and reagents for oligonucleotide synthesis and purification</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2584051A1?cl=en">EP2584051A1</a></td><td class="patent-data-table-td patent-date-value">May 21, 2007</td><td class="patent-data-table-td patent-date-value">Apr 24, 2013</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expressions of IKK-B gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2617828A1?cl=en">EP2617828A1</a></td><td class="patent-data-table-td patent-date-value">Dec 10, 2008</td><td class="patent-data-table-td patent-date-value">Jul 24, 2013</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of factor VII gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2639316A1?cl=en">EP2639316A1</a></td><td class="patent-data-table-td patent-date-value">May 12, 2008</td><td class="patent-data-table-td patent-date-value">Sep 18, 2013</td><td class="patent-data-table-td ">The Johns Hopkins University</td><td class="patent-data-table-td ">Biomarkers for melanoma</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2690175A2?cl=en">EP2690175A2</a></td><td class="patent-data-table-td patent-date-value">Sep 2, 2009</td><td class="patent-data-table-td patent-date-value">Jan 29, 2014</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals</td><td class="patent-data-table-td ">Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2700720A2?cl=en">EP2700720A2</a></td><td class="patent-data-table-td patent-date-value">Mar 15, 2005</td><td class="patent-data-table-td patent-date-value">Feb 26, 2014</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and methods for optimizing cleavage of RNA by RNASE H</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2712926A2?cl=en">EP2712926A2</a></td><td class="patent-data-table-td patent-date-value">Mar 5, 2009</td><td class="patent-data-table-td patent-date-value">Apr 2, 2014</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of Eg5 and VEGF genes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2743265A1?cl=en">EP2743265A1</a></td><td class="patent-data-table-td patent-date-value">Oct 9, 2009</td><td class="patent-data-table-td patent-date-value">Jun 18, 2014</td><td class="patent-data-table-td ">Tekmira Pharmaceuticals Corporation</td><td class="patent-data-table-td ">Improved amino lipids and methods for the delivery of nucleic acids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2000018781A1?cl=en">WO2000018781A1</a></td><td class="patent-data-table-td patent-date-value">Sep 23, 1999</td><td class="patent-data-table-td patent-date-value">Apr 6, 2000</td><td class="patent-data-table-td ">Elizabeth J Ackermann</td><td class="patent-data-table-td ">Antisense modulation of survivin expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2003070904A2?cl=en">WO2003070904A2</a></td><td class="patent-data-table-td patent-date-value">Feb 19, 2003</td><td class="patent-data-table-td patent-date-value">Aug 28, 2003</td><td class="patent-data-table-td ">Stanley T Crooke</td><td class="patent-data-table-td ">Human rnase iii and compositions and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004044138A2?cl=en">WO2004044138A2</a></td><td class="patent-data-table-td patent-date-value">Nov 4, 2003</td><td class="patent-data-table-td patent-date-value">May 27, 2004</td><td class="patent-data-table-td ">Isis Pharmaceuticals Inc</td><td class="patent-data-table-td ">Chimeric oligomeric compounds and their use in gene modulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2004072284A1?cl=en">WO2004072284A1</a></td><td class="patent-data-table-td patent-date-value">Feb 11, 2004</td><td class="patent-data-table-td patent-date-value">Aug 26, 2004</td><td class="patent-data-table-td ">Antisense Therapeutics Pty Ltd</td><td class="patent-data-table-td ">Modulation of insulin like growth factor i receptor expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006086821A1?cl=en">WO2006086821A1</a></td><td class="patent-data-table-td patent-date-value">Oct 20, 2005</td><td class="patent-data-table-td patent-date-value">Aug 24, 2006</td><td class="patent-data-table-td ">Antisense Therapeutics Ltd</td><td class="patent-data-table-td ">ANTISENS MODULATION OF INTEGRIN Î±4 EXPRESSION</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006133022A2?cl=en">WO2006133022A2</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 2006</td><td class="patent-data-table-td patent-date-value">Dec 14, 2006</td><td class="patent-data-table-td ">Chi V Dang</td><td class="patent-data-table-td ">Compositions and methods for decreasing microrna expression for the treatment of neoplasia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007115168A2?cl=en">WO2007115168A2</a></td><td class="patent-data-table-td patent-date-value">Mar 30, 2007</td><td class="patent-data-table-td patent-date-value">Oct 11, 2007</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals Inc</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of eg5 gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008098248A2?cl=en">WO2008098248A2</a></td><td class="patent-data-table-td patent-date-value">Feb 11, 2008</td><td class="patent-data-table-td patent-date-value">Aug 14, 2008</td><td class="patent-data-table-td ">Univ Northwestern</td><td class="patent-data-table-td ">Particles for detecting intracellular targets</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008101157A1?cl=en">WO2008101157A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 15, 2008</td><td class="patent-data-table-td patent-date-value">Aug 21, 2008</td><td class="patent-data-table-td ">Isis Pharmaceuticals Inc</td><td class="patent-data-table-td ">5&#39;-substituted-2&#39;-f modified nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009023855A2?cl=en">WO2009023855A2</a></td><td class="patent-data-table-td patent-date-value">Aug 15, 2008</td><td class="patent-data-table-td patent-date-value">Feb 19, 2009</td><td class="patent-data-table-td ">Isis Pharmaceuticals Inc</td><td class="patent-data-table-td ">Tetrahydropyran nucleic acid analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009149182A1?cl=en">WO2009149182A1</a></td><td class="patent-data-table-td patent-date-value">Jun 3, 2009</td><td class="patent-data-table-td patent-date-value">Dec 10, 2009</td><td class="patent-data-table-td ">The Board Of Regents Of The University Of Texas System</td><td class="patent-data-table-td ">Modulation of gene expression through endogenous small rna targeting of gene promoters</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010068816A1?cl=en">WO2010068816A1</a></td><td class="patent-data-table-td patent-date-value">Dec 10, 2009</td><td class="patent-data-table-td patent-date-value">Jun 17, 2010</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Gnaq targeted dsrna compositions and methods for inhibiting expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010089221A1?cl=en">WO2010089221A1</a></td><td class="patent-data-table-td patent-date-value">Jan 26, 2010</td><td class="patent-data-table-td patent-date-value">Aug 12, 2010</td><td class="patent-data-table-td ">F. Hoffmann-La Roche Ag</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of ptp1b genes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010091308A2?cl=en">WO2010091308A2</a></td><td class="patent-data-table-td patent-date-value">Feb 5, 2010</td><td class="patent-data-table-td patent-date-value">Aug 12, 2010</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Oligomeric compounds and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010099341A1?cl=en">WO2010099341A1</a></td><td class="patent-data-table-td patent-date-value">Feb 25, 2010</td><td class="patent-data-table-td patent-date-value">Sep 2, 2010</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of mig-12 gene</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010107733A2?cl=en">WO2010107733A2</a></td><td class="patent-data-table-td patent-date-value">Mar 16, 2010</td><td class="patent-data-table-td patent-date-value">Sep 23, 2010</td><td class="patent-data-table-td ">Curna, Inc.</td><td class="patent-data-table-td ">Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010124231A2?cl=en">WO2010124231A2</a></td><td class="patent-data-table-td patent-date-value">Apr 23, 2010</td><td class="patent-data-table-td patent-date-value">Oct 28, 2010</td><td class="patent-data-table-td ">The Board Of Regents Of The University Of Texas System</td><td class="patent-data-table-td ">Modulation of gene expression using oligomers that target gene regions downstream of 3&#39; untranslated regions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010132665A1?cl=en">WO2010132665A1</a></td><td class="patent-data-table-td patent-date-value">May 13, 2010</td><td class="patent-data-table-td patent-date-value">Nov 18, 2010</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010135329A2?cl=en">WO2010135329A2</a></td><td class="patent-data-table-td patent-date-value">May 18, 2010</td><td class="patent-data-table-td patent-date-value">Nov 25, 2010</td><td class="patent-data-table-td ">Curna, Inc.</td><td class="patent-data-table-td ">Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011022420A1?cl=en">WO2011022420A1</a></td><td class="patent-data-table-td patent-date-value">Aug 17, 2010</td><td class="patent-data-table-td patent-date-value">Feb 24, 2011</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Methylation biomarkers and methods of use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011028950A1?cl=en">WO2011028950A1</a></td><td class="patent-data-table-td patent-date-value">Sep 2, 2010</td><td class="patent-data-table-td patent-date-value">Mar 10, 2011</td><td class="patent-data-table-td ">Genentech, Inc.</td><td class="patent-data-table-td ">Mutant smoothened and methods of using the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011053994A1?cl=en">WO2011053994A1</a></td><td class="patent-data-table-td patent-date-value">Nov 2, 2010</td><td class="patent-data-table-td patent-date-value">May 5, 2011</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011054939A2?cl=en">WO2011054939A2</a></td><td class="patent-data-table-td patent-date-value">Nov 5, 2010</td><td class="patent-data-table-td patent-date-value">May 12, 2011</td><td class="patent-data-table-td ">F. Hoffmann-La Roche Ag</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of kif10 genes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011056215A1?cl=en">WO2011056215A1</a></td><td class="patent-data-table-td patent-date-value">Nov 3, 2010</td><td class="patent-data-table-td patent-date-value">May 12, 2011</td><td class="patent-data-table-td ">Landers James P</td><td class="patent-data-table-td ">Versatile, visible method for detecting polymeric analytes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011056687A2?cl=en">WO2011056687A2</a></td><td class="patent-data-table-td patent-date-value">Oct 27, 2010</td><td class="patent-data-table-td patent-date-value">May 12, 2011</td><td class="patent-data-table-td ">Swift Biosciences, Inc.</td><td class="patent-data-table-td ">Polynucleotide primers and probes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011063403A1?cl=en">WO2011063403A1</a></td><td class="patent-data-table-td patent-date-value">Nov 23, 2010</td><td class="patent-data-table-td patent-date-value">May 26, 2011</td><td class="patent-data-table-td ">Swift Biosciences, Inc.</td><td class="patent-data-table-td ">Devices to extend single stranded target molecules</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011073218A1?cl=en">WO2011073218A1</a></td><td class="patent-data-table-td patent-date-value">Dec 15, 2010</td><td class="patent-data-table-td patent-date-value">Jun 23, 2011</td><td class="patent-data-table-td ">F. Hoffmann-La Roche Ag</td><td class="patent-data-table-td ">Compositons and methods for inhibiting expression of il-18 genes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011079261A2?cl=en">WO2011079261A2</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 2010</td><td class="patent-data-table-td patent-date-value">Jun 30, 2011</td><td class="patent-data-table-td ">Curna, Inc.</td><td class="patent-data-table-td ">Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011079263A2?cl=en">WO2011079263A2</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 2010</td><td class="patent-data-table-td patent-date-value">Jun 30, 2011</td><td class="patent-data-table-td ">Curna, Inc.</td><td class="patent-data-table-td ">Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011082409A2?cl=en">WO2011082409A2</a></td><td class="patent-data-table-td patent-date-value">Jan 4, 2011</td><td class="patent-data-table-td patent-date-value">Jul 7, 2011</td><td class="patent-data-table-td ">Curna, Inc.</td><td class="patent-data-table-td ">Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011084455A2?cl=en">WO2011084455A2</a></td><td class="patent-data-table-td patent-date-value">Dec 15, 2010</td><td class="patent-data-table-td patent-date-value">Jul 14, 2011</td><td class="patent-data-table-td ">Opko Curna, Llc.</td><td class="patent-data-table-td ">Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011085347A2?cl=en">WO2011085347A2</a></td><td class="patent-data-table-td patent-date-value">Jan 11, 2011</td><td class="patent-data-table-td patent-date-value">Jul 14, 2011</td><td class="patent-data-table-td ">Opko Curna, Llc</td><td class="patent-data-table-td ">Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011088076A2?cl=en">WO2011088076A2</a></td><td class="patent-data-table-td patent-date-value">Jan 12, 2011</td><td class="patent-data-table-td patent-date-value">Jul 21, 2011</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Structured rna motifs and compounds and methods for their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011095495A1?cl=en">WO2011095495A1</a></td><td class="patent-data-table-td patent-date-value">Feb 2, 2011</td><td class="patent-data-table-td patent-date-value">Aug 11, 2011</td><td class="patent-data-table-td ">F. Hoffmann-La Roche Ag</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of ikk2 genes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011097388A1?cl=en">WO2011097388A1</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2011</td><td class="patent-data-table-td patent-date-value">Aug 11, 2011</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Selective inhibition of polyglutamine protein expression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011097407A1?cl=en">WO2011097407A1</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2011</td><td class="patent-data-table-td patent-date-value">Aug 11, 2011</td><td class="patent-data-table-td ">Ico Therapeutics Inc.</td><td class="patent-data-table-td ">Dosing regimens for treating and preventing ocular disorders using c-raf antisense</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011105900A2?cl=en">WO2011105900A2</a></td><td class="patent-data-table-td patent-date-value">Feb 23, 2011</td><td class="patent-data-table-td patent-date-value">Sep 1, 2011</td><td class="patent-data-table-td ">Academisch Ziekenhuis Bij De Universiteit Van Amsterdam</td><td class="patent-data-table-td ">Antagonists of complement component 8-alpha (c8-alpha) and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011105901A2?cl=en">WO2011105901A2</a></td><td class="patent-data-table-td patent-date-value">Feb 23, 2011</td><td class="patent-data-table-td patent-date-value">Sep 1, 2011</td><td class="patent-data-table-td ">Academisch Ziekenhuis Bij De Universiteit Van Amsterdam</td><td class="patent-data-table-td ">Antagonists of complement component 9 (c9) and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011105902A2?cl=en">WO2011105902A2</a></td><td class="patent-data-table-td patent-date-value">Feb 23, 2011</td><td class="patent-data-table-td patent-date-value">Sep 1, 2011</td><td class="patent-data-table-td ">Academisch Ziekenhuis Bij De Universiteit Van Amsterdam</td><td class="patent-data-table-td ">Antagonists of complement component 8-beta (c8-beta) and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011112516A1?cl=en">WO2011112516A1</a></td><td class="patent-data-table-td patent-date-value">Mar 7, 2011</td><td class="patent-data-table-td patent-date-value">Sep 15, 2011</td><td class="patent-data-table-td ">Ico Therapeutics Inc.</td><td class="patent-data-table-td ">Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011113054A2?cl=en">WO2011113054A2</a></td><td class="patent-data-table-td patent-date-value">Mar 14, 2011</td><td class="patent-data-table-td patent-date-value">Sep 15, 2011</td><td class="patent-data-table-td ">Aurasense Llc</td><td class="patent-data-table-td ">Crosslinked polynucleotide structure</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011133695A2?cl=en">WO2011133695A2</a></td><td class="patent-data-table-td patent-date-value">Apr 20, 2011</td><td class="patent-data-table-td patent-date-value">Oct 27, 2011</td><td class="patent-data-table-td ">Swift Biosciences, Inc.</td><td class="patent-data-table-td ">Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011150226A1?cl=en">WO2011150226A1</a></td><td class="patent-data-table-td patent-date-value">May 26, 2011</td><td class="patent-data-table-td patent-date-value">Dec 1, 2011</td><td class="patent-data-table-td ">Landers James P</td><td class="patent-data-table-td ">Method for detecting nucleic acids based on aggregate formation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011156202A1?cl=en">WO2011156202A1</a></td><td class="patent-data-table-td patent-date-value">Jun 2, 2011</td><td class="patent-data-table-td patent-date-value">Dec 15, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Substituted 2 &#39;-amino and 2 &#39;-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011156278A1?cl=en">WO2011156278A1</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 2011</td><td class="patent-data-table-td patent-date-value">Dec 15, 2011</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Bicyclic nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011163466A1?cl=en">WO2011163466A1</a></td><td class="patent-data-table-td patent-date-value">Jun 23, 2011</td><td class="patent-data-table-td patent-date-value">Dec 29, 2011</td><td class="patent-data-table-td ">The United States Of America, As Represented By The Secretary, Department Of Health And Human Services</td><td class="patent-data-table-td ">Regulation of skin pigmentation by neuregulin-1 (nrg-1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012021554A1?cl=en">WO2012021554A1</a></td><td class="patent-data-table-td patent-date-value">Aug 9, 2011</td><td class="patent-data-table-td patent-date-value">Feb 16, 2012</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012047968A2?cl=en">WO2012047968A2</a></td><td class="patent-data-table-td patent-date-value">Oct 5, 2011</td><td class="patent-data-table-td patent-date-value">Apr 12, 2012</td><td class="patent-data-table-td ">Curis, Inc.</td><td class="patent-data-table-td ">Mutant smoothened and methods of using the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012052258A1?cl=en">WO2012052258A1</a></td><td class="patent-data-table-td patent-date-value">Sep 27, 2011</td><td class="patent-data-table-td patent-date-value">Apr 26, 2012</td><td class="patent-data-table-td ">Arrowhead Research Corporation</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of rrm2 genes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012064824A1?cl=en">WO2012064824A1</a></td><td class="patent-data-table-td patent-date-value">Nov 9, 2011</td><td class="patent-data-table-td patent-date-value">May 18, 2012</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012078209A1?cl=en">WO2012078209A1</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 2011</td><td class="patent-data-table-td patent-date-value">Jun 14, 2012</td><td class="patent-data-table-td ">The United States Of America, As Represented By The Secretary, Department Of Health And Human Services</td><td class="patent-data-table-td ">Diagnosis and treatment of adrenocortical tumors using human microrna-483</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012106509A1?cl=en">WO2012106509A1</a></td><td class="patent-data-table-td patent-date-value">Feb 2, 2012</td><td class="patent-data-table-td patent-date-value">Aug 9, 2012</td><td class="patent-data-table-td ">The Trustees Of Princeton University</td><td class="patent-data-table-td ">Sirtuin modulators as virus production modulators</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012106586A1?cl=en">WO2012106586A1</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2012</td><td class="patent-data-table-td patent-date-value">Aug 9, 2012</td><td class="patent-data-table-td ">Mirna Therapeutics, Inc.</td><td class="patent-data-table-td ">Synthetic mimics of mir-124</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012106591A1?cl=en">WO2012106591A1</a></td><td class="patent-data-table-td patent-date-value">Feb 3, 2012</td><td class="patent-data-table-td patent-date-value">Aug 9, 2012</td><td class="patent-data-table-td ">Mirna Therapeutics, Inc.</td><td class="patent-data-table-td ">Synthetic mimics of mir-34</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012149154A1?cl=en">WO2012149154A1</a></td><td class="patent-data-table-td patent-date-value">Apr 26, 2012</td><td class="patent-data-table-td patent-date-value">Nov 1, 2012</td><td class="patent-data-table-td ">Swift Biosciences, Inc.</td><td class="patent-data-table-td ">Polynucleotide primers and probes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012151268A1?cl=en">WO2012151268A1</a></td><td class="patent-data-table-td patent-date-value">May 2, 2012</td><td class="patent-data-table-td patent-date-value">Nov 8, 2012</td><td class="patent-data-table-td ">University Of Virginia Patent Foundation</td><td class="patent-data-table-td ">Method and system for high throughput optical and label free detection of analytes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012151289A2?cl=en">WO2012151289A2</a></td><td class="patent-data-table-td patent-date-value">May 2, 2012</td><td class="patent-data-table-td patent-date-value">Nov 8, 2012</td><td class="patent-data-table-td ">University Of Virginia Patent Foundation</td><td class="patent-data-table-td ">Method and system to detect aggregate formation on a substrate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013040548A2?cl=en">WO2013040548A2</a></td><td class="patent-data-table-td patent-date-value">Sep 17, 2012</td><td class="patent-data-table-td patent-date-value">Mar 21, 2013</td><td class="patent-data-table-td ">Yale University</td><td class="patent-data-table-td ">Fluoride-responsive riboswitchs, fluoride transporters, and methods of use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013138374A2?cl=en">WO2013138374A2</a></td><td class="patent-data-table-td patent-date-value">Mar 12, 2013</td><td class="patent-data-table-td patent-date-value">Sep 19, 2013</td><td class="patent-data-table-td ">Curna, Inc.</td><td class="patent-data-table-td ">Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013154798A1?cl=en">WO2013154798A1</a></td><td class="patent-data-table-td patent-date-value">Mar 20, 2013</td><td class="patent-data-table-td patent-date-value">Oct 17, 2013</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Tricyclic nucleic acid analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013154799A1?cl=en">WO2013154799A1</a></td><td class="patent-data-table-td patent-date-value">Mar 20, 2013</td><td class="patent-data-table-td patent-date-value">Oct 17, 2013</td><td class="patent-data-table-td ">Isis Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Tricyclic nucleosides and oligomeric compounds prepared therefrom</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013155204A2?cl=en">WO2013155204A2</a></td><td class="patent-data-table-td patent-date-value">Apr 10, 2013</td><td class="patent-data-table-td patent-date-value">Oct 17, 2013</td><td class="patent-data-table-td ">Alnylam Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Compositions and methods for inhibiting expression of the alas1 gene</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S023100">536/23.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S023500">536/23.5</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S024500">536/24.5</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S024100">536/24.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S025300">536/25.3</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S023700">536/23.7</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S023600">536/23.6</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc536/defs536.htm&usg=AFQjCNHex3TR9tihVxBKQnsQg6n8YmdVYg#C536S025310">536/25.31</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019040000">C07H19/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031705200">A61K31/7052</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12Q0001700000">C12Q1/70</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031704200">A61K31/7042</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0009020000">C12N9/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12P0021000000">C12P21/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031706400">A61K31/7064</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019230000">C07H19/23</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038000000">A61K38/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019160000">C07H19/16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031700000">A61K31/70</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0023000000">C07H23/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0048000000">A61K48/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0031120000">A61P31/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0043000000">A61P43/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031708000">A61K31/708</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019190000">C07H19/19</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019052000">C07H19/052</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0021000000">C07H21/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0021020000">C07H21/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019056000">C07H19/056</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019200000">C07H19/20</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014160000">C07K14/16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019060000">C07H19/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031705600">A61K31/7056</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031707600">A61K31/7076</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07J0043000000">C07J43/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12Q0001680000">C12Q1/68</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019100000">C07H19/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031706000">A61K31/706</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031706800">A61K31/7068</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019120000">C07H19/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031708800">A61K31/7088</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031707200">A61K31/7072</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019140000">C07H19/14</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0021040000">C07H21/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0015090000">C12N15/09</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0019000000">C07H19/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0015113000">C12N15/113</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N9/0069">C12N9/0069</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/32">C12N2310/32</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/321">C12N2310/321</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H19/16">C07H19/16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07J43/003">C07J43/003</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/336">C12N2310/336</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/3533">C12N2310/3533</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K14/005">C07K14/005</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/3511">C12N2310/3511</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/3125">C12N2310/3125</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/3521">C12N2310/3521</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H23/00">C07H23/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H21/00">C07H21/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12Q1/6813">C12Q1/6813</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N15/113">C12N15/113</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H19/06">C07H19/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K48/00">A61K48/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/333">C12N2310/333</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/00">A61K38/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/33">C12N2310/33</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2740/16322">C12N2740/16322</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N15/1137">C12N15/1137</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/315">C12N2310/315</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H19/20">C07H19/20</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12Y113/11012">C12Y113/11012</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/3531">C12N2310/3531</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12Q1/68">C12Q1/68</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H19/04">C07H19/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/3527">C12N2310/3527</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/322">C12N2310/322</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C12N2310/3523">C12N2310/3523</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=M75DBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07H19/10">C07H19/10</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07H23/00</span>, <span class="nested-value">C07H19/10</span>, <span class="nested-value">C12Y113/11012</span>, <span class="nested-value">C07K14/005</span>, <span class="nested-value">C12N9/00P28</span>, <span class="nested-value">C07H19/16</span>, <span class="nested-value">C07H19/06</span>, <span class="nested-value">C07J43/00B</span>, <span class="nested-value">C07H21/00</span>, <span class="nested-value">C12Q1/68B</span>, <span class="nested-value">A61K48/00</span>, <span class="nested-value">C12Q1/68</span>, <span class="nested-value">C07H19/20</span>, <span class="nested-value">C07H19/04</span>, <span class="nested-value">C12N15/113D</span>, <span class="nested-value">C12N15/113</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Aug 20, 2013</td><td class="patent-data-table-td ">FPB1</td><td class="patent-data-table-td ">Expired due to reexamination which canceled all claims</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 24, 2011</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20101116</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ISIS PHARMACEUTICALS, INC., CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">RELEASE BY SECURED PARTY;ASSIGNOR:DRI CAPITAL INC.;REEL/FRAME:025685/0658</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 11, 2010</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20100218</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 24, 2009</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 1, 2005</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">DRUG ROYALTY USA, INC., CANADA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY INTEREST;ASSIGNOR:ISIS PHARMACEUTICALS, INC.;REEL/FRAME:016323/0001</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20041221</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">DRUG ROYALTY USA, INC. ROYAL BANK PLAZA, SUITE 312</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY INTEREST;ASSIGNOR:ISIS PHARMACEUTICALS, INC. /AR;REEL/FRAME:016323/0001</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 21, 2004</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">DRUG ROYALTY USA, INC., CANADA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:ISIS PHARMACEUTICALS, INC.;REEL/FRAME:016105/0488</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20041221</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">DRUG ROYALTY USA, INC. ROYAL BANK PLAZA, SUITE 312</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">SECURITY AGREEMENT;ASSIGNOR:ISIS PHARMACEUTICALS, INC. /AR;REEL/FRAME:016105/0488</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 3, 2004</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 29, 2004</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 9, 2003</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PFIZER INC., NEW YORK</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CONFIRMATION OF EXCLUSIVE PATENT SUBLICENSE;ASSIGNOR:EYETECH PHARMACEUTICALS, INC.;REEL/FRAME:014462/0870</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20021217</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">PFIZER INC. 235 EAST 42ND STREETNEW YORK, NEW YORK</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 26, 2001</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 19, 1999</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 19, 1995</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ISIS PHARMACEUTICALS INC., CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COOK, PHILLIP DAN;KAWASAKI, ANDREW;REEL/FRAME:007557/0575;SIGNING DATES FROM 19950419 TO 19950428</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_4ff636b3d23669b7103f3b3a3a18b4cd.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U1_BCEwWlIAs2hSeYZuT2TO9ZTf4A\u0026id=M75DBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U25YxAiqkzFOTfr1FetgElAYt-ssg\u0026id=M75DBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U18nJEeHFUj-LTdvD_PilBduSIu0A","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Sugar_modified_oligonucleotides_that_det.pdf?id=M75DBAABERAJ\u0026output=pdf\u0026sig=ACfU3U0c4fviYeUHtyJ48yBJwN6cbIjExQ"},"sample_url":"http://www.google.com/patents/reader?id=M75DBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>